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The Impact of Myeloid Derived Suppressor Cells on 
Vaccine Immunogenicity in South African HIV-infected 
and Uninfected Mothers and their Infants 
 
1Elvis Banboye KIDZERU 
1 Division of Immunology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape 
Town, South Africa 
Date: day of 15th March 2016 
BACKGROUND  
Each year over 4 million infants die from infections, of which many are vaccine-preventable. 
Young infants respond poorly to vaccines, but the basis of reduced immunity is controversial. 
We hypothesized that myeloid-derived suppressor cells (MDSC) that might be induced during 
gestation, would persist at birth leading to active suppression of infant-immune responses. 
 
OBJECTIVE  
We evaluated the ontogeny of MDSC and the effect of MDSC on vaccine immunogenicity 
during early life in South African infants and mothers, and in HIV-exposed uninfected (HEU) 
infants and HIV+ mothers. 
METHODS  
HIV-infected and uninfected mothers and their infants were recruited from Khayelitsha, Cape 
Town and followed-up for one year. In whole PBMC and after MDSC (CD15+) depleted, we 
measured BCG, Hepatitis B, Tetanus toxoid and Bordetella pertussis vaccine-specific CD4+ T 
cell proliferation by CFSE and IFN-γ responses using ELISpot assay. 
RESULTS  
MDSC frequency mothers and their infants were significantly higher at delivery, and decreased 
over time through 1 year of age. HIV+ mothers had a significantly higher MDSC frequency at 
one year postpartum, but there was no difference in MDSC frequency between their HIV-
exposed and unexposed infants. In infants, MDSC depletion had variable effects on CD4+ T cell 
proliferation and IFN-γ production to deferent antigens. In both infants and mothers, MDSC 
depletion significantly increased responses to Tetanus and Hep B, but BCG responses were 
significantly lower after MDSC depletion in infants and mothers. HIV-exposure significantly 
reduced IFN-γ production to Tetanus toxoid vaccinations in infants.  
CONCLUSION  
High frequencies of MDSC are present at birth, but decrease with age in infants. Therefore 
MDSC effects on vaccine responses may be short-lived, and dependent on the type of antigen. 
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1.1 Introduction 
Immunization against vaccine-preventable infections is essential to reducing childhood 
morbidity and mortality. The complexity of the immune system of infants renders them 
susceptible to infectious diseases and makes induction of protective immunity via vaccines a 
challenge(Ota et al., 2012). Neonates are thought to predominantly make type 2 cytokines, which 
include; interleukins (IL) IL-4, IL-5, and IL-13(Lambert et al., 2005). This immunologic state 
may be beneficial in utero, but it is suggested to pre-dispose infants to severe infections. In 
contrast, Type 1 T Helper cells (Th1) that secrete interferons-gamma (IFN-), IL-2 and tumour 
necrosis factors (TNF), which are important for control of intracellular pathogens such as HIV, 
Tuberculosis, and Hepatitis B virus(Hassan, 2000), are impaired in neonatal responses to 
infections, and some vaccinations (Siegrist, 2001)(Makrigiannakis et al., 2011). In addition 
altered T cell function in neonates, innate immune cells are different from those elicited later in 
life, and this may contribute to neonatal vulnerability to pathogens(Siegrist, 2001). It is not clear 
if the decreased ability to mount antigen-specific responses is due to an inherent immaturity of 
the effector cells and antigen-presenting cells (APC), or the functions of these cells are actively 
suppressed by foetal regulatory cells induced during gestation for tolerance(Gantt et al., 
2014)(Gervassi et al., 2014). In order to contribute to developing more effective vaccination 
strategies that elicit better responses in infancy, it is helpful to understand neonatal 
immunological characteristics, including the impact of regulatory and suppressor cell 
populations. Recently in collaboration with our lab, a population of innate MDSC were 
discovered to be present in significantly high numbers in neonates, and could be responsible for 
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1.2 Myeloid-derived Suppressor Cells (MDSC) 
Myeloid-derived suppressor cells are a heterogeneous population of immature, activated myeloid 
cells with immuno-suppressive function(Poschke et al., 2012)(Gabrilovich et al., 2012)(Ostrand-
rosenberg et al., 2012)(Pillay et al., 2013). These cells, have been termed myeloid derived 
suppressor cells (MDSC) based on their myeloid origin and immunosuppressive 
nature(Gabrilovich et al., 2007). MDSC can be best defined based on their immuno-suppressive 
effect on T cells(Greten et al., 2011). MDSC are defined by phenotype into two subsets: 
granulocytic type (G-MDSC) that are often identified as CD11b+CD14-CD33+CD15+HLA-DR-, 
or the monocytic type (M-MDSC) described as CD11b+CD14+CD33+CD15-HLA-DR-(Greten et 
al., 2011). The definition of MDSC is challenging, and no consensus has been reached regarding 
the best markers in human studies(Damuzzo et al., 2015). Immature myeloid cells generated in 
the bone marrow differentiate into mature, functional macrophages, dendritic cells, and 
granulocytes. In malignancy and pathologies involving persistent inflammation, there is 
accumulation and activation of immature granulocytic or monocytic myeloid cells expressing 
suppressive factors including, Arginase-1 (ARG), reactive oxygen species (ROS), and inducible 
nitric oxide synthase (NOS)(Gabrilovich et al. 2012)(Ostrand-rosenberg et al., 2012). ARG and 
NOS, are a substantial aspect of MDSC-mediated immune suppression. ARG and NOS share a 
common substrate L-arginine, which is metabolized to produce urea and L-ornithine (or NO and 
L-citrulline) respectively(Bogdan, 2001). 
ARG depletes L-arginine which leads to extracellular or intracellular L-arginine 
starvation(Rodriguez et al., 2007)(Rodriguez et al., 2004). L-arginine starvation decreases CD3 
zeta chain expression on T-cell receptors (TCR)  and compromises TCR-mediated 
signalling(Zeng et al., 2014)(Bronte et al., 2005). NOS arrest T cell proliferation from G1 to G0 
phase of the cell cycle inducing T cell apoptosis(Marigo et al., 2008).  
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 Immune suppression by MDSC is mediated through a variety of diverse mechanisms (Figure 
1.1). In some cases, MDSC have been shown to inhibit T-cell responses in a NOS and ROS- 
dependent manner (Garg et al., 
2014). 
In other cases, the suppressive 
mechanism by which MDSC 
mediate immune responses may be 
via induction of T-regs. In 
humans, MDSC have been 
reported to enhance differentiation 
of naïve CD4+ T cells to T-
regs(Hoechst et al., 2011)(Brown 
et al., 2008). Vollbrecht et al. and 
Garg et al. found that granulocytic 
and monocytic MDSC respectively 
induced the expansion of 
CD4+CD25+FoxP3+ T-
regs(Vollbrecht et al., 2012)(Garg 
et al., 2014).  
The frequency of MDSC is low in 
healthy adults and 6-10 fold 
increased in cancer 
patients(Gabitass et al., 2011). 
While many studies on these cells has focussed on MDSC in murine cancer models and humans 
with malignancy(Poschke et al., 2012), little is known about the role of MDSC in healthy people.  
In healthy pregnancy, the immune environment in pregnant women during gestation is altered. 
Pregnant women are relatively immune compromised, which is thought to be due to the need for 
maternal-foetal tolerance (Nair et al., 2015)(Serafini, 2013). High frequency of T regulatory cells 
 
Figure 1.1: MDSC suppress immunity through different 
mechanisms. The production of Arginase and ROS, the nitration 
of the TCR, cysteine deprivation, and the induction of T-regs 
suppress T cell activation. The down-regulation of IL-12 
producing macrophages, the increase in MDSC production of IL-
10, and the suppression of NK cell cytotoxicity impair innate 
immunity. MDSC expansion limits Ag presentation at the cost of 
DC [From (Ostrand-Rosenberg et al., 2009)]. 
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(T-regs) have been shown in pregnancy, and T-regs have been found to induce MDSC(Burt, 
2013)(Gantt et al., 2014)(Bansal, 2010)(Nair et al., 2015)(Ostrand-rosenberg et al., 2012). 
Indeed, pregnant women have recently been shown to have high MDSC frequency in peripheral 
blood(Rieber et al., 2013). High frequency of T-regs as well as MDSC could be a physiologic 
phenomenon to maintain a healthy pregnancy via the induction of foeto-maternal tolerance, 
which if compromised could lead to miscarriage(Nair et al., 2015)(Serafini, 2013). Nair et al. 
recently found that MDSC deficiency in the blood and endometrium of pregnant women was 
associated with early miscarriages(Nair et al., 2015), and the important role MDSC play to 
maintain foeto-maternal tolerance may be detrimental postnatally as MDSC may persist after 
birth. 
Since MDSC are found in high frequency in human neonates(Gervassi et al., 2014)(Rieber et al., 
2013)(Jacobson et al., 2011), it is plausible that this is due to delayed clearance of these cells 
postnatally, and that the persistence of these cells may contribute negatively in the ability of 
infants to respond to infections and vaccines.  
 
1.3 MDSC and responses to infections and vaccination 
Several factors are involved in the induction of MDSC including infections, inflammation, 
vaccines, adjuvants, and T-regulatory cells (Garg et al., 2013)(Obermajer et al., 2012)(Movahedi 
et al., 2008)(du Plessis et al., 2013)(Sui et al., 2014)(Sinha et al., 2012)(Guo et al., 
2012)(Vollbrecht et al., 2012)(Verschoor et al., 2013)(R. S. Tacke et al., 2012)(Rieber et al., 
2013)(Cripps et al., 2010)(Martino et al., 2010). Increased frequency of MDSC have been 
associated with active tuberculosis disease, and after recent tuberculosis infection, and dampen T 
cell responses(du Plessis et al., 2013)(Kumar et al., 2014). IFN-γ secreting T cells have been 
shown to enhance MDSC levels(Guo et al., 2012)(Cripps et al., 2010)(Greifenberg et al., 2009). 
Also, high IL-6 secretion in plasma enhances MDSC levels in HIV infected individuals(Garg et 
al., 2013). MDSC have been linked to viral persistence and down regulation of CD8 zeta TCR 
expression in chronic Hepatitis C infection(Zeng et al., 2014)(Cripps et al., 2010). In a murine 
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model, MDSC have been shown in Rotavirus-induced immunodeficiency and reduce lymphocyte 
responses leading to immune deficiency(Green et al., 2013).  
Although the suppressive effect of MDSC in several infection states have been well described 
(du Plessis et al., 2013), (Tacke et al., 2012), (Pallett et al., 2015)(Weber, 2015)(Garg et al., 
2013)(Macatangay et al., 2012), MDSC have also been shown to induce certain beneficial 
effects. Interferon gamma secreting MDSC have been shown to protect against invasive group A 
streptococcus infection(Matsumura et al., 2012). Most recently, Pallet et al. showed that MDSC 
regulate hepatitis B liver immunopathology metabolically in hepatitis B infection(Pallett et al., 
2015)(Weber, 2015).  
There is limited data on the effect of MDSC on immune responses to vaccines in infants. There 
is evidence of vaccine induced MDSC in adult macaques, which can dampen vaccine-induced 
immune responses(Sui et al., 2014). Rieber et al. showed that MDSC cause alteration of both 
innate and adaptive immune responses in cord blood to non-specific stimulation(Rieber et al., 
2013). We have also shown that in neonates, MDSC dampens T cell responses in cord blood to 
polyclonal stimulation(Gervassi et al., 2014). There is little or no information about the effect of 
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1.4 Infants and maternal Human Immuno-deficiency Virus (HIV) 
Human Immuno-deficiency virus (HIV)-1 infection is still a major pandemic. It causes Acquired 
Immunodeficiency Syndrome (AIDS) and is one of the world’s most serious health and 
development challenge(UNAIDS, 2012)(UNAIDS, 2011b). Currently, approximately 34 million 
people have died of 
AIDS-related causes 
since the first cases 
were reported in 




2011a).  Almost all 
cases of HIV (97%) 




SSA(The Henry J. Kaiser Family Foundation/UNAIDS, 2012). Over 3.5 million women of 
childbearing age are infected annually with HIV in SSA and large numbers of children are born 
to HIV-positive women(UNAIDS, 2012). Figure 1.2 depicts global HIV prevalence rates. 
It is estimated that there are more than 2 million children infected with HIV-1 worldwide and 
that more than 1800 new HIV infections occur daily from mothers to infants(UNAIDS/WHO, 
2006). Transmission rate can be reduced to as low as 1-2% with the use of antiretroviral therapy 
(ART) (UNAIDS, 2012). Through Prevention of Mother to Child Transmission (PMTCT) 
programs, this leaves an ever-increasing number of HIV-exposed, uninfected (HEU) infants.  
 
 
Figure 1.2: Adult HIV Prevalence Rate [Age: 15-49, Source: (UNAIDS, 2012)] 
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1.4.1 MDSC and Human Immuno-deficiency Virus (HIV) 
The immune system of HIV infected is compromised and makes them prone to common 
infections and altered responses to vaccination(Epalza et al., 2010). High frequencies of 
monocyte derived MDSC levels have been shown in the peripheral blood mononuclear cells 
(PBMC) of HIV positive individuals compared to healthy controls(Qin et al., 2013), and there is 
evidence that MDSC suppress T cell function in HIV-1 infection. Based on the elevated levels of 
MDSC in HIV infection, this suggests that the surge in MDSC levels may be a mechanism by 
which HIV mediates suppression of the immune system.  
HIV infection has long been causally related to T cell activation, considered to be the central 
mediator of HIV pathogenesis(Hunt, 2007)(Andrieu et al., 2014). High T cell activation levels 
have been shown to predict more rapid disease progression in untreated patients and decreased 
treatment-mediated CD4+ T cell gains during antiretroviral therapy. This may be the primary 
aspect distinguishing pathogenic from non-pathogenic HIV infection(Vollbrecht et al., 
2012)(Lieberman et al., 2010)(O’Connell et al., 2011). It is therefore possible that MDSC are 
induced in response to the extreme immune activation during HIV infection(Qin et al., 
2013)(Gama et al., 2012)(Nagaraj et al., 2013). On the other hand, MDSC may suppress antiviral 
responses and therefore play a role in AIDS pathogenesis(Gama et al., 2012)(Garg et al., 2013). 
HIV-1 gp120 has been shown to induce expansion of MDSC in vitro? and hence suppress 
immunity to anti-CD3CD28, and these data suggest a phenotype that may be linked to viral 
replication(Garg et al., 2013). Further, it has been shown that HIV-1 gp120-induced MDSC 
dampens CD4+ and CD8+ T cell responses in a cell-to-cell contact fashion(Garg et al., 2013). 
Chronic progressive HIV-1 infection has been shown to be associated with increased levels of 
MDSC(Vollbrecht et al., 2012). The HIV-1 gp120-induced MDSC have been shown to enhance 
T-regs expansion and IL-10 production by CD4+ T cells(Garg et al., 2013).  
In a non-human primate macaque model, vaccine-induced MDSC have been shown to dampen 
protective immunity to SIV in vaccinated macaques(Sui et al., 2014). However, little is known 
about the effect of MDSC in HIV-exposed uninfected infants.  
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1.5 HIV-exposure in infants 
The absence of an effective HIV vaccine requires innovative approaches, immunology of several 
immune cells to provide new information into vaccine development. While the immunobiology 
of regulatory T cells has been studied intensively in non-human primates(Connor et al., 
2007)(Bumseok et al., 2009)(Gama et al., 2011) and HIV-unexposed (HEU) infants(Mold et al., 
2009), there is little data about how regulatory T cells and MDSC could hinder vaccine responses 
in HEU especially in sub-Saharan Africa (SSA)(Legrand et al., 2006). 
HIV-exposed but uninfected (HEU) infants are infants born to HIV-infected mothers but escape 
HIV infection(Afran et al., 2013). An estimated two million infants are exposed in utero to HIV 
of which an approximately 1.5 million are HIV uninfected. Moreover, due to the high maternal 
HIV prevalence in SSA coupled with the successful and ever improving prevention of mother-to-
child transmission (PMTCT) programs in many parts of the world(Mbori-ngacha et al., 2001), 
there is a growing proportion of HEU infants (Filteau, 2009).  
 
1.5.1 Alterations in the immune system of HEU infants 
HIV-exposed but uninfected infants are a group of vulnerable infants with increase morbidity 
and mortality compared to the HIV-unexposed (HU) infants(Epalza et al., 2011)(Kuhn et al., 
2006)(Mussi-pinhata, 2006)(Marinda et al., 2007)(Kidzeru et al., 2014). Maternal 
immunosuppression due HIV infection tends to have adverse influence on the health of infants in 
addition to the risks of vertical HIV transmission(Kuhn et al., 2006). However, Zambian HIV 
exposed infants who remained uninfected after perinatal or early breastfeeding-related HIV 
exposure were of high risk of mortality and morbidity (pneumonia and/or sepsis) during the first 
few months of life regardless of their maternal disease stage or Socioeconomic status(Kuhn et 
al., 2006).   
Skin/mucous membrane infections and respiratory tract infections are common infections 
observed in HEU infants more often than HIV-unexposed infants(Mussi-pinhata, 2006)(Kidzeru 
et al., 2014). Also, the incidence of Group B Streptococcal infection is significantly higher in 
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HEU than in the unexposed infants(Epalza, 2010). There are data documenting different 
responses to vaccine immunogens(van Rie et al., 2006)(Jones, 2011)(Mazzola, Marcos, & 
Abramczuk, 2011), and an increased risk of Pneumocystis jeroveci pneumonia an opportunistic 
infection (Marinda et al., 2007)  in HEU infants. HIV-exposure has been shown to impair 
cellular immune responses in infants(Rie et al., 2006)(Mazzola et al., 2011), this impairment has 
also been shown in early life to humoral immune responses to vaccine but developed with 
age(Jones et al., 2011).  
HEU infants have increased immune activation and we have also shown increased T cell 
proliferation to antigens (Kidzeru et al., 2014), possibly as a result of in utero exposure to HIV 
antigens and/or antigens related to other infections in HIV-infected mothers(Rich et al., 1997). 
Also, elevated levels of pro-inflammatory cytokines are present in HEU infants(Hygino et al., 
2008). Both immune activation and a proinflammatory cytokine profile are known to induce 
MDSC (Davenport et al., 2007)(Lieberman et al., 2010)(Hunt, 2007).  However, the role that 
MDSC play in the immunological abnormalities caused by HIV exposure in infants has not been 
investigated. 
To improve the morbidity of this immunologically vulnerable group of infants, we need to 
understand the mechanisms of their altered immune responsiveness to determine optimal 
vaccination and disease prevention strategies.  
 
1.5.2 Cellular immunity in HEU infants 
 
We showed that HIV-exposure is associated with increased T cell proliferation to BCG, but that 
these proliferating cells are poor cytokine producers(Kidzeru et al., 2014). In a study by Mazzola 
et al, it was found that compared to HIV-unexposed infants, very young HEU infants produced 
less IFN- and TNF-α in response to BCG, but the level of IFN- produced in response to BCG 
increased with age suggesting there may be defects in immune responses early in life in HEU 
infants (Mazzola et al., 2011). We have also shown that in HEU infants, delaying BCG 
vaccination until 8 weeks of age enhances BCG-specific T cell responses(Tchakoute et al., 
2014).  
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1.6 Vaccination and immunity 
Before the Expanded Programme on Immunization (EPI) was launched in 1974, fewer than 5% 
of the world's children were immunized during their first year of life against the six killer 
Table 1.1: The EPI vaccination schedule used in South Africa;(1) BCG given at birth, (2) DTaP-IPV/Hib 
primed at 6 weeks, first, second boosters at 10, 14 weeks and third booster at 18 months of life and further at 6 
and 12 years of age  (Source: http://www.amayeza-info.co.za/) 
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diseases in that same year; polio, diphtheria, tuberculosis, pertussis (whooping cough), measles 
and tetanus(UNICEF/WHO, 2011). Today, immunization is been carried out effectively 
throughout the world, with some vaccines have been prioritized in areas where the disease 
burden is of major public health concern(CDC, 2005). Table 1.1 shows the EPI vaccination 
schedule used in South Africa.  
 
1.6.1 Vaccination 
1.6.1.1 Bacillus Calmette-Guérin (BCG) 
BCG, a live attenuated Mycobacterium bovis vaccine, is almost universally given in SSA, where 
the brunt of the global paediatric HIV burden is concentrated. BCG is usually given at birth; its 
coverage worldwide is estimated at over 100 million doses per year, resulting in vaccination of 
75% of infants born in 2002 globally. In HIV-uninfected children, BCG is safe, efficacious and 
cost-effective against disseminated tuberculosis(Trunz et al., 2006). BCG can elicit potent type 1 
responses and effective cytotoxic T cell (CTL) responses in infants, even when given at birth.  
We do not know, however, how efficacious BCG is in HEU infants, although some evidence 
suggests that it may not be as immunogenic as in HU infants(Rie et al., 2006)(Mazzola et al., 
2011). Recently in our lab we found that BCG induces significantly higher T-cell proliferation in 
HEU than in HU infants(Kidzeru et al., 2014). Also, we showed that in HEU infants, delaying 
BCG vaccination until 8 weeks of age enhance robust BCG-specific T cell responses(Tchakoute 
et al., 2014). Owing to the fact that neonates are potent type 2 cytokines (IL-4, IL-5, IL-13) 
producers(Lambert et al., 2005) important for B cell development, neonatal T cell response to 
HIV and BCG vaccination may be an ideal model for an HIV vaccine study. BCG is widely 
known to elicit Th1 responses and although the correlate of protection is unknown, induction of 
IFN-γ is thought to be important in protection against TB(Beveridge et al., 2008)(Mansoor et al., 
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1.6.1.2 Tetanus toxoid (TT) 
Tetanus is a deadly infectious disease for which immunization is available in EPI schedules of 
most countries worldwide and tetanus boosters are recommended every 5 – 10 years for 
everyone(Aziz, 2010). Tetanus results from infection with Clostridium tetani, a commensal 
bacterium in the gut of humans and domestic animals which is found also in soil. It is not the 
presence of the bacteria which causes disease, but the toxins that are produced by the bacteria 
under anaerobic conditions(CDC, 2005). These toxins can be spread through the blood vessels 
and finally affect the nervous system causing tetanic muscle contraction and pain. The condition 
is extremely painful and potentially lethal(Aventis Pasteur, 1989)(Gaublomme, 2007).  
In South Africa, immunization against tetanus is carried out by the administration of DTaP in 
infants and dTap in adults, both containing Tetanus toxoid with aluminium hydroxide as an 
adjuvant, and the vaccine is available in combination with other antigens as well as alone. 
Tetanus vaccine is available on the EPI schedule in many countries for children at 6, 10 and 14 
weeks and at 18 months of age(CDC, 2012)(Gaublomme, 2007). Tetanus toxoid vaccination is 
widely known to elicit antibody responses and the correlate of protection is known to be the 
induction of serum IgG(Claire-anne Siegrist, 2008), and this has been shown in HIV-exposed 
uninfected infants(Jones et al., 2011). Therefore, little is known about tetanus toxoid induced T 
cell responses. However, in healthy children tetanus toxoid vaccine responses have been shown 
to be initially Th2 polarized(Rowe et al., 2000), also, Cooper et al. have shown impaired 
Tetanus-specific cellular immune responses after tetanus vaccination(Cooper et al., 1998). 
Cellular immune responses to tetanus vaccination have been shown to contribute to long-term 
immunity(Graziani et al., 2013).  
 
1.6.1.3 Acellular Bordetella Pertussis (aP) 
Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium Bordetella 
pertussis. Pertussis was one of the most common childhood diseases in the 20th century and a 
major cause of childhood mortality in the United States. Before the availability of pertussis 
vaccine in the 1940s, more than 200,000 cases of pertussis were reported annually. Since the 
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widespread use of pertussis vaccination began, incidence has decreased more than 80%(Mooi et 
al., 2009)(States, 2008). Two forms of vaccines have been used (i) Whole-cell pertussis vaccine 
(wP) and (ii) acellular Pertussis vaccine (aP). The wP vaccine is composed of a suspension of 
formalin-inactivated Bordetella pertussis cells. Whole-cell Pertussis vaccine is 70%-90% 
effective in preventing serious pertussis disease. However, its protection decreased with time, 
resulting in little or no protection 5 to 10 years following the last dose. Reactions such as 
redness, swelling, and pain at the injection site, fever and other systemic events were relatively 
common with wP (CDC, 2005)(Demirjian et al., 2009). This raised concerns about its safety and 
led to the development of more purified (acellular) Pertussis vaccines that was associated with a 
lower frequency of adverse reactions. South Africa is the only African country using aP, the rest 
are using wP. 
 
Acellular Pertussis vaccines are subunit vaccines that contain purified, inactivated components of 
Bordetella pertussis cells(Sato, 1999). Several acellular Pertussis vaccines have been developed 
for different age groups; these contain different Pertussis components in varying concentrations 
which include; the paediatric formulation (DTaP) often available in combination with other 
antigens [Infanrix hexa™ (DTaP-hepB-IPV-Hib); Infanrix-IPV™ (DTaP-IPV); Infanrix Penta™ 
(DTaP-hepB-IPV)]. The adolescent and adult formulation (dTap) has four types available 
containing reduced Pertussis antigen content in comparison to the vaccines for young children 
[Boostrix™ (dTap) and Boostrix-IPV™ (dTap -IPV), and Adacel™ (dTap) and Adacel Polio™ 
(dTap-IPV) (available since 2005)](NCIRS, 2009). Pertussis vaccine is available on the EPI 
schedule in many countries for children at 6, 10 and 14 weeks and at 18 months of age(Gebhart, 
1980). An adolescent booster dose is available via school-based programs at 12-17 years of age 
which vary by countries(CDPH, 2010)(NCIRS, 2009). There is some data about Bordetella 
pertussis induced T cell responses, Ross et al. have shown that Th1 and Th17 both contribute to 
protective immunity by wP immunization but aP induce Th2 and Th17 cells but week Th1 
responses(Ross et al., 2013). Also, long term pertussis-specific T cell responses were observed 
after primary vaccination in HIV-unexposed infants(Esposito et al., 2001). We recently showed 
that pertussis vaccination caused equal T cell proliferation in both HIV-unexposed and HIV-
exposed uninfected infants(Kidzeru et al., 2014). Bordetella pertussis vaccination is known to 
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elicit antibody and CD4+ T cell responses, and the correlate of protection is known to be the 
induction of serum IgG(Claire-anne Siegrist, 2008). 
 
1.6.1.4 Hepatitis B (Hep B) 
Hepatitis B virus (HBV) is the major cause of cirrhosis and liver cancer resulting in 
approximately 620,000 deaths annually worldwide(Goldstein et al., 2005). Infections acquired 
during the perinatal period, in early childhood (<5 years old), and ≥5 years of age accounted 
for 21, 48, and 31% of Hepatitis B deaths, respectively(Goldstein et al., 2005). Two major 
modes of HBV transmission occur during infancy;  
(1.) Perinatally from an infected mother during delivery, and  
(2.) From infected household contact to the infant.  
Perinatal transmission accounts for approximately 21% of HBV-related deaths 
globally(Goldstein et al., 2005). Transmission of HBV is prevented through immunization(Lu 
et al., 2008); universal neonatal and infant hepatitis B vaccine, a sub-unit/conjugate vaccine 
which induces antibody against hepatitis B surface antigen (anti-HBs), has proved to be highly 
effective against  HBV infection(YEN et al., 2007). In 1992, the World Health Organization 
(WHO) recommended all countries to introduce hepatitis B (Hep B) vaccine into national EPI 
schedule by 1997(CDC, 2007), this resulted in a significant decrease in prevalence of chronic 
HBV infection in most parts of the world(EI-HWEI et al., 1997)(Chen et al., 1999)(Su et al., 
2007). It is estimated that without vaccination, 64.8 million would become HBV-infected and 
1.4 million would die from HBV-related disease since 2000. In countries with high percentage 
of HBV infection, WHO recommends administration of the first dose of Hep B vaccine <24 
hours after birth to prevent perinatal HBV transmission(CDC, 2008) and also provides early 
pre-exposure protection to infants born to HBV uninfected mothers if exposure were to occur 
and the risk of developing chronic HBV infection is greatest and consequently death(Mast et 
al., 2005).  
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However, administration of Hep B vaccine at birth is not feasible in developing countries where 
Hepatitis B is highly endemic, as is a practice that often results in missed post-exposure 
prophylaxis of infants(Mast et al., 2005). In South Africa, Hep B vaccine is first administered at 
6 weeks of age when EPI programs in most developing countries initiate administration of other 
vaccines to infants(Department of Health, 2009). Hep B vaccination is widely known to elicit 
antibody responses and the correlate of protection is known to be the induction of serum 
IgG(Claire-anne Siegrist, 2008). The current Hep B vaccine has been shown to be highly 
immunogenic in infants(Wang et al., 2011). Few studies have looked at Hepatitis B humoral 
immune responses in HIV-exposed uninfected infants, (Rustein et al., 1994) and little is known 
about cellular immunity to Hepatitis B in this vulnerable group. Mizukoshi et al. showed that 
Hep B vaccine immune responses were more stronger during acute, self-limiting and after 
recovery than during chronic hepatitis B infection(Mizukoshi et al., 2004). Hep B vaccination 
known to elicit antibody responses(Claire-anne Siegrist, 2008), and this has been shown in HIV-
exposed uninfected infants(Jones et al., 2011)(Abramczuk et al., 2011).It should be noted that 
HIV-infected mothers are more likely to transmit HBV to their neonates than HIV-negative 
women.  
Hence, HIV exposure together with high frequency of MDSC in neonates could hinder vaccine 
immune responses in South African infants. In this study we will look at the quantity and 
ontogeny of MDSC in infants and how MDSC influence cellular immune responses to vaccines 
critical for providing information towards protection of infants from infectious diseases.  The 
ultimate goal is to design interventions to improve the health of infants, especially HEU infants, 
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1.7 Introduction to the thesis 
Hypothesis  
We hypothesise that MDSC, present during gestation for fetomaternal tolerance, might persist 
into infancy, leading to active suppression of infant immune responses, which wanes over time. 
We further hypothesize that due to heightened MDSC in HIV-infection, HEU infants may have 




We aim to evaluate the effect of MDSC on immune responses to EPI vaccines. To this end we 
have three specific objectives: 
1. To evaluate the quantity and ontogeny of MDSC in infants and their mothers from birth 
to one year postpartum 
Hypothesis 
The prevalence of MDSC will diminish with age and become comparable to that of adults by one 
year of life. MDSC frequency will be high immediately after delivery in mothers, and decrease 
by one year postpartum. MDSC frequency will be lower in HU infants and HIV-negative 
mothers, compared to the HEU and HIV-positive infants and mothers respectively. 
  
2. To assess the effect of MDSC on T cell proliferative responses to vaccines in infants and 
their mothers from birth to one year postpartum 
Hypothesis 
MDSC inhibit proliferative responses to vaccination in infants and their mothers. T cell 
proliferation will be lower in infants exposed to HIV and mothers infected with HIV due to the 
effects of higher frequencies of MDSC.    
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3. To assess the effect of MDSC on cytokine production to vaccines in infants and their 
mothers from birth through one year postpartum 
Hypothesis 
MDSC will inhibit cytokine in response to vaccination in infants and their mothers.Cytokine 
responses will be lower in infants exposed to HIV and mothers infected with HIV due to the 
effects of higher frequencies of MDSC.    
 
Finally, to all the objectives, we aim to evaluate the effect of HIV-exposure or infection on 
MDSC frequency and function i.e. on all the above parameters. 
 
Rationale 
Studies focus on MDSC in murine cancer models and humans with malignancy. High 
frequencies of MDSC are found in peripheral blood of healthy neonates. Yet little is known 
about the effect of these MDSC on vaccine immune responses in infants. HIV-exposed infants 
display relative immune deficiencies. Understanding the impact of MDSC on immune responses 
of HIV-exposed infants will contribute to guide with design of neonatal HIV vaccines and other 
vaccines for this vulnerable group of infants.
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2.1 Study design 
This was a prospective longitudinal observational cohort study. 
The outcome measures were MDSC quantity and ontogeny, as well as T cell proliferation and 
IFN- production in response to Bacillus Calmette-Guérin (BCG), tetanus toxoid (TT), 
Bordetella pertussis (BP) and Hepatitis B surface antigen (Hep. B) with and without MDSC in 
infants at, 6, 10 and 14 weeks;  and at 6 and 9 months and 1 year of age (Figure 2.1). 
This study was exploratory, since the true variance of MDSC frequency during infancy was 
unknown. As our primary outcome, using estimates based on our preliminary cord blood and 
cross-sectional data during infancy, with a sample size of 100 infants, the study had an 80% 
power (2-sided, alpha = 0.05) to detect an inverse correlation of at least 0.3 between MDSC 
frequencies at the time a given vaccine was administered and immune responses to that vaccine, 
such as antigen-specific T cell responses. All of these estimates were highly conservative, 
 
Figure 2.1: Study design. Participants recruitment and follow-ups in Khayelitsha, Midwife Obstetric 
Unit (MOU), site B, Western Cape Province. HIV test done to HIV-exposed uninfected infants (HEU) 
only, respective vaccines administered to the infants and blood samples collected from both infants and 
mothers at respective time points. 
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however, as they assumed comparisons at only a single time point. Additional power was 
obtained using longitudinal data from all infants. 
 2.1.1 Participants and blood collection 
This thesis is censored after 70 infants-mother pairs were enrolled into the cohort. Participants 
were mothers and their infants, regardless of HIV infection status. After informed consent was 
obtained, whole blood and/or cord blood of neonates, as well as whole blood from mothers was 
collected. Infants were followed up at 6, 10 and 14 weeks; and at 6 and 9 months; and finally at 
one year, and blood was obtained at these visits prior to vaccinations where applicable. In 
addition, maternal blood was collected at one year postpartum. The participant recruitment 
process involved completion of a screening form for eligibility assessment (see section 2.1.3) 
after informed consent was obtained. Physical examination including knowledge about maternal 
HIV status and health, infant gestational age, maternal history on antenatal clinic visits during 
gestation, parameters such as gestational diabetes, eclampsia, preeclampsia and placental 
abruption. The participant contact form was completed for follow up reminders. 
2.1.2 Recruitment of participants 
2.1.2.1 Study setting 
Infants-mother pairs were recruited from Khayelitsha at the Midwife Obstetric Unit (MOU) at 
site B, Western Cape Province. Khayelitsha is historically an informal settlement located 56 km 
from the centre of Cape Town, with an estimated population of 500 000(Nelson, 2014)(van 
Pletzen et al., 2013). Antenatal (ANC) HIV seroprevalence rose from 19.3% in 2000 to 29% in 
2009, and to 37% in 2011 and is the highest in the Western Cape(Stinson et al., 2014)(Nelson, 
2014). Site B has good existing research capacity and with established prevention of mother-to-
child transmission (pMTCT) and pediatric antiretroviral (ARV) clinics(Stinson et al., 2014). The 
mother to child transmission (MTCT) rate in the district as a whole was 2.7% in 2011 (Goga et 
al., 2014). The Western Cape has one of the highest tuberculosis (TB) rates globally, with an 
infant TB rate estimated (culture-confirmed) at 1596 cases per 100,000 population among HIV-
infected infants (95% CI, 1151-2132) and 66 cases per 100,000 population among HIV-
uninfected infants (95% CI, 56-75)(Hesseling et al., 2009). BCG and oral polio vaccine (OPV) 
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are routinely given at birth. Since April 2009, infants receive Rotavirus vaccine (RV) at 6 and 14 
weeks and three doses of Diphtheria-Tetanus-aPertussis(DPT)-iPV/Hib, Hepatitis B, and 
pneumococcal conjugate (PCV) vaccinations at 6, 10 and 14 weeks of age(Department of Health, 
2009) (Table 1.1)(Figure 2.1). In South Africa, pregnant women are not routinely given Tetanus 
toxoid vaccine boosters during gestation.   
2.1.3 Exclusion criteria and HIV testing 
2.1.3.1 Exclusion criteria 
For both groups of infants, exclusion criteria included the following; 
1. Mother was not willing and able to give consent 
2. Baby weighed less than 2.4 kg 
3. Baby was not healthy (presented with sepsis/ convulsions/ asphyxia/ severe respiratory 
distress/ severe congenital abnormality) 
4. Mother or anyone in her house had known TB or a cough; then she was refered to the TB 
clinic. 
5. Mother was planning to move herself or the infant away from Khayelitsha in the next 12 
months 
6. Prematurity (i.e. <36 weeks) 
7. Mother was younger than 18 years 
Additionally for the HIV-exposed infants, eligibility was based on the following; 
1. Infant HIV DNA PCR test was negative at 6 weeks after birth 
 
2.1.3.2 HIV testing 
a.  For HIV-exposed infants, HIV testing was performed routinely by the pMTCT program at 6 
weeks of age and, if breastfeeding, at 6 weeks after cessation of breastfeeding or at 9 months, 
whichever was earliest. Infants were excluded if they test positive for HIV infection.  
b.  If the mother’s HIV status was positive, the infant was tested for HIV infection according to 
local standard of care and if positive, was excluded from further follow-up and from the analysis. 
Any infected infants were immediately referred for HIV treatment and care. 
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2.2 Characteristics of the cohort 
We evaluated the characteristics of 70 mother-infant pairs recruited, which included 24 HIV-
infected women and their exposed uninfected (HEU) infants, and the remainder (46) HIV-
negative women and their unexposed (HU) infants. In total 70 mother-infant pairs were recruited 
at delivery, 39 followed up at 6 weeks, 32 at 10 weeks, 30 at 14 weeks, 20 at 6 months, 15 at 9 
months and lastly 14 infant-mother pairs completed the study at one year postpartum. 
Among the infants there were 30 female (12 HEU and 18 HU] and 40 male [12 HEU and 28 
HU], there was no significant difference between HIV-exposure groups (p=0.383) (Table 2.1).  
Among all the parameters recorded, birth weight (p=0.019), weight at 6 months (p=0.048), and 
the weight at 9 months (p=0.007), were all significantly lower in the HEU infants. Also, a 
significantly lower frequency of HEU infants were breastfed (BF) at birth (p=0.004), 6 weeks 
(p=0.022), 14 weeks (p=0.031) and at 6 months (p=0.007) compared to HU infants (Table 2.1). 
The percentage (%) of HEU versus HU infants that were breastfed (BF) at 10 weeks [i.e. 66.7% 
versus 86.2%, p=0.099], at 9 months and at one year were not significantly different (Table 2.1). 
The median and the interquartile range (IQR) of the weight of the HEU versus HU infants at 6 
weeks [i.e. 4.3 (3.7-4.5) Kg versus 4.2 (4.2-4.8) Kg, p=0.258] as well as the weight at 10 weeks, 
14 weeks and one year were not significantly different (Table 2.1). Also, there were no 
significant differences in the median gestational age between groups, as well as the percentage of 
common infections between HEU compared to the HU infants at all-time points by history 
(Table 2.1).  
All mother infected with HIV were on antiretroviral (ARV) therapy, as well as in the prevention 
of mother to child transmission (PMTCT) program during pregnancy. Also, all infants born to 
HIV infected mothers were given nevirapine for at least 6 weeks. 
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Table 2.1: Characteristics of the cohort between HEU versus HU infants at 6 and 14 weeks of life; 
the read outs for each parameter is indicated as medians and interquartile ranges (IQR) as well as in 
percentages (%) and p-values with red fonts illustrate parameters that were significantly different between 
HEU vs. HU infant groups i.e. p-values<0.05, statistical significance was obtained using **Rank sum, 
*Chi square or $Fisher’s exact tests. 







Gender Male/Female (%) 28/18 (70%/60%) 12/12 (30%/40%) 0.383* 
Median birth weight (Kg)  (IQR) 3.2 (3.0-3.5) 3.0 (2.8-3.1) 0.019** 
Median weight at 6 weeks (Kg) (IQR) 4.2 (4.2-4.8) 4.3 (3.7-4.5) 0.258** 
Median weight at 10 weeks (Kg) (IQR) 5.4 (4.9-5.9) 5.4 (5.2-5.7) 0.920** 
Median weight at 14 weeks (Kg) (IQR) 6.1 (5.7-6.6) 5.7 (5.4-6.4) 0.545** 
Median weight at 6 months (Kg) (IQR) 7.6 (7.4-8.8) 6.9 (6.6-7.8) 0.048** 
Median weight at 9 months (Kg) (IQR) 8.9 (8.4-9.5) 7.4 (6.4-7.8) 0.007** 
Median weight at 1 year (Kg) (IQR) 9.9 (9.1-10.3) 9.7 (8.5-9.8) 0.275** 
Breastfed (BF) at birth (%) 100% 79.2% 0.004$ 
Breastfed (BF) at 6 weeks (%) 93.5% 69.2% 0.022$ 
Breastfed (BF) at 10 weeks (%) 86.2% 66.7% 0.099$ 
Breastfed (BF) at 14 weeks (%) 92% 55.6% 0.031$ 
Breastfed (BF) at 6 months (%) 82.4% 37.5% 0.007$ 
Breastfed (BF) at 9 months (%) 70.6% 40% 0.077$ 
Breastfed (BF) at 1 year (%) 83.3% 50.0% 0.099$ 
Median gestation age in weeks (IQR) 39.3 (38-40) 38.5 (37.8-40.1) 0.349** 
Median maternal CD4 count (cells/mL) (IQR) ~ 275 (176-381)  
Morbidity (%): 
Birth to 6 weeks 
- Cough/fever 
- Diarrhoea 
- Skin rash 
6 weeks to 10 weeks 
- Cough/fever 
- Diarrhoea 
- Skin rash 
10 weeks to 14 weeks 
- Cough/fever 
- Diarrhoea 
- Skin rash 
14 weeks to 6 months 
- Cough/fever 
- Diarrhoea 
- Skin rash 
6 months to 9 months 
- Cough/fever 
- Diarrhoea 
- Skin rash 
9 months to 1 year 
- Cough/fever 
- Diarrhoea 
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2.3 Discussion 
In this observational cohort, there were some significant differences between HIV-exposed 
uninfected infants and their unexposed counterparts. The median birth weight of HIV-exposed 
uninfected (HEU) infants was significantly lower compared to the HIV-unexposed (HU) infants, 
as well as some of the time points postnatally. Lower birth weight and poor growth has been 
described before in previous cohorts(Rollins et al., 2013)(Mussi-pinhata et al., 2006)(C. Epalza 
et al., 2010)(Kuhn et al., 2006)(Mazzola et al., 2011)(Filteau, 2009)(Jones et al., 2011)(Kidzeru 
et al., 2014). In a separate cohort, we found some of these differences observed in this study 
(Kidzeru et al., 2014). We found that HEU infants had a significantly lower birth weight and 
weight at 6 and 14 weeks of age were significantly lower in the HEU infants compared to their 
un-exposed counterparts(Kidzeru et al., 2014). However, these differences were not observed at 
all time points, and the differences disappeared by one year after birth. These differences could 
be due to the lower proportion of breastfed infants among the HEU.  
It has been recommended by WHO that infants in developing countries born to HIV infected 
mothers be exclusively breastfed, since this improves HIV-free survival(UNAIDS/WHO, 
2010)(Yezingane Network and UNICEF, 2011). Exclusive breastfeeding has been shown to be 
safer compared to mixed feeding for infants born to HIV-positive mothers(Thomas, 2007). There 
is substantial evidence that HIV infected mothers who exclusively breastfed have a lower risk of 
transmitting HIV to their infants(Coutsoudis et al., 2001)(Coutsoudis et al., 1999)(Coutsoudis et 
al., 2001).  All HIV infected mothers were on ART and PMTCT and all HEU infants were given 
nevirapine (NVP) for up to 6 weeks postnatally. All infants regardless of HIV-exposure were 
breastfeed at all-time points except at 6 weeks, 14 weeks and at 6 months postnatally were the 
frequency of breastfeed HEU infants were significantly lower compared to their unexposed 
counterparts. In a separate cohort by Kidzeru et al., all HIV infected mothers were on HAART 
and PMTCT, and also, HEU infants were administered NVP(Kidzeru et al., 2014). We found 
that the proportion of women who intended to exclusively breastfeed (EBF) infants were 
significantly lower in the HEU infants compared to their un-exposed counterparts(Kidzeru et al., 
2014).        
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Some of the differences we have observed here could have an effect on vaccine immune 
responses in these infants. However, we have also earlier shown that after a linear regression 
estimating the association between HIV exposure and T cell proliferation including other a priori 
confounders, HIV exposure was significantly associated with better CD4+ proliferative responses 
to BCG and staphylococcal enterotoxin B (SEB) after adjusting for birth weight, feeding mode 
and gestational age(Kidzeru et al., 2014). Also, maternal CD4+ cell count was not significantly 
associated with CD4+ or CD8+ T cell proliferation. The maternal median duration of exposure to 
antiretroviral was not a predictive factor of CD4+ or CD8+ proliferative responses to BCG and 
SEB(Kidzeru et al., 2014). Therefore, HIV-exposure may play a role amidst the other factors 
between the groups that could potentially affect MDSC frequency. 
Moreover, the main aim of this study is to evaluate the effect of MDSC on immune responses to 
EPI vaccines in infants and mothers as well as in HEU versus HU infants, and their HIV infected 
and uninfected mothers.  We evaluated the quantity and ontogeny of MDSC, the effect of MDSC 
on T cell proliferation and the effect of MDSC on cytokine production to vaccines and antigens 
in infants and mothers. We evaluated these differences generally, and in a sub-analysis between 
HEU versus HU infants from birth, followed-up at 6, 10 and 14 weeks, at 6 and 9 months and at 
one year postnatally; and between HIV+ versus HIV- mothers at delivery and at one year 
postpartum.
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3.1 Introduction 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of activated immature 
myeloid cells with suppressive function(Poschke et al., 2012)(Ostrand-Rosenberg et al., 
2012)(Gabrilovich et al., 2007). These cells have been well described in cancer patients and very 
few can be found in healthy adults(Gabrilovich et al., 2012)(Gantt et al., 2014). MDSC can be 
divided into two different subtypes, either granulocytic or monocytic. In our group, we showed 
that the frequency of M-MDSC were less than 1% of live cells in healthy individuals, and did not 
differ significantly between cord blood and adult peripheral blood(A. Gervassi et al., 2014). 
Granulocytic MDSC are not generally seen at elevated frequencies in healthy adults and have 
recently been described in healthy infants(Rieber et al., 2013). In our group, the granulocytic 
MDSC that we observed in cord blood highly expressed CD15(Gervassi et al., 2014) (Figure 
3.1). Hence, throughout the remainder of this thesis we will use MDSC synonymously with G-
MDSC. 
Tolerance and an anti-inflammatory state that may be induc ed by Tregs as well as MDSC during 
gestation are beneficial for full-term viviparity(Nair et al., 2015)(Makrigiannakis et al., 
2008)(Makrigiannakis 
et al., 2011)(Bansal, 
2010). This same 
immune tolerance is 
also observed in 
certain pathologic 
conditions such as 
cancer and persistent 
inflammatory states, 
and the accumulation 




















































         
Figure 3.1: (a) Representative plot depicting CD15+ MDSC in infant blood. 
Data are gated on CD33+HLA-DR-CD14-CD11b+CD15+ live mononuclear cells 
(MNCs). (b) Quantity of MDSC in adults and infants. Frequency of 
CD33+HLA-DR- CD14- CD11b+CD15+ MDSC in adult (n=21) or cord blood 
(n=23) samples(Fig. 3.4b modified from Gervassi et al., 2014). 
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suppressive factors including Arginase-1 (Arg), reactive oxygen species (ROS), and inducible 
nitric oxide synthase (NOS) have been found (Poschke et al., 2012)(Gabrilovich et al., 
2012)(Ostrand-Rosenberg et al., 2012). Most research on MDSC to date has focused on murine 
cancer models and in humans with malignancy(Poschke et al., 2012)(Gabrilovich et al., 
2012)(Ostrand-Rosenberg et al., 2012). Our group and others have observed high frequency of 
granulocytic (G)-MDSC in cord blood and maternal blood during pregnancy(Rieber et al., 
2013)(Gervassi et al., 2014). This environment may persist after birth leading to increased levels 
of MDSC that may have suppressive effects on the infant’s immunity. Using Wright-Giemsa 
cytospin staining on cord blood mononuclear cells (CBMC) (Figure 3.2), we recently showed 
that MDSC in infants are predominantly made up of a population of immature myeloid cells 
distinct from mature neutrophils. MDSC predominantly made up of population of immature 
myeloid cells with hypodense neutrophils, Metamyelocytes, band neutrophils and myelocytes, 
whereas mature neutrophils consisting of mature myeloid cells(Gervassi et al., 2014). In the 
haematopoietic stem cell progeny, MDSC are located at the interface between myeloblast and 
 
Figure 3.2: Wright-Giemsa cytospin of cord blood. MDSC predominantly made of population of immature 
myeloid cells [**** Hypodense neutrophils (47-69%), ***Metamyelocytes (11-25%), **Band neutrophils (7-
16%), Myelocytes *(6-8%)]; mature neutrophils made up of mature myeloid cells(Modified from Gervassi et 
al., 2014). 
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monocytes for the monocytic MDSC, or myeloblast and neutrophils for the granulocytic MDSC 
(Figure 3.3). These cells can either mature to monocytes and neutrophils respectively.  In this 
chapter, we aim to evaluate the quantity and ontogeny of granulocytic MDSC in infants from 
birth to one year of life and in mothers at delivery and one year postpartum.  
3.1.1 Myeloid Derived Suppressor Cells (MDSC) presence and ontogeny 
Several studies have measured MDSC by identifying different cellular markers including the 
expression of CD14 (Monocytic MDSC)(Qin et al., 2013)(Schlecker et al., 2012)(Kotsakis et al., 
2012), CD15 (Granulocytic MDSC)(Pillay et al., 2013)(Khaled et al., 2014)(Trellakis et al., 
2013)(Rieber et al., 2013)(Kotsakis et al., 2012)(Gervassi et al., 2014) and the potential 
immuno-suppressor molecule Arginase (Arg) (Greten et al., 2011)(Gervassi et al., 2014). 
 
Figure 3.3: Progeny of myeloid derived suppressor cells (MDSC). MDSC can be located at the interface of 
transition between myeloblast and neutrophils (red arrow) for the granulocytic MDSC; or myeloblast and 
monocytes (green arrow) for the monocytic MDSC. These cells can further mature to neutrophils and monocytes 
respectively(Gervassi et al., 2014)(Modified from http://www.allthingsstemcell.com). 
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It has been proposed that the frequency of MDSC in mothers and foetuses is increased during 
gestation to allow tolerance between the mother and the foetus(Rieber et al., 2013)(Gervassi et 
al., 2014)(Nair et al., 2014). This has been shown to persist postnatally in infants(Gervassi et al., 
2014).  
Little is known about the effect of MDSC in HIV-exposed uninfected infants and HIV+ mothers. 
High MDSC levels have been shown in the peripheral blood mononuclear cells (PBMC) of 
HIV+ individuals compared to healthy controls(Qin et al., 2013)(Gama et al., 2012)(Vollbrecht 
et al., 2012). HIV Type 1 gp120 has been shown to induce expansion of MDSC and is suggestive 
of a typical phenotype that may be linked to viral replication(Garg et al., 2013), and MDSC have 
been shown to be induced by hepatitis C virus(Tacke et al., 2013).  Also, du Plessis et al. have 
shown an increase in MDSC in TB disease(du Plessis et al., 2013). In this chapter the effect of 
HIV-exposure on MDSC frequency in uninfected infants and HIV-infection in mothers was also 
assessed. 
Hence, in this chapter we hypothesize that in infants and mothers the MDSC frequency will 
decrease with age/time postpartum and that MDSC frequency in HIV-exposed uninfected (HEU) 
infants and HIV-infected (HIV+) mothers will be higher compared to the HIV un-exposed (HU) 
infants and HIV-uninfected (HIV-) mothers respectively. 
It must be emphasised that, the inclusion of mothers in this study is to test our hypothesis that 
MDSC are present during gestation and wane afterwards and mothers in this case are not a true 
representative of normal adults since they have just been pregnant. Also, mothers would have to 
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3.2 Materials and method 
The primary outcome measure in this chapter was the frequency of granulocytic MDSC in 
PBMC quantified by the expression of HLADR-CD14-CD33+CD11b+CD15+ cells (see Figure 
3.5). The overall process of quantifying MDSC involved three main procedures: 
      1. Peripheral/cord blood mononuclear cells (PBMC/CBMC) isolation 
2. Glycophorin A micro beads red blood cell (RBC) depletion technique 
3. Flow cytometry [MDSC cellular staining characterisation] 
 
Figure 3.4: Peripheral/cord blood mononuclear cells (PBMC/CBMC) isolation using Ficoll density-
gradient medium (Modified from http://textbookhaematology4medical-scientist.blogspot.sg/). 
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3.2.1  Peripheral/cord blood mononuclear cells (PBMC/CBMC) isolation  
Between 1-5mL whole/cord blood was collected from infants at birth, 6, 10 and 14 weeks; at 6 
and 9 months and one year of age. From mothers, about 10mL of whole blood was collected at 
time of delivery and again followed-up at one year postpartum. All blood samples were collected 
in heparinised tubes and transported to the laboratory within 6 hours of blood draw. Samples 
were processed immediately after they were delivered to the lab from the collection site. Plasma 
was collected for storage at -800C and the whole blood diluted with phosphate buffered saline 
(PBS) for mononuclear cells isolation.  
As previously described(Gervassi et al., 2014), we used a sterile 15mL polystyrene tube 
containing 4mL Ficoll density-gradient separation medium per 10mL of diluted whole blood. 
The PBS-diluted whole blood was poured gently with the tube tilted at an angle of 450 to prevent 
any mixing with the separation medium. After prolonged centrifugation at 2500 rpm, the 15mL 
polystyrene tube was used to “purify” and isolate the PBMC. Ficoll medium is a specially 
formalized separation medium that has a density of 1.077g/mL. Since RBCs and 
polymorphonuclear granulocytes (Mature neutrophils, Eosinophils) are cells that have a density 
more than 1.077g/mL, moved to the pellet at the bottom of the tube(Breit, 2013). As a 
consequence, the Ficoll medium is displaced and pushed upwards. The PBMC/CBMC – 
lymphocytes and monocytes as well as MDSC (immature myeloid cells) will concentrate at the 
interface between the upper phase (plasma, thrombocytes) and the lower phase (Ficoll) according 
to their specific density with density lighter than 1.077g/mL moved above the Ficoll density-
gradient medium, and this layer is commonly known as the buffy coat layer(Breit, 2013) (Figure 
3.4). In some infants both CBMC and PBMC were obtained and frequency of MDSC compared. 
3.2.2 Glycophorin A micro beads red blood cell (RBC) depletion technique 
In certain samples where the intensity of PBMC/CBMC contamination by red blood cells (RBC) 
was intense, RBC was depleted using glycophorin A micro beads (Miltenyi Biotech). Briefly, 
where glycophorin A micro beads RBC depletion technique was required, it was performed as 
follows: in a 5mL FACS tube, cells were suspended in ice cold MACS separation buffer [0.1% 
heat inactivated human serum (HS) and 0.4% of 2mM EDTA, into 500mL phosphate buffered 
saline (PBS)] i.e. 16uL MACS buffer per 1 x 107 cells, plus 4uL glycophorin A micro beads. The 
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Table 3.1: MDSC multicolour flow cytometry panel. The seven colour flow 
cytometry panel employed with the various antibodies markers, fluorochromes, their 
suppliers and rational (importance for inclusion in the panel).  
Antibody Fluorophore Clone Supplier Rationale 
VIVID Pacific Blue - Life technologies Dead cells exclusion 
CD11b PE-Cy7 ICRF44 BD  Biosciences Leukocytes 
CD14 PE M5E2 BD  Biosciences Monocytes 
CD15 APC H198 Biolegend Neutrophils 
CD33 PE-Cy5 WM53 BD  Biosciences Myeloid cells 
HLA-DR APC-Cy7 L243 BD  Biosciences Macrophages, B-cells and DC 






cell suspension was further incubated in the dark at 40C for 15 minutes. After, the suspension 
was then topped-up to 2.5mL with MACS separation buffer and the tube inserted in the 
EasySep® magnet for 10 minutes, without a cap. Positively selected RBC bound to the walls of 
the tube, and the rest of the cells remained in the cell suspension. After incubation, the negatively 
selected cells were decanted out of the tube with the tube still in the magnet (see Figure 4.1). The 
depletion process was repeated twice, to complete three rounds of RBC depletion. 
3.2.3  Flow cytometry [Characterization of MDSC by cellular staining] 
Briefly, using a pre-labelled 96 well round bottom plate, about 1 x 106 cells/well of the 
different cell populations i.e. whole CBMC and/or PBMC, were plated for staining. Staining 
for MDSC quantification was done only on fresh blood samples, and not cryopreserved, as it 
has been shown that few MDSC survive cryopreservation (Kotsakis et al., 2012). Extracellular 
staining with 50uL of optimized concentration of flourochrome-bound antibodies and Violet 
fluorescent 
reactive dye 
(VIVID) to stain 
dead cells was 
performed (Table 
3.1). Cells were 
incubated for 20 
minutes in the 
dark at RT. After 
incubation, the 
cells were washed off the excess VIVID with 200uL of 2% FACS wash buffer i.e. 2% Human 
Serum in PBS, and the plate was centrifuged at 2100 rpm, repeated once. Cells were further 
fixed with 100uL of 10% BD FACSTM Lysing Solution in distil H2O to lyse any red cells and 
fix white cells, and incubated for 10 minutes. After incubation, the cells were washed, with 
200uL of 2% FACS wash buffer, repeated once.  
Further, using 200uL of 10% BD FACSTM Permeabilizing Solution 2 in distilled H2O; cells 
were permeabilized, and incubated for another 10 minutes. After incubation, the plate was 
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centrifuge to take off the permeabilizing solution 2, and the cells were washed with 200uL of 
2% FACS wash buffer, repeated once. The plate was now ready for intracellular staining with 
an optimized concentration of fluorochrome conjugated Arginase 1 antibody. Acquisition was 
performed using BD LSRII flow cytometer and analysis with FlowJo v9.4.7. Table 3.1 shows 
the multicolour flow cytometry panel used.  
Granulocytic MDSC was defined as CD33+, HLA-DR-, CD14-, CD11b+ and CD15+ immature 
myeloid cells as the cells of interest. Flow cytometry was used to assess all the cell populations, 
and we also evaluated the presence of MDSC after HIV exposure; between HIV-exposed 
uninfected (HEU) and HIV unexposed (HU) infants from birth through one year postnatal, and 
between HIV-infected (HIV+) and HIV uninfected (HIV-) mothers at time of delivery and a year 
postpartum. MDSC were reported as frequency of Live cells, and absolute numbers were 
calculated as number of cells per millilitre of suspension media i.e. 1% formaldehyde. 
3.2.3.1 Data analysis 
Flow cytometry data was extracted for analysis after sample acquisition. Below is a summary of 
the data analysis strategy.    
After sample acquisition by flow cytometry, the flow files were first analyzed using FlowJo 
v9.4.7 (Tree Star). After compensation was performed using singly stained compensation 
controls with the seven fluorochromes employed (see table 3.1), gating for singlets (using the 
size and granularity parameters) and live cells was performed. Using Fluorescence Minus One 
(FMO’s) to all the fluorochromes used to assign the gates of interest, HLA-DR- and CD14- cells 
were selected, from which CD33+ cells were gated. Finally, CD15+ cells were gated against 
CD11b+ cells, (Figure 3.5) and (Table 3.1). Data were reported as frequency of live 
CD11b+CD15+ expressing cells. Although Arg staining was performed, it was not used to define 
MDSC, as it is not conclusively known whether all MDSC suppression is mediated through this 
mechanism. However, routinely>90% cells were Arg positive.  
We obtained full blood counts (FBC) from infants at birth and at 6 months of age using the 
Sysmex® XN-Series automated haematology analyser. Correlations were performed between 
MDSC versus neutrophil frequencies and counts at birth and later at 6 months of life. MDSC 
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absolute counts were obtained as number of CD11b+CD15+ cells per 106 PBMC in a millilitre of 
suspension media i.e. 1% formaldehyde. However, as one of the limitations of the study, we did 
not take into consideration the complete blood count when calculating the MDSC absolute count, 







Figure 3.5: Gating strategy of live MDSC cells of an infant at birth. After gating on lymphocytes using the 
size and granularity parameters, singlets were gated from which Live cells, HLA-DR-CD14- and CD33+ cells 
were gated. MDSC was measured as frequency of  live CD11b+CD15+ cells. Since MDSC express Arginase, 
considered to be a potential immuno-suppressor molecule, we finally gated on Arginase+ MDSC.  
KIDZERU, 2016 
Chapter 3: Quantity and ontogeny of MDSC 68 
 
3.2.3.2 Statistical considerations 
Different statistical packages were used to complete the data analysis after obtaining data from 
flow cytometry as listed in the table below (Table 3.2). 
Table 3.2: Statistical packages used for data analysis 
No SOFTWARE PROGRAM ANALYSIS TYPE DATA TYPE 
1 FLOWJO v9.4.7 (for MAC, Stanford University, 1995-96; Tree Star, Inc. 1997-2012) 
To analyze flow cytometry data 
after acquisition Flow cytometry data 
analysis 
2 Microsoft Excel 2013 To clean and organize data 
3 GraphPad Prism v5 (for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com”). 
To analyze quantity and ontogeny 
of MDSC from birth to one year 
of age (infants), and between 




 -(HEU vs. HU) 
-(HIV+ vs. HIV-) 
4 STATA v11 (for windows, StataCorp LP, 
College station, TX77845, USA). 




-Fisher’s exact test 





3.2.3.3 Statistical data analyses 
Data analysis was performed by applying the following statistical tests; 
Table 3.3: Statistical tests used to complete data analyses 
Statistical test Rationale Statistical package Data type 
Chi-square test Relationship between two 
categorical variables  
STATA v11 Cohort description 
(HEU vs. HU) 
Fisher’s exact test Relationship between two 
categorical variables (one or more 
of the values in the cells has an 
expected frequency ≤5)  
STATA v11 Cohort description 




Compare continuous data between 
two categories that is not normally 
distributed. 
- GraphPad Prism v5 
- STATA v11 
- (HEU vs. HU) 




Compare continuous data between 
two matched categories that is not 
normally distributed. 
- GraphPad Prism v5 
 
-Quantity of MDSC  
 (HEU vs. HU) 
(HIV+ vs. HIV-) 
Spearman 
Correlation 
Correlations between two 
continuous variables 
- GraphPad Prism v5 
 
(Infants MDSC frequencies 
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3.3 Results 
In this chapter we were interested in quantifying MDSC in infants and mothers from the time 
of delivery to one year postpartum. We evaluated the presence and ontogeny of granulocytic 
MDSC as described in section 3.1.1.  
To effectively evaluate and understand the ontogeny of MDSC, we investigated whether there 
was a correlation between MDSC and neutrophil absolute counts and frequencies, since 
granulocytic MDSC are predominantly immature neutrophils. We obtained full blood counts 
(FBC) from infants at birth and at 6 months of age. To also understand the relation between 
infants and maternal MDSC we performed correlations between infants and maternal MDSC 
frequencies and absolute counts. From the cohort characteristics (Chapter 2), we obtained 
infants weights at the follow-up time points as well as gestational ages. We investigated the 
correlation between infants MDSC frequency and absolute counts versus infants weights at all 
the follow-up time points at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of 
age. Further, we performed correlations between infants MDSC at all the follow-up time 
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(a) Correlation between the infants MDSC frequencies versus maternal 
MDSC frequencies 
Spearman correlations were performed between infants and maternal MDSC frequencies at 
delivery and later at one year of age [Figures 3.6 (i and ii)]. At delivery, there was a 
significant positive correlation between the infants versus maternal MDSC frequencies 
(r=0.849 and p-value=<0.001) [Figure 3.6 (i)]. At one year postpartum, the significant 
positive correlation remained (r=0.621 and p-value=0.027) [Figure 3.6 (ii)]. 
 
 
Figure 3.6: Correlation between infants MDSC frequency versus maternal MDSC frequencies. (i) 
Infants MDSC and maternal MDSC frequencies correlated at birth, and (ii) at one year postnatal. The line 
indicate the correlation curve and r indicate the correlation coefficient, p<0.05 significant level and statistical 
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(b) Correlation between the counts of infants MDSC versus maternal 
MDSC counts 
Spearman correlations were performed between infants and maternal MDSC absolute counts at 
delivery and later at one year of age [Figures 3.7 (i and ii)]. At delivery, there was a positive 
correlation between infants and maternal MDSC absolute counts (r=0.851 and p-value=<0.001) 
[Figure 3.7 (i)]. This significant positive correlation was also observed at one year postpartum 




Figure 3.7: Correlation between infants MDSC counts versus maternal MDSC counts. (i) Infants MDSC 
and maternal MDSC counts correlated at birth, and (ii) at one year postpartum. The line indicate the 
correlation curve and r indicate the correlation coefficient, p<0.05 significant level and statistical significance 
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As shown in Appendix 3.1 (Figures A1 and B1), Spearman correlations were performed 
between MDSC versus neutrophil frequencies and absolute counts at birth and later at 6 
months of life. At birth, there was a significant positive correlation between MDSC frequency 
of live cells in PBMC versus frequency of leukocytes that were neutrophils in the FBC 
(r=0.449 and p-value=0.036) [Figure A1(i)], but at 6 months of age, there was no correlation  
(r=-0.361 and p-value=0.205) [Figure A1(ii)]. Also, at birth and 6 months of age, there were 
no correlations between the absolute counts of MDSC versus absolute counts of neutrophils 
(r=0.311 and p-value=0.182) [Figure B1(i)], and (r=-0.383 and p-value=0.313) [Figure B1(ii)] 
respectively.  
Also, Spearman correlations were performed between infant MDSC frequencies and absolute 
counts versus infants’ weights at birth, at 6, 10, and 14 weeks, at 6 and 9 months, and at one 
year of age (see Appendix 3.1, Figures A2 and B2). There was no significant correlation 
between the infants’ MDSC frequencies and their birth weights (r=0.071 and p-value=0.560) 
[Figure A2(i)]. This lack of significant correlation was also observed at other time points at 6, 
10 and 14 weeks (r=-0.034 and p-value=0.838; r=0.099 and p-value=0.599; and r=-0.102 and 
p-value=0.590 respectively), at 6 and 9 months (r=0.275 and p-value=0.241; and r=-0.038 and 
p-value=0.889 respectively), and at one year of age (r=0.125 and p-value=0.671) [Figure 
A2(ii-vii)]. Also, at birth, there was no significant correlation between infant MDSC absolute 
counts versus birth weights (r=0.221 and p-value=0.135) [Figure B2(i)]. This lack of 
significant correlation persisted at other time points between infants MDSC absolute counts 
and infants weights at 6, 10 and 14 weeks (r=0.230 and p-value=0.154; r=-0.031 and p-
value=0.863; and r=-0.072 and p-value=0.701), at 6 and 9 months (r=0.141 and p-
value=0.512; and r=-0.017 and p-value=0.945), and at one year of age (r=0.066 and p-
value=0.835) [Figure B2(ii)]. 
Spearman correlations were also performed between infants MDSC frequencies and absolute 
counts at birth, at 6, 10, and 14 weeks, at 6 and 9 months, and at one year of age versus infant 
gestational age (see Appendix 3.1, Figures A3 and B3). At birth, there was no significant 
correlation between the infants’ MDSC frequencies and gestational ages (r=0.046 and p-
value=0.708) [Figure A3(i)]. This lack of correlation persisted at 6, 10 and 14 weeks (r=0.055 
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and p-value=0.745; r=-0.021 and p-value=0.913; and r=-0.026 and p-value=0.892 
respectively), at 6 and 9 months (r=-0.192 and p-value=0.458; and r=-0.051 and p-
value=0.819 respectively), and at one year of age (r=0.433 and p-value=0.141) [Figure A3(ii-
vii)]. Also, at birth, there was no significant correlation between infants’ MDSC absolute 
counts versus gestational ages (r=-0.143 and p-value=0.345) [Figure B3(i)]. This lack of 
correlation persisted at other time points (r=0.173 and p-value=0.293 at 6 weeks; r=-0.174 and 
p-value=0.326 at 10 weeks; and r=-0.168 and p-value=0.374 at 14 weeks.), at 6 and 9 months 
(r=0.272 and p-value=0.210; and r=-0.015 and p-value=0.956), and at one year of age 
(r=0.067 and p-value=0.837) [Figure B3(ii-vii)].  
Hence, there was no major correlation between MDSC and neutrophil frequencies or absolute 
counts at 6 months of age in infants; while at birth the proportion of MDSC increased with 
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3.3.1 MDSC presence and ontogeny in infants 
We evaluated the quantity and ontogeny of MDSC in infants over time from birth to one year of 
age. This was done by measuring the frequency of CD11b+CD15+ cells in CBMC/PBMC from 
fresh blood as described in the methods (see section 3.2). 
3.3.1.1 Neonatal MDSC frequency in cord blood and peripheral blood at birth 
The frequency of MDSC in cord blood (CB) was slightly lower than that of peripheral blood 
(PB) of neonates at birth (D0) but this difference was not significant (median MDSC in 




Figure 3.8 (a): Frequency of MDSC in cord blood and peripheral blood at birth or Day 0 (D0). 
Frequency of MDSC in cord blood  (blue) and peripheral blood (orange) determined by flow cytometry, 
measuring CD11b+CD15+ expressing cells in cord blood mononuclear cells (CBMC) and  peripheral blood 
mononuclear cells (PBMC) respectively at birth. Bars indicate medians; p<0.05 significant level and 
statistical analysis was performed using Mann-Whitney U test.   
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3.3.1.2 Quantity and ontogeny of MDSC over time from birth to one year of age 
At birth, there was a significantly higher MDSC frequency compared to other time points. The 
median MDSC at birth (D0) (cord and peripheral blood combined) was 1.480% versus 0.468% at 
week 6 (p<0.001), 0.664% at week 10 (p=0.006), 0.243% at week 14 (p<0.001), 0.318% at 6 
months (p=0.003), 0.371% at 9 months (p=0.004) and 0.581% at one year of age (p=0.021) 





Figure 3.8 (b): Frequency of MDSC decreases over time from birth to 1 year of age. Frequency of MDSC 
measured at birth in cord blood (CB) and peripheral blood (PB) combined (green), and at weeks 6 (blue), 10 
(black) and 14 (purple), at months 6 (yellow) and 9 (red), and at one year (dark green) determined by flow 
cytometry. MDSC was measured as frequency of CD11b+CD15+ expressing cells. Bars indicate medians; 
p<0.05 significant level and statistical significance was tested using non-parametric Wilcoxon matched-pairs* 
sign rank test.   
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However, between preceding time points from 6 weeks of age, MDSC frequency did not 
significantly differ between WK6=0.542% versus WK10=0.548% and p-value=0.639, 
WK10=0.739% versus WK14=0.255% and p-value=0.218, WK14=0.265% versus 
Mth6=0.303% and p-value=0.854, Mth6=0.354% versus Mth9=0.278% and p-value=0.391, and 





Figure 3.8 (b) (ii): Frequency of MDSC not significantly different between preceding time point 
after 6 weeks of age. Frequency of MDSC measured at birth in cord blood (CB) and peripheral blood 
(PB) combined (green), and at weeks 6 (blue), 10 (black) and 14 (purple), at months 6 (yellow) and 9 
(red), and at one year (dark green) determined by flow cytometry. MDSC was measured as frequency of 
CD11b+CD15+ expressing cells. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test and non-parametric 
Wilcoxon matched-pairs* sign rank test.   
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3.3.1.3 MDSC presence and ontogeny in HEU compared to HU infants 
 
We compared the quantity and ontogeny of MDSC in infants born to HIV+ mothers compared to 
their HIV un-exposed counterparts at each time point.  
Although at most time points, MDSC frequency was higher in HEU versus HU infants [Figure 
3.8 (c)], significant differences in MDSC frequency in HEU vs. HU infants were not evident 
[Figure 3.6 (c)]. Also, there was no significant difference between MDSC frequency at birth 
versus preceding time points in both HEU as well as HU infants [Figure 3.6 (d)(i-ii)].  
 
 
Figure 3.8 (c): No significant difference in MDSC frequency between HEU vs. HU infants. Frequency of 
MDSC in HEU infants (blue) and in HU infants (black )at birth in CB and PB combined, and at weeks 6, 10 
and 14, at months 6  and 9, and at one year determined by flow cytometry. MDSC was measured as frequency 
of CD11b+CD15+ expressing cells. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was obtained using Mann-Whitney U test.   
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Figure 3.8 (d): No significant difference in MDSC frequency in HEU as well as HU infants between 
birth and preceding time points. Frequency of MDSC in HEU infants (blue) and in HU infants (black )at 
birth in CB and PB combined, and at weeks 6, 10 and 14, at months 6  and 9, and at one year determined by 
flow cytometry. MDSC was measured as frequency of CD11b+CD15+ expressing cells. Bars indicate medians 
and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was obtained 
using Mann-Whitney U test.   
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3.3.2 Quantification of maternal MDSC at delivery and one year postpartum 
We evaluated the quantity of MDSC in mothers at time of delivery and at one year postpartum as 
described in section 3.2. 
3.3.2.1 Quantity and ontogeny of maternal MDSC at delivery and one year postpartum 
In the matched time point analysis maternal MDSC frequency was significantly higher at 
delivery compared to one year postpartum (median MDSC D0=3.160% versus YR1=1.213% 
and p=0.045) [Figure 3.9 (a) (i)]. For this thesis we included a total of 70 mothers and their 
infants at delivery, however blood samples were only successfully obtained from 69 mothers at 
delivery and only 14 mothers and their infants had completed the study after one year follow-up 
postpartum from whom whole blood samples were collected [Figure 3.9 (a) (ii)].   
 
Figure 3.9 (a) (i): Matched comparison of frequency of maternal MDSC in peripheral blood at 
delivery versus at one year postpartum. Frequency of maternal MDSC in peripheral blood at delivery 
(D0-green) and at one year postpartum (YR1-red) determined by flow cytometry, measuring CD11b+CD15+ 
expressing cells. Bars indicate medians; p<0.05 significant level and statistical significance was tested using 
non-parametric Wilcoxon matched-pairs* sign rank test.   
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Differences were not evident in maternal MDSC frequency between delivery and one year 
postpartum in the unmatched time point analysis including all 69 mothers enrolled at delivery 
and the 14 mothers at one year postpartum (median MDSC D0=1.010% versus YR1=1.465% 




Figure 3.9 (a) (ii): Comparison of median frequency of MDSC in maternal peripheral blood at delivery 
and one year postpartum. Frequency of maternal MDSC in peripheral blood at delivery (D0-green) and at 
one year postpartum (YR1-red) determined by flow cytometry, measuring CD11b+CD15+ expressing cells. 
Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and statistical 
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3.3.2.2 Presence and ontogeny of maternal MDSC in HIV+ compared to HIV- mothers 
There was a significantly higher MDSC frequency in HIV+ mothers compared to their 
uninfected counterparts at one year postpartum (median MDSC HIV+ YR1=6.650% versus HIV- 
YR1=0.914% and p=0.014), but not at delivery (median MDSC HIV+ D0 =1.20% versus HIV- 
D0=0.923% and p=0.805) [Figure 3.9 (b)]. However, the number of HIV+ women that had 




Figure 3.9 (b): MDSC frequency significantly higher in HIV+ mothers at one year postpartum. 
Frequency of MDSC measured in peripheral blood of HIV+ mothers (blue) and HIV- mothers (black) at 
delivery (D0) and at one year (YR1) postpartum by flow cytometry. MDSC was measured as frequency of 
CD11b+CD15+ expressing cells. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
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3.4 Discussion 
Understanding cells that are involved in immune response regulation is critical for better vaccine 
development. The traditional T-regulatory (Tregs) cells have been well studied, and their 
influence on immune response regulation is well characterised in foetuses, neonates and 
infants(Gervassi et al., 2014)(Mold et al., 2008)(Wayne et al., 2005)(Takahata et al., 
2004)(Mackroth et al., 2004)(Mackroth et al., 2004). There are potential ways of eliciting strong 
immune responses in neonates amidst the predominant regulatory mechanisms; these include 
understanding neonatal immunological characteristics such as the impact of Tregs and other 
suppressor cell populations, importantly Myeloid Derived Suppressor Cells (MDSC) on vaccines 
immunity that may contribute to the development of effective vaccination strategies. The 
persistence of these cells postnatally may have a negative effect on immunity and protection 
against infections.  
To the best of our knowledge, there is no published study evaluating the quantity and ontogeny 
of MDSC in infants over time from birth to one year of age. In line with our hypothesis, over 
time, from birth through one year we found a significant decrease in MDSC frequency in infants 
[Figure 3.6 (b)]. Also, there were some distinct spikes in MDSC frequency for some infants 
particularly at 6 weeks and 6 months’ time points when compared to preceding time points. The 
possible reasons may be that since infants are administered a bunch of vaccines at 6, 10 and 14 
weeks of age, these vaccines may be involved in MDSC induction. Furthermore, these spikes in 
MDSC frequency may be non-specifically induced.  
No study has compared MDSC frequency and ontogeny between HEU and HU infants. We 
found that HIV-exposure had little effect on MDSC frequency. However, there were few 
samples in the HEU infants group and this would be one of the limitations in the study. We had 
hypothesised that HEU infants are born from a highly activated immune environment and the 
increased frequency of regulatory immune cells during gestation(Rich et al., 1997)(Kidzeru et 
al., 2014)(Nair et al., 2014), this effect may persist postnatally in HEU infants. However, we 
could not confirm our hypothesis. This may be because although born to HIV-infected mothers, 
the infants did not encounter any HIV antigen in-utero due to maternal antiretroviral therapy. 
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Also, it may be due to the limited number of HEU infants and a higher sample size would 
provide a better understanding. 
Consistent with our hypothesis, maternal MDSC frequency was significantly higher at delivery 
compared to one year postpartum in the matched time point analysis [Figure 3.7 (a)]. This 
suggests that MDSC may be induced during pregnancy to maintain tolerance, and that they wane 
postpartum. In support of our findings, we and others have previously shown that the frequency 
of MDSC in mothers and foetuses is increased during gestation to allow tolerance between the 
mother and the foetus(Rieber et al., 2013)(Gervassi et al., 2014)(Nair et al., 2014), and MDSC 
persist postnatally in infants(Gervassi et al., 2014).  
We found no significant difference in MDSC frequency between HIV+ versus HIV- mothers at 
delivery [Figure 3.7 (b)]. This could be due to the dominant influence of pregnancy-induced 
levels of MDSC masking the effect of HIV infection. In accordance with our hypothesis, at one 
year postpartum, HIV+ mothers had significantly higher MDSC frequency compared to their 
uninfected counterparts [Figure 3.7 (b)]. However, due to the small number of HIV+ mothers at 
one year follow-up time point, we recommend future experiments and a higher sample size to 
confirm this finding.  In support of our findings, Vollbrecht et al. have shown that elevated levels 
of MDSC are associated with chronic uncontrolled HIV-infections(Vollbrecht et al., 2012). Garg 
et al. also found an expansion of MDSC induced by the  HIV-1 envelope protein gp120(Garg et 
al., 2013).  
We do not know what would happen at a further time point, say two years postpartum. The 
presence of high MDSC frequencies may be cleared over time. Since the study was performed in 
a high tuberculosis (TB) endemic area, maternal exposure to TB and helminths infections may be 
responsible for the MDSC levels in healthy African women(du Plessis et al., 2013)(van 
Ginderachter et al., 2010). Also, the women may had become pregnant again by one year post 
previous delivery and as one of the limitations of this study we did not have male controls to 
evaluate what is normal with this population of cells.   
This study differs from other studies of MDSC in humans, particularly in the cohort 
characteristics. The cohort in Rieber et al. was different from ours and composed of cord blood 
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from healthy term neonates, infants at 2-16 years of age, both male and female healthy 
individuals(Rieber et al., 2013). This was irrespective of whether the females donors recruited in 
the cohort were pregnant or not. Our cohort was made of women at delivery and they were 
followed up at one year postpartum. Our study and that of Reiber et al. was similar in that we 
evaluated the frequency of granulocytic MDSC (G-MDSC) cell population characterised as 
CD11b+cd14-CD33+CD15+HLA-DR- expressing cells(Rieber et al., 2013). There were some 
differences between this study and that of Gervassi et al.  The infants in this study were recruited 
from normal vaginal delivery exposed to maternal vaginal microbiome and some exposed to in-
utero HIV-infection which may play a role in MDSC frequency, while the infants in the Gervassi 
et al. study were born from caesarean-sections and non-exposed to in-utero HIV-
infection(Gervassi et al., 2014). 
Our data shows that the relative immunodeficiency in infants in the first few weeks of life could 
be secondary to MDSC, but that this effect should wane by one year of age. We showed a 
significant positive correlation between infants and maternal MDSC frequencies as well as 
absolute counts. This shows that, increased MDSC frequencies during gestation may persist 
postnatally in infants and decrease over time postnatally in both infants and mothers. Since this 
study was the first to show MDSC frequency over time in children, we recommend further 
studies addressing MDSC ontogeny to be performed for better understanding and interpretation. 
This would provide information that would contribute to guide the design of vaccine strategies in 
infants. 
The study had a few limitations; the number of HEU infants as well as the HIV+ mothers that 
completed the study was small compared to the control group however, our primary interest was 
the general ontogeny of these cells. Furthermore, due to censoring of the cohort and high loss to 
follow-up, few infants and their mothers were included at the later time points.  
The clinical importance of these findings remains unknown, but these data may have important 
implications as far as evaluating vaccine immune responses in infants. The high MDSC at birth 
may alter responses to vaccines administered at birth and should be taken into consideration 
when designing neonatal vaccines.
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4.1 Introduction  
It has been shown that infants have compromised vaccine immune responses in the first few 
weeks of life compared to older children and healthy adults(Gervassi et al., 2014). Gasparoni 
et al. have shown that there is a gradual reduction of immunity and cellular mediated immune 
system immaturity during gestation, but a gradual development at birth in infants(Gasparoni et 
al., 2003). There is evidence that T cell immuno-proliferation to mitogen concanavalin A (con 
A) is significantly lower in cord blood than in children and adults(Gasparoni et al., 2003).  
Several studies have shown evidence of immune suppression by MDSC(Poschke et al., 
2012)(Gabrilovich et al., 2012)(Ostrand-rosenberg et al., 2012)(Pillay et al., 2013)(Serafini, 
2013). The immune suppressive effect of MDSC on T cell proliferation to different antigens 
has been widely described in non-human primate(Green et al., 2013)(Sui et al., 2014)(Raber et 
al., 2014) and cancer patients(Lindau et al., 2012)(Gabrilovich et al., 2012)(Raychaudhuri et 
al., 2011).  
There is limited data on the effect of MDSC on vaccine immune responses in infants. Most of 
the studies have looked at T cell proliferation in response to non-specific stimulation. We 
recently showed that, MDSC suppress in vitro T cell proliferation in neonates in response to 
anti-CD3CD28(Dynabead) (Gervassi et al., 2014). Also, Rieber and colleagues showed that 
after stimulation with a combination of IL-2 and muromonab-CD3 (OKT3), neonatal MDSC 
suppress adult T cell proliferation(Rieber et al., 2013). Several studies have looked at the 
effect of MDSC on cellular immune responses mostly in adults with disease (Vollbrecht et al., 
2012)(Zeng et al., 2014)(du Plessis et al., 2013).   
We and others have shown that the immune system of HIV exposed infants is compromised 
and makes them susceptible to infections(Epalza et al., 2011), and alters their immune 
responses to vaccines(Miles et al., 2010)(Jones et al., 2011)(Slogrove et al., 2012)(van Rie et 
al., 2006)(Mazzola et al., 2011)(Kidzeru et al., 2014). We and others have also shown altered 
T cell proliferation in HEU infants; we showed a significant increase in T cell proliferation in 
HEU infants to BCG and non-specific stimulation with SEB compared to HIV-unexposed 
infants, but T cell proliferation to Bordetella pertussis stimulation was comparable between 
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groups(Kidzeru et al., 2014). However, this increase in T cell proliferation observed was less 
protective as there was a significant reduction in cytokine production in HEU infants by 
proliferating T cell(Kidzeru et al., 2014)  And Mazzola et al.  showed that HIV-exposure 
impaires BCG-specific T cell proliferation and cytokine responses in uninfected 
infants(Mazzola et al., 2011).  
HIV infection has been associated with immune activation much more than other disease 
states(Paiardini et al., 2013)(Chang et al., 2010)(Catalfamo et al., 2011)(d’Ettorre et al., 2011). 
In HIV-infected individuals, vigorous HIV-1 specific CD4+ T cell proliferation to viral protein 
p-24 have been observed(Rosenberg et al., 2012). There is depletion in CD4+ T cells in chronic 
HIV infected patients due to immune activation(Hammond et al., 2008)(Okoye et al., 2013). 
HIV-1 antigen gp120 has been shown to induce expansion of MDSC in HIV infected 
individuals(Garg et al., 2013). There is evidence that MDSC suppress T cell proliferation in 
HIV-infected individuals, reflecting an anti-proliferative response against the extreme immune 
activation during HIV infection(Qin et al., 2013)(Gama et al., 2012)(Nagarajet al., 
2013)(Vollbrecht et al., 2012).  
It was recently shown that MDSC reduced protective immune responses to SIV in SIV 
vaccinated macaques in a non-human primate macaque model(Sui et al., 2014). However, little 
is known on how MDSC affect T cell proliferation in response to vaccines in humans 
generally. More specifically, there is little about the effect of MDSC in vaccine induced T cell 
proliferation in HIV-exposed uninfected (HEU) infants or in HIV+ individuals, and in mothers 
postpartum.  
We compare T cell proliferative responses to vaccines using Tuberculin purified protein 
derivative (PPD), Tetanus toxoid (TT) and Hepatitis B surface antigen (HepB); cells alone with 
medium as negative control (CA), and stimulation with Dynabeads, a human T cell activator 
anti-CD3/CD28 as positive control (Dynabead, Life Technologies). We assess the consequences 
of MDSC on the development of antigen specific cellular proliferative immune responses 
between birth and one year in infants and in mothers at delivery and at one year postpartum. This 
was done by measuring the frequency of T cells with low expression of Carboxyfluorescein 
KIDZERU, 2016 
Chapter 4: T-cell proliferation in whole PBMC vs. without MDSC     92 
 
Succinimidyl Ester (CFSE) stain i.e. CFSElow-expressing CD4+ T-cells in whole cord blood 
mononuclear cells (CBMC) and/or peripheral blood mononuclear cells (PBMC), and MDSC 
depleted (CD15-) CBMC and/or PBMC in cultures after stimulating with optimized 
concentrations of the respective antigens. Hence, in this chapter we were interested in 
determining the potential effect of MDSC on T cell proliferation in response to vaccine antigens 
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Table 4.1: Description of how experiments were prioritized based on the volume of blood and total 
CBMC/PBMC isolated. The three experiments performed (MDSC staining for characterisation of MDSC 
(Chapter 3 above), and CFSE proliferation assay ( Chapter 4) with IFN-γ ELISpot assay (Chapter 5) both 
involving comparisons between CD15+ non-depleted versus CD15+ depletion (Depl.) experiment. Antigens 
of importance included Hep B, BCG and PHA. 
Total CBMC/PBMC isolated & amounts 
for experiments prioritized based on 
importance and cells available (million 
cells) 
1 2 3 4 5 6 7 8 9 10 11 
MDSC stain √ √ √ √ √ √ √ √ √ √ √ 
IFN-γ ELISpot assay  √ √  √ √ √ √ √ √ √ 
IFN-γ ELISpot with CD15 Depl.   √   √ √  √ √ √ 
CFSE (neg, Hep B, PHA)    √ √ √ √ √ √ √ √ 
CFSE with CD15 Depl. (neg, Hep B, PHA)        √ √ √ √ 
CFSE (BCG)          √ √ 
CFSE with CD15 Depl. (BCG)           √ 
 
4.2 Materials and method 
Using the standard ficoll gradients, CBMC and PBMC were isolated as described above (Section 
3.2.1). Where required, in some samples red blood cells (RBC) were depleted using glycophorin 
A micro beads (Section 3.2.2). Further, depending on the number of cells recovered, cells were 
divided into two aliquots; those for non-depletion (CD15+ ND) and MDSC depletion (CD15-). 
Depletion of MDSC was perform by depleting CD15+ cells from whole CBMC and/or PBMC by 
employing the EasySep® magnetic cell separation technique as described below (section 4.2.1). 
We prioritised experiments according to blood volume obtained, and often the volume of whole 
blood collected from infants was insufficient for CD15+ depletion, and the number of 
CBMC/PBMC not enough. Due to this, we prioritized experiments for which samples were 
provided since there were only a limited number of infants and their mothers at most time points 
for which depletion was able to be performed and further permitting MDSC non-depleted versus 
MDSC depleted match paired analyses to be performed. Table 4.1 describes how experiments 
were prioritized based on the total CBMC/PBMC isolated with respect to the volume of blood 
collected. 
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4.2.1 EasySep® magnetic cell separation techniques 
The EasySep® magnetic cell separation technique was performed as follows; in a 5mL FACS 
tube, cells were suspended in ice cold MACS separation buffer [0.1% heat inactivated human 
serum (HS) and 0.4% of 2mM EDTA, into 500mL phosphate buffered saline (PBS)] i.e. 1mL 
MACS buffer per 1 x 108 cells, plus 100uL EasySep® Custom Anti-Human CD15 TAC cocktail. 
The cell suspension was further incubated in the dark for 10 minutes. After, 100uL of EasySep® 
Magnetic Nanoparticles Positive Selection reagent was added to the mixture, and further 
incubated for another 10 minutes. The suspension was then topped-up to 2.5mL with MACS 
separation buffer and the tube inserted in the EasySep® magnet for 10 minutes, without cap. 
Positively selected CD15+ cells bound to the walls of the tube, and CD15- cells located in the cell 
suspension. After incubation, the negatively selected cells were decanted out of the tube with the 
tube still in the magnet (Figure 4.1). The depletion process was repeated twice, to complete three 
rounds of CD15 depletion. 
 
 
Figure 4.1: EasySep® magnetic cell separation technique. CD15 expressing [CD15(+)] cells positively 
selected bind to the walls of the tube in the magnetic and the negatively selected cells remain in the cell 
suspension (Source: Modified from STEMCELLTM TECHNOLOGIES - 
http://www.stemcell.com/en/Pages/EasySep-Magnets.aspx). 
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4.2.2 Mononuclear cell CFSE incorporation technique  
After obtaining all the populations of cells required for CFSE incorporation i.e. whole PBMC - 
CD15 non-depleted cells (CD15+), and absence of MDSC - CD15 depleted cells (CD15-); CFSE 
incorporation was performed.  
Briefly, 0.25uL of Cell TraceTM CFSE (Life Technologies, USA) was added into 1 x 107 cells in 
1mL PBS and incubated for 8 minutes in the dark at room temperature (RT). Thereafter, 2mL ice 
cold, heat inactivated foetal calf serum (FCS) was added to cells for an additional 3 minutes, to  
“quench” the CFSE, as CFSE has been shown to be highly toxic to cells(Quah et al., 
 
Figure 4.2: Mononuclear cells CFSE incorporation. CBMC and/or PBMC from infants and mothers were 
stained with anti-CFSE conjugately bound to Flourescien Isothiocynate (FITC) flourescent dye. Stained cells 
were further acquired using a BD LSRII Flow cytometer.  
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2007)(Wang et al., 2005).  After, 10mL of 10% FCS in Roswell Park Memorial Institute (RPMI) 
1640 culture medium (Sigma Aldrich) containing 1% penicillin-streptomycin antibiotics, was 
added into the stained cells to wash off the excess CFSE stain, and centrifuged at 1200 rpm for 
10 minutes. The washing step was repeated once and the cell pellet re-suspended (Figure 4.2). 
Using a 48 well flat bottom plate, 1 x 106 cells/well of the different cell populations i.e. whole 
CBMC and/or PBMC with and without MDSC, were plated, and incubated for 2-3 days in 
600uL/well RPMI culture medium containing antigen; 1% penicillin-streptomycin, 15% Human 
Serum and 0.02% of 0.5ug/mL recombinant human IL-7 (rhIL-7), in a 370C, 5% CO2 humidified 
incubator. Daily, 0.1% of 0.5ug/mL IL-7 was added per well for the rest of the incubation period 
as it is required to enhance the survival and development of cells(Rathmell et al., 2001)(Cieri et 
 
Figure 4.3: Gating strategy of live CD4+CFSElow cells of an infant at birth. After gating on lyphocytes using 
the size and granularity parameters, singlets were gated from which live cells and CD3+ cells were gated. CD4+ 
cells were then selected, and proliferating CD4+ T cells were measured as frequency of  live CD4+CFSElow cells. 
We also show proliferating total CD3+ T cells.  
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Table 4.2: The CFSE multicolour flow cytometry panel. The four colour flow 
cytometry panel employed with the various antibodies markers, fluorochromes, 
their suppliers and rational (importance for inclusion in the panel).  
Antibody Fluorophore Clone Supplier Rationale 
VIVID Pacific Blue - Life technologies Dead cells exclusion 
CD3 APC-Cy7 SK7 BD  Biosciences T cells 
CD4 APC L200 BD  Biosciences T cells 
CFSE FITC - Life technologies Proliferating cells 
 
al., 2013)(Sara et al., 2002)(van Lent et al., 2009).  Optimized concentrations of the respective 
antigens were used, in order to measure the frequency of proliferating CFSElow-expressing CD4+ 
T-cells (i.e. CD4+CFSElow) in response to various vaccines and antigens in infants and their 
mothers.  
Specifically, the following antigens were added: 1ug/mL Tuberculin purified protein derivative 
(PPD) [STATENS SERUM INSTITUT, DK-2300, Copenhagen, Denmark], 0.25ug/mL Tetanus 
toxoid (TT) [TETAVAX, Aventis Pharma (Pty) Ltd], and 5ug/mL Hepatitis B surface antigen 
(HepB) [Advanced Immunochemical Inc.]. Cells alone without any stimuli served as a negative 
control (CA), and 5ug/mL Dynabeads®, a human T cell activator CD3/CD28 served as positive 
control [Life Technologies]. In the wells with TT and HepB antigens, 0.01ug/mL and 0.5ug/mL 
BD FastimmuneTM CD28/CD49d co-stimulation was added respectively.  
T cell proliferation with and without MDSC was compared. Using a 96 well round bottom plate, 
antigen specific CFSElow proliferating T cells were stained. 
After 2-3 days cell culture, the cells were transferred to a pre-labelled 96 well round bottom 
plate. Extracellular staining with an optimized concentration of 50uL Violet fluorescent reactive 
dye (VIVID) [Life Technologies] was performed; cells were incubated for 10 minutes in the dark 
at RT, to stain dead cells. After incubation, the cells were washed off the excess VIVID with 
200uL of 2% FACS wash buffer i.e. 2% Human Serum in PBS, and the plate was centrifuged at 
2100rpm, repeated 
once. Cells were 
further fixed with 
100uL of 10% BD 
FACSTM Lysing 
Solution, in distilled 
H2O, and incubated for 
10 minutes. After 
incubation, the cells were washed with 200uL of 2% FACS wash buffer, repeated once. Further, 
using 200uL of 10% BD FACSTM Permeabilizing Solution II, in distilled H2O; cells were 
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permeabilized, and incubated for another 10 minutes. After incubation, the plate was centrifuged, 
and the cells washed with 200uL of 2% FACS wash buffer, repeated once. The cells in the plate 
were then stained with optimized concentrations of the respective fluorochromes bound 
antibodies, to stain proliferating T cells (CD4+CFSElow) (Table 4.2). Responses were measured 
using BD LSRII flow cytometer and analysis with FlowJo v9.4.7.  
Based on the amount of whole blood sample obtained, the number of CBMC/PBMC yield was 
prioritized per experiment if the volume was insufficient for all assays. Hence, the number of 
cells used for every assay was not the same; for CFSE, 4 million cells were required for the assay 
to be performed. Where the number of CBMC/PBMC was 4 million and above CFSE assay 
preferentially performed (where at least Hep B proliferative responses were prioritized to be 
assessed, including the cells alone and Dynabead wells as negative and positive controls 
respectively) to all the other assays that are less cell intensive i.e. a million cells required for 
MDSC staining and 2 – 3 million cells for IFN-γ ELISpot assay. 
4.2.2.1 Data analysis 
Flow cytometry data was extracted for analysis after sample acquisition. Below is a summary of 
the data analysis strategy.    
After sample acquisition by BD LSRII, the FCS files were first analyzed using FlowJo v9.4.7 
(Tree Star, College Park). After gating for singlets (using the size and granularity parameters) 
and live cells, we gated on CD3+ cells, from which CD4+ cells were gated. Finally, proliferating 
T cells were gated as CFSElow against CD4+ cells (Figure 4.3). The negative and positive 
controls were employed to decide where gates were to be placed as T cell proliferative responses 
varied between antigens as well as between individuals. Final decision on placing the gates was 
made and the same gates applied to the other samples to keep consistency.  
Since it is an exploratory study, investigating CD4+ T cells is due to the fact that CD4+ T cells 
have been shown to be rapidly activated post stimulation with the specific antigens and vaccines 
we assessed in this current study and proliferate at a higher rate than CD8+ T cell(Caggiari et al., 
2001)(Tham et al., 2002). This would provide a better understanding of the effect of MDSC on T 
cell proliferation to these vaccines antigens (BCG, PPD, BP, TT and HepB). 
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4.2.2.2 Standard rules for cut-offs and controls for the flow cytometry data 
Following analysis by FlowJo, the data was exported and organized for further analysis. In order 
to prevent data bias and to perform background subtraction, the following rules were put in 
place:  
1. Assay validity and positivity (before background subtraction) 
A. The test antigens (i.e. PPD, TT, HepB and Dynabeads) % CD4+CFSElow were only 
quantified if the negative control (i.e. Media) % CD4+CFSElow proliferating T cells 
were ≤ 5%, or the sample was excluded. 
i.e. % CD4+CFSElow [Media or cell alone] ≤ 5 
B. The frequency of CD4+CFSElow proliferating T cells in response to Dynabeads had to 
be greater than the median plus 3 times the MAD of the negative control, or the 
sample was excluded.  
i.e. % CD4+CFSElow [Dynabeads] > % CD4+CFSElow (Median + 3MAD) [Media] 
[MAD=Median Absolute Deviation) 
MAD is defined as the deviation of each sample’s negative control frequency from the negative 




2. Proportion of proliferating cells (CD4+CFSElow) 
The frequency of CD4+ T cells with low CFSE expression of the test antigens (PPD, TT, 
HepB and Dynabeads) minus background (% CD4+CFSElow T cells in the media control) 
i.e. (PPD, TT, HepB and Dynabeads induced % CD4+CFSElow cells) – (% 
CD4+CFSElow cells in the media) 
3.) CD15-depletion (CD15-) purity 
Only samples with CD15-depletion purity of 90% and above were included in the data 
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4.2.2.3 Statistical considerations 
Different statistical packages were used to complete the data analysis after obtaining data from 
flow cytometry as listed in the table below (Table 4.3). 
Table 4.3: Statistical packages used for data analysis 
No SOFTWARE PROGRAM ANALYSIS TYPE DATA TYPE 
1 FLOWJO v9.4.7 (for MAC, Stanford University, 1995-96; Tree Star, Inc. 1997-2012) 
To analyze flow cytometry data 
after acquisition 
Flow cytometry data 
analysis 
2 Microsoft Excel 2013 To clean and organize data 
3 Microsoft Excel 2013 To perform background subtraction 
5 GraphPad Prism v5 (for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com”). 
To analyze differences in T cell 
proliferation cells between 
groups. 
Graphics 
-(CD15+ vs. CD15-) 
 -(HEU vs. HU) 
6 STATA v11 (for windows, StataCorp LP, 
College station, TX77845, USA). 




-Fisher’s exact test 





4.2.2.4 Statistical data analyses 
Data analysis was performed by applying the following statistical tests; 
Table 4.4: Statistical tests used to complete data analyses 
Statistical test Rationale Statistical package Data type 
Chi-square test Relationship between two 
categorical variables  
STATA v11 Cohort description 
(HEU vs. HU) 
Fisher’s exact test Relationship between two 
categorical variables (one or more 
of the values in the cells has an 
expected frequency ≤5)  
STATA v11 Cohort description 




Compare continuous data between 
two categories that is not normally 
distributed. 
- GraphPad Prism v5 
- STATA v11 
-T cell Proliferation  
 (CD15+ vs. CD15-) 




Compare continuous data between 
two matched categories that is not 
normally distributed. 
- GraphPad Prism v5 
 
-T cell Proliferation  
 (CD15+ vs. CD15-) 
Spearman 
Correlation 
Correlations between two 
continuous variables 
- GraphPad Prism v5 
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4.3 Results 
In this chapter, we assessed the effect of MDSC on T cell proliferative responses to TT and 
HepB vaccination, to PPD (for BCG vaccination) and Dynabead antigens, in whole CBMC 
and/or PBMC compared with versus without MDSC, in HEU as well as HIV-unexposed (HU) 
infants, and in HIV-infected (HIV+) as well as HIV-uninfected (HIV-) mothers postpartum. T 
cell proliferative responses were assessed in infants at birth, 6, 10 and 14 weeks, 6 and 9 
months, and at one year of age; and in mothers only after delivery and one year postpartum. 
This chapter aimed to test the hypothesis that in the presence of MDSC, infant and adult T 
cells will have low proliferative ability in response to vaccines in early life. Furthermore, we 
hypothesised to increased frequencies or higher suppressive abilities of MDSC, HEU infants 
and their HIV-infected (HIV+) mothers, will have lower proliferation in the presence of 
MDSC compared to the HIV-unexposed (HU) infants and HIV-uninfected (HIV-) mothers 
respectively. 
To better understand the effect of MDSC on T cell proliferation, we employed two analytical 
processes;  
1. We performed binary analyses by comparing MDSC frequency of live PBMC as 
well as MDSC absolute counts per million PBMC between vaccine “responders” 
versus “non-responders” based on their CD4+ T cell proliferative response to vaccine 
antigens. The frequency of CD4+ T cell proliferation in response to vaccine antigens 
was considered as responder when proliferative responses were greater than or equal to 
2.5%/106 PBMC after back ground subtraction of the negative control responses from 
that of the test antigens. The basis of our consideration of 2.5%/106 PBMC was due to 
the fact that CD4+ T cell proliferation was generally low in response to vaccine 
stimulations, and is supported by the finding by Soares et al. that the dye dilution of 
Oregon Green (OG), a CFSE derivative had an intra assay variability of 2-3% for CD4+ 
T cells(Soares et al., 2010).  
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2. (a) We compared CD4+ T cell proliferation to vaccines and antigens in PBMC 
(presence of MDSC) versus without MDSC (after MDSC depletion, only if depletion 
was considered successful ie.  ≥90%) at all individual time points (i.e. at birth, at 6, 10 
and 14 weeks, at 6 and 9 months, and at one year of age), and in mothers (i.e. at 
delivery and one year postpartum). 
(b) In infants, we evaluated the ontogeny of the effect of MDSC on CD4+ T cell 
proliferation to vaccines and antigens in a grouped analysis.  
We grouped close follow-up time points together to increase the sample sizes. For Hep 
B and TT, which is given first at 6 weeks of age, we grouped the 10 and 14 week time 
points (after the first and second vaccine doses and before the last vaccine doses), and 
the 6, 9 months and one year time points (after the last vaccine doses and the last 
follow-up time points). However, for PPD, since BCG is given at birth, follow-up ages 
were grouped into two, at 6, 10 and 14 weeks (first few weeks after priming and peak 
response(Kagina et al., 2009)), and at 6 and 9 months and one year (the last follow-up 











Chapter 4: T-cell proliferation in whole PBMC vs. without MDSC     103 
 
Generally, vaccine responses to the different antigens varied. Also, responses varied between 
infants and their mothers. Appendix 4.2 shows the general ontogeny of each vaccine response 
(median frequency of proliferating cells) to the different antigens in infants and mothers 
through time.  
Hep B CD4+ T cell proliferative responses peaked at 10 weeks after priming at 6 weeks in 
infants and then dropped at 14 weeks post second vaccine dose. The responses then further 
rose after the last and third vaccine dose at 14 weeks then varied till one year of age[Appendix 
4.2, Figure G (i)]. In the mothers, Figure G (ii), Hep B responses increased from delivery to 
one year postpartum. 
TT CD4+ T cell proliferative responses were low throughout, from priming at 6 weeks of age, 
through one year of age [Appendix 4.2, Figure H (i)]. Likewise in mothers, Figure H (ii), TT 
responses were low from delivery to one year postpartum. 
PPD responses peaked between 6, 10 and 14 weeks after BCG vaccination at birth in infants 
to 9 months and one year of age [Appendix 4.2, Figure I (i)], as previously described (Kagina 
et al., 2009). In mothers, [Appendix 4.2, Figure I (ii)], PPD responses increased from delivery 
to one year postpartum. 
As expected of a positive control and strong stimulation, Dynabead induced T cell proliferation 
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4.3.1 Infant MDSC frequency and absolute counts in responders versus non-
responders as measured by CD4+ T cell proliferation  
We evaluated the relationship between the frequency and absolute count of MDSC versus the 
frequency of CD4+ T cell proliferation in response to vaccines and antigens from birth to one 
year of age in infants.  
To assess the degree at which MDSC may affect T cell proliferation, we evaluated the 
frequency and the absolute count of MDSC in infants that responded and that that did not 
respond as stated above in Section 4.3 (1). Also, we evaluated maternal MDSC frequency of 
CD4+ T cell proliferation to antigen stimulation in mothers who responded versus non-
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4.3.1.1 Infant MDSC frequency in responders versus non-responders to Hep B 
stimulation as measured by CD4+ T cell proliferation 
The frequency of MDSC after Hep B vaccine stimulation in infants whose CD4 T cell 
proliferation was responsive versus non-responders was measured in the grouped time point 
analysis at 10 and 14 weeks grouped time points, and at 6 and 9 months and one year of age 
grouped time points, as there were too few data in the analysis at individual time points. As 
shown in Figure 4.4, there were no significant differences in MDSC frequency between 
responders and non-responders at all grouped time points (median of responders=0.451% versus 
non-responders=0.472% and p=0.767 at 10 and 14 weeks; median of responders=0.180% versus 
non-responders=0.359% and p=0.143 at 6 and 9 months and one year).  
 
Figure 4.4: Infants MDSC frequency in CD4+ T cell proliferative responders versus non-responders to 
Hep B stimulation. The frequency of MDSC as percentage of PBMC was measured at 10 and 14 weeks of age, 
and at 6 and 9 months and one year of age  in infants as well as the frequency of CD4+ T cells proliferative 
responses to Hep B at the respective time points. The frequency of CD4+ T cell proliferation in responders was 
≥2.5%/106 PBMC after Hep B stimulation. Time points were grouped; i.e. 10 and 14 weeks grouped time points 
post first dose of Hep B vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the 
last follow-up time points 6 and 9 months and one year of age grouped time points post the last vaccine dose. 
Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
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4.3.1.2 Infant MDSC absolute counts in responders versus non-responders to Hep B 
stimulation as measured by CD4+ T cell proliferation  
The absolute MDSC counts after Hep B vaccine stimulation in infants who responded were 
compared to infants who responded poorly in terms of CD4+ T cell proliferative responses. 10 
and 14 week time points were grouped, as well as 6 and 9 months and one year of age. There 
were no significant differences between responder and non-responder MDSC counts at all 
grouped time points; at 10 and 14 weeks (median of responders=386.0 MDSC counts versus 
non-responders=882.5 MDSC counts and p=0.599), and at 6 and 9 months and one year (median 
of responders=4511.0 MDSC counts versus non-responders=846.0 MDSC counts and p=0.072) 
(Figure 4.5). However, there was a trend towards high MDSC counts in the non-responders with 
CD4+ T cell proliferation ≥2.5% at 6, 9 months and one year follow-up grouped time points post 
Hep B vaccination.  
 
Figure 4.5: Infants MDSC absolute counts in CD4+ T cell proliferative responders versus non-responders 
to Hep B stimulation. The absolute  counts of MDSC per mL of 106 PBMC was measured at 10 and 14 weeks 
of age, and at 6 and 9 months and one year of age  in infants, as well as the frequency of CD4+ T cells 
proliferative responses to Hep B at the respective time points. The frequency of CD4+ T cell proliferation in 
responders was ≥2.5%/106 PBMC after Hep B stimulation. Time points were grouped; i.e. 10 and 14 weeks 
grouped time points post first dose of Hep B vaccination at 6 weeks and before the second vaccine dose at 14 
weeks of age, and the last follow-up time points 6 and 9 months and one year of age grouped time points post 
the last vaccine dose. Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 
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4.3.1.3 Infant MDSC frequency in responders versus non-responders to TT stimulation as 
measured by CD4+ T cell proliferation 
The frequency of MDSC in infants who responded versus non-responders in terms of  CD4+ T 
cell proliferative responses ≥2.5%/106 PBMC to TT were compared in the grouped time point 
analysis at 10 and 14 weeks grouped time points, and at 6 and 9 months and one year of age 
grouped time points. As shown in Figure 4.6, there were no significant differences between 
responders’ and non-responders’ MDSC frequencies at all grouped time points at 10 and 14 
weeks (median of responders=0.227% versus non-responders=0.619% and p=0.606), and at 6 
and 9 months and one year (median of responders=0.601% versus non-responders=0.369% and 
p=0.966). 
     
Figure 4.6: Infants MDSC frequency in CD4+ T cell proliferative responders versus non-responders to TT 
stimulation. The frequency of MDSC as percentage of PBMC was measured at 10 and 14 weeks of age, and at 6 
and 9 months and one year of age  in infants as well as the frequency of CD4+ T cells proliferative responses to 
TT at the respective time points. The frequency of CD4+ T cell proliferation in responders was ≥2.5%/106 PBMC 
after TT stimulation. Time points were grouped; i.e. 10 and 14 weeks grouped time points post first dose of Hep 
B vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last follow-up time 
points 6 and 9 months and one year of age grouped time points post the last vaccine dose. Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and 
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4.3.1.4 Infants MDSC absolute counts in responders versus non-responders to TT 
stimulation as measured by CD4+ T cell proliferation 
The absolute MDSC counts in infants who responded compared to infants who did not with 
regards to TT poorly was measured at 10 and 14 weeks grouped time points, and at 6 and 9 
months and one year of age grouped time points. There were no significant differences 
between responders’ and non-responders’ MDSC counts at all grouped time points; at 10 and 
14 weeks (median of responders=1649.0 MDSC counts versus non-responders=1476.0 MDSC 
counts and p=0.325), and at 6 and 9 months and one year (median of responders=3164.0 
MDSC counts versus non-responders=1925.0 MDSC counts and p=0.855) (Figure 4.7). 
 
Figure 4.7: Infants MDSC absolute counts in CD4+ T cell proliferative responders versus non-responders 
to TT stimulation. The absolute  counts of MDSC per mL of 106 PBMC was measured at 10 and 14 weeks of 
age, and at 6 and 9 months and one year of age  in infants, as well as the frequency of CD4+ T cells proliferative 
responses to TT at the respective time points. The frequency of CD4+ T cell proliferation in responders was 
≥2.5%/106 PBMC after TT stimulation. Time points were grouped; i.e. 10 and 14 weeks grouped time points 
post first dose of TT vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last 
follow-up time points 6 and 9 months and one year of age grouped time points post the last vaccine dose. Each 
dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
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4.3.1.5 Infant MDSC frequency in responders versus non-responders to PPD stimulation as 
measured by CD4+ T cell proliferation 
The frequency of MDSC in infants who responded and non-responders in terms of CD4+ T cell 
proliferative responses after PPD stimulation was compared in the grouped time point analysis 
at 6, 10 and 14 weeks, and at 6 and 9 months and one year of age. As shown in Figure 4.8, 
there were no significant differences between responders’ and non-responders’ MDSC 
frequencies at both grouped time points; 6, 10 and 14 weeks (median of responders=0.254% 
versus non-responders=0.169% and p=0.246), and at 6 and 9 months and one year (median of 
responders=0.589% versus non-responders=0.266% and p=0.365). 
 
Figure 4.8: Infants MDSC frequency in CD4+ T cell proliferative responders versus non-responders to 
PPD stimulation after BCG vaccination. The frequency of MDSC as percentage of PBMC was measured at 6, 
10 and 14 weeks of age, and at 6 and 9 months and one year of age  in infants as well as the frequency of CD4+ T 
cells proliferative responses to PPD at the respective time points. The frequency of CD4+ T cell proliferation in 
responders was ≥2.5%/106 PBMC after PPD stimulation. Time points were grouped; i.e. 6, 10 and 14 weeks 
grouped time points post BCG vaccination at birth, and at the last follow-up time points 6 and 9 months and one 
year of age grouped time points. Each dot on the plot represent an infant. Bars indicate medians and whiskers 
indicate interquartile range; p<0.05 significant level and statistical significance was tested using Mann-Whitney 
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4.3.1.6 Infants MDSC absolute counts in responders versus non-responders to PPD 
stimulation as measured by CD4+ T cell proliferation 
The absolute counts of MDSC in infants who responded compared to infants who poorly 
responded in terms of CD4+ T cell proliferative responses to PPD stimulation was compared in 
the grouped time point analysis at 6, 10 and 14 weeks grouped time points, and at 6 and 9 
months and one year of age grouped time points. There were no significant differences 
between responders’ and non-responders’ MDSC counts at 10 and 14 weeks grouped time 
points (median of responders=345.5 MDSC counts versus non-responders=250.0 MDSC 
counts and p=0.726), and at 6 and 9 months and one year (median of responders=1356.0 




Figure 4.9: Infants MDSC absolute counts in CD4+ T cell proliferative responders versus non-
responders to PPD stimulation after BCG vaccination. The absolute  counts of MDSC per mL of 106 
PBMC was measured at 6, 10 and 14 weeks of age, and at 6 and 9 months and one year of age  in infants, as 
well as the frequency of CD4+ T cells proliferative responses to PPD at the respective time points. The 
frequency of CD4+ T cell proliferation in responders was ≥2.5%/106 PBMC after PPD stimulation. Time 
points were grouped; i.e. 6, 10 and 14 weeks grouped time points post BCG vaccination at birth, and at the 
last follow-up time points 6 and 9 months and one year of age grouped time points. Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
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Overall, in infants MDSC frequency and absolute count between infants who were responders 
and non-responders to vaccine induced T cell proliferation were not significant at most time 
points. MDSC frequency and count varied between responders and non-responders to different 
vaccine antigens and at different grouped time points.  
4.3.1.7 Maternal MDSC frequency in responders versus non-responders to Hep B 
stimulation as measured by CD4+ T cell proliferation 
The frequency of maternal MDSC was not significantly different in mothers with frequency of 
CD4+ T cell proliferative responses ≥2.5%/106 PBMC to Hep B stimulation compared to those 
who responded poorly with T cell proliferative responses ≤2.5%. As shown in Figure 4.10, 
median of responders=0.746% versus non-responders=1.290% and p=0.947, and at one year 
postpartum median of responders=1.286% versus non-responders=1.213% and p=0.849. 
 
Figure 4.10: Maternal MDSC frequency in CD4+ T cell proliferative responders versus non-responders to 
Hep B stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as the frequency of CD4+ T cells proliferative responses to Hep B at the respective 
time points. The frequency of CD4+ T cell proliferation in responders was ≥2.5%/106 PBMC after Hep B 
stimulation. Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
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4.3.1.8 Maternal MDSC frequency in responders versus non-responders to TT stimulation 
as measured by CD4+ T cell proliferation 
The frequency of maternal MDSC at delivery as well as at one year postpartum was not 
significantly different between responders and non-responders to TT stimulation. Maternal 
MDSC frequencies at delivery were; median of responders=0.648% versus non-
responders=0.678% and p=0.344, and at one year postpartum were median of 
responders=0.892% versus non-responders=2.750% and p=0.158 (Figure 4.11). However, the 
lack of a significant difference at year one may be due to the small sample size, a significant 
different difference may be obtained with a larger sample size. 
 
 
                  
Figure 4.11: Maternal MDSC frequency in CD4+ T cell proliferative responders versus non-responders to 
TT stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as the frequency of CD4+ T cells proliferative responses to TT at the respective 
time points. The frequency of CD4+ T cell proliferation in responders was ≥2.5%/106 PBMC after TT 
stimulation. Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
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4.3.1.9 Maternal MDSC frequency in responders versus non-responders to PPD 
stimulation as measured by CD4+ T cell proliferation 
Maternal MDSC frequency at delivery was not significantly different in mothers who responded 
to PPD stimulation versus those with poor CD4+ T cell proliferative responses to PPD at birth 
and at one year postpartum. As shown in Figure 4.12, maternal MDSC frequencies at delivery 
were median of responders=0.285% versus non-responders=0.532% and p=0.425, and at one 
year postpartum were median of responders=0.831% versus non-responders=1.500% and 
p=0.260. Also, similarly to the observation with TT, the lack of a significant difference at year 
one may be due to the small sample size, a significant different difference may be obtained with 
a larger sample size. 
 
                     
Figure 4.12: Maternal MDSC frequency in CD4+ T cell proliferative responders versus non-responders to 
PPD stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as the frequency of CD4+ T cells proliferative responses to PPD at the respective 
time points. The frequency of CD4+ T cell proliferation in responders was ≥2.5%/106 PBMC after PPD 
stimulation. Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
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Table 4.5: Summary of the results of all infant and mothers MDSC frequency and absolute counts measured in 
responders versus non-responders as measured by CD4+ T cell proliferation. P-values of infants and mothers 
MDSC frequency (%) and absolute count (#) measured in responders versus non-responders as measured by CD4+ T 
cell proliferation to the following antigens [Hepatitis B (Hep B), Tetanus toxoid (TT) and Purified Protein 
Derivatives of M. bovis (PPD)]. Blue highlights represent the parameters (p-values and type of data sets), Red 
highlights represent the different time points [birth (D0), 6, 10 and 14 weeks (WK6, WK10 and WK14), 6 and 9 
months (Mth6 and Mth9), and 1 year (YR1)]. GRP=Group, Indv.=Individual, TP= Time point, B=Baby, and 
M=Mother.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B  GRP TP (%MDSC) (B)   0.767 0.143 
Hep B  GRP TP (#MDSC) (B)   0.599 0.072 
TT  GRP TP (%MDSC) (B)   0.606 0.966 
TT  GRP TP (#MDSC) (B)   0.325 0.855 
PPD  GRP TP (%MDSC) (B)  0.246 0.365 
PPD  GRP TP (#MDSC) (B)  0.726 0.979 
Hep B  Indv. TP (%MDSC) (M) 0.947      0.849 
TT  Indv. TP (%MDSC) (M) 0.344      0.158 
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4.3.2 CD4+ T cell proliferation to vaccines and antigens in PBMC (presence 
of MDSC) versus without MDSC (after MDSC depletion) in infants and 
mothers  
The T cell proliferative responses to HepB and TT vaccinations and to PPD and Dynabead 
antigens in CBMC and/or PBMC were evaluated in infants and mothers in the presence and 
absence of MDSC, to evaluate the effects of MDSC more directly (Figure 4.1). Since MDSC 
highly express CD15, as described in section 4.2.1, the EasySep® magnetic cell separation 
technique was performed to deplete CD15+ expressing cells from a portion of the CBMC 
and/or PBMC. The effect of MDSC on T cell proliferative responses to vaccines and antigens 
was then measured by performing the CFSE incorporation technique on cells depleted of 
CD15+ cells (absence of MDSC) and in whole PBMC (presence of MDSC) (Figure 4.2). 
Among the MDSC depleted sample group, only samples with depletion purity of 90% or more 
were included in the analysis (Appendix 4.3).  
As described in section 4.3 (2), T cell proliferative responses were measured in infants at 
individual time points after the different vaccines were administered to infants (i.e. at 6, 10 and 
14 weeks, at 6 and 9 months, and at one year of age), and in mothers after stimulation with the 
different antigens, T cell proliferation was measured at delivery and again at one year 
postpartum. We also evaluated the effect of MDSC on CD4+ T cell proliferation to vaccines 
and antigens in grouped time point analyses, based on the time points described in section 4.3 
(2) (b). 
The data as presented below include matched pair of samples as whole PBMC (presence of 
MDSC) and the absence of MDSC (MDSC depleted). Also, unmatched comparison between 
HEU versus HU infants as well as HIV+ versus HIV- mothers at the respective time points 
either in whole PBMC (presence of MDSC) and after MDSC depletion when the number of 
participants were enough for statistical analyses to be performed. Table 4.6 and 4.7 below 
shows the summary of the results. 
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One of the challenges of this study was the large volumes of blood required for all the assays 
from infants, and the volume of blood collected from most infants was not always enough for 
CD15+ depletion. MDSC depletion was only performed when there was enough PBMC to 
perform the assays. Due to this, there were only a limited number of infants and their mothers 
at most time points for which depletion was performed to permit MDSC non-depleted versus 
MDSC depleted match paired analyses to be performed. Shown in Appendix 4.4 is the 
unmatched analyses between MDSC non-depleted versus MDSC depleted samples in all 
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4.3.2.1 Hep B induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in infants 
As shown in Figure 4.13 (i), there were generally no significant differences in Hep B-induced 
CD4+ T cell proliferation  at the individual time points in whole PBMC and without MDSC in 
infants at 10 and 14 weeks (p=0.125 and p=0.998), at 6 and 9 months (p=0.094 and p=0.625 
respectively). However, at 1 year of age (median of CD15 non-depleted=0.099% versus CD15 
depleted=0.550%; p=0.031) there were significantly higher CD4+ T cell proliferative responses 
to Hep B after MDSC depletion. There were no significant differences in the grouped time point 
 
Figure 4.13 (i): CD4+ T cell proliferative responses to Hep B in infants in whole PBMC versus 
without MDSC in the individual time points. In the individual time point analyses, CD4+ T cells 
proliferative responses to Hep B were measured in whole PBMC (CD15 non-depleted – green) versus 
without MDSC (CD15 depleted – red) post vaccination at 10 and 14 weeks, at 6 and 9 months and at one 
year of age in infants. Matched pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 
significant level and statistical significance was tested using non-parametric Wilcoxon matched-pairs* 
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analyses in whole PBMC and without MDSC at 10 and 14 weeks (median of CD15 non-
depleted=0.300% versus CD15 depleted=0.200%; p=0.769) and at 6, 9 months and 1 year 




Figure 4.13 (ii): CD4+ T cell proliferative responses to Hep B in infants in whole PBMC versus without 
MDSC in the grouped time points. In the grouped time point analyses, at 10 and 14 weeks (after first and 
second doses of Hep B vaccination), at 6 and 9 months and one year of age (after last dose of Hep B 
vaccination). Matched pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 significant 
level and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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4.3.2.2 Hep B induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, the CD4+ T cell proliferative responses to Hep B were evaluated in PBMC with and 
without MDSC at delivery and again at one year postpartum. As shown in Figure 4.14, there was 
a significantly higher CD4+ T cell proliferation to Hep B stimulation at delivery (median of 
CD15 non-depleted=0.140% versus CD15 depleted=1.050%, p<0.001) but this difference was 
not significant at one year postpartum (median of CD15 non-depleted=0.450% versus CD15 
depleted=1.580%; p=0.063). 
 
Figure 4.14: CD4+ T cell proliferative responses to Hep B in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to Hep B were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 Non-depleted – green) versus without MDSC (CD15 Depleted 
– red). Matched pair of dots on the plot represent a mother. Bars indicate medians; p<0.05 significant level 




Chapter 4: T-cell proliferation in whole PBMC vs. without MDSC     120 
 
4.3.2.3 Hep B induced CD4+ T cell proliferation in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants  
We compared the frequency of proliferating T cells to Hep B vaccination between HEU versus 
HU infants at 10 and 14 weeks; at 6 and 9 months and at one year in whole PBMC.  
There were no significant differences either at the individual time points in CD4+ T cell 
proliferative responses between groups at all time points (however, at 10 weeks and at 9 
months, the number of HEU infants for which Hep B proliferative responses were measured 
 
 
Figure 4.15: CD4+ T cell proliferative responses to Hep B in whole PBMC in HEU versus HU infants. 
CD4+ T cells proliferative responses to Hep B in whole PBMC (CD15 non-depleted) were measured at birth, 
at 6, 10 and 14 weeks, at 6 and 9 months, and at one year of age (data not enough for ploting), and in the 
grouped analysis, at birth and 6 weeks (before Hep B priming), 10 and 14 weeks (after first and second doses 
of Hep B vaccination), at 6 and 9 months and one year of age (after last dose of Hep B vaccination) in HEU 
infants (blue) versus HU infants(black). Each dot on the plot represent an infant. Bars indicate medians and 
whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested using 
Mann-Whitney U test.    
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was small and statistical analysis could not be performed; data not shown). In the grouped 
analyses, there was no significant difference in proliferative response in the HEU versus HU 
infants at 10 and 14 weeks grouped time points (median of HEU=0% versus HU=0.490%; 
p=0.231) and at 6, 9 months and 1 year (median of HEU=0.102% versus HU=0.40%; p=0.613) 
(Figure 4.15). 
4.3.2.4 Hep B induced CD4+ T cell proliferation after MDSC depletion in HEU versus 
HU infants  
Although we found no statistically significant differences in MDSC frequency in HEU vs HU 
infants (Chapter 3, section 3.3.1.2) even though there was a trend towards a high MDSC 
frequency in HEU infants, we evaluated if HIV-exposure would alter the functional effect of 
MDSC on CD4+ T cell proliferation. We compared the frequency of proliferating T cells to 
Hep B after MDSC depletion between HEU versus HU infants at 10 and 14 weeks; at 6 and 9 
months and at one year of age. There were no significant differences at the individual time 
points in CD4+ T cell proliferative responses between groups (however, at 10 weeks and at 9 
months, the number of HEU infants for which Hep B proliferative responses were measured 
was small and statistical analysis could not be performed; data not shown). In the grouped time 
point analyses at 10 and 14 weeks (median of HEU=0.001% versus HU=0.380%; p=0.524) 
and at 6, 9 months and 1 year (median of HEU=0.275% versus HU=0.2.981%; p=0.739) there 











Figure 4.16: CD4+ T cell proliferative responses to Hep B without MDSC in HEU versus HU infants. 
CD4+ T cells proliferative responses to Hep B after MDSC depletion (CD15 depleted) were measured at 
birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age (data not enough for ploting), and in the 
grouped analysis, at birth and 6 weeks (before Hep B priming), 10 and 14 weeks (after first and second doses 
of Hep B vaccination), at 6 and 9 months and one year of age (after last dose of Hep B vaccination) in HEU 
infants (blue) versus HU infants(black). Each dot on the plot represent an infant. Bars indicate medians and 
whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested using 
Mann-Whitney U test.   
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4.3.2.5 Hep B induced CD4+ T cell proliferation in HIV+ versus HIV- mothers  
We compared the frequency of proliferative T cell responses to Hep B in PBMC between HIV+ 
versus HIV- mothers at delivery and at one year postpartum. As shown in Figure 4.17, there 
were no significant differences in CD4+ T cell proliferative responses between groups either at 
delivery or at one year postpartum.  
 
Figure 4.17: CD4+ T cell proliferative responses to Hep B in HIV+ versus HIV- mothers in whole 
PBMC. CD4+ T cells proliferative responses to Hep B were measured at delivery and at one year postpartum 
in mothers in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on 
the plot represent a mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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4.3.2.6 Hep B induced CD4+ T cell proliferation in HIV+ versus HIV- mothers after MDSC 
depletion  
We compared the effect of MDSC depletion on CD4+ T cell proliferation to Hep B in HIV-
infected versus negative mothers at delivery and at one year postpartum. Depleting MDSC had 
little effect on CD4+ T cell proliferative responses between groups at all time points (however, 
at 1 year postpartum the number of HIV+ mothers for which Hep B proliferative responses 
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4.3.2.7 TT induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in infants 
The CD4+ T cell proliferative responses to TT vaccination were evaluated in whole PBMC and 
without MDSC in infants at all time points post TT vaccination in infant [Figure 4.18 (i)]. We 
compared CD4+ T cell proliferative responses at the individual time points after TT 
 
Figure 4.18 (i): CD4+ T cell proliferative responses to TT in infants in whole PBMC versus without 
MDSC in the individual time points. In the individual time point analyses, CD4+ T cells proliferative 
responses to TT were measured in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 
depleted – red) post vaccination at 10 and 14 weeks, at 6 and 9 months and at one year of age in infants. 
Matched pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 significant level and 
statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
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vaccination between whole PBMC and without MDSC in infants. There was no significant 
difference at 10 and 14 weeks (p=0.156 and p=0.125 respectively), at 6 and 9 months (p=0.750 
and p=0.438 respectively) and at one year (p=0.501) of age. In the grouped time point analyses 
in whole PBMC versus without MDSC, there was no significant difference in CD4+ T cell 
proliferative responses to TT at 10 and 14 weeks (p=0.078), and at 6, 9 months and one year 




Figure 4.18 (ii): CD4+ T cell proliferative responses to TT in infants in whole PBMC versus without 
MDSC in the grouped time points. In the grouped time point analyses, at 10 and 14 weeks (after first and 
second doses of TT vaccination), at 6 and 9 months and one year of age (after last dose of TT vaccination). 
Matched pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 significant level and 
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4.3.2.8 TT induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, the CD4+ T cell proliferative responses to TT were evaluated in whole PBMC and 
without MDSC at delivery and again at one year postpartum. As shown in Figure 4.19, there was 
a significantly higher maternal CD4+ T cell proliferative responses to TT stimulation at delivery 
after MDSC depletion (median of CD15 non-depleted=0%, IQR=0-0.580 versus CD15 
depleted=0.780%, IQR=0.397-1.715 and p=0.012) but not at one year postpartum (median of 
CD15 non-depleted=0%, IQR=0-0.070 versus CD15 depleted=0%, IQR=0.101-1.370 and 
p=0.250). 
 
Figure 4.19: CD4+ T cell proliferative responses to TT in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to TT were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 Non-depleted – green) versus without MDSC (CD15 Depleted 
– red). Matched pair of dots on the plot represent a mother. Bars indicate medians; p<0.05 significant level 
and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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4.3.2.9 TT induced CD4+ T cell proliferation in HIV-exposed uninfected (HEU) versus 
HIV-unexposed (HU) infants  
We compared the frequency of proliferating CD4+ T cells to TT vaccination in whole PBMC 
between HEU versus HU infants at all time points post TT vaccination. There were no 
significant differences in CD4+ T cell proliferative responses between groups at any time point 




Figure 4.20: CD4+ T cell proliferative responses to TT in whole PBMC in HEU versus HU infants. (a) 
In the individual time point analysis, CD4+ T cells proliferative responses to TT in whole PBMC (CD15 non-
depleted) were measured at 10 and 14 weeks, at 6 and 9 months, and at one year of age, and (b) in the 
grouped analyses, at 10 and 14 weeks (after first and second doses of TT vaccination), at 6 and 9 months and 
one year of age (after last dose of TT vaccination) in HEU infants (blue) versus HU infants(black). Each dot 
on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
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4.3.2.10 TT induced CD4+ T cell proliferation after MDSC depletion in HEU versus HU 
infants  
To evaluate if HIV-exposure would contribute to the effect of MDSC on CD4+ T cell 
proliferation, we compared the frequency of proliferative responses to TT vaccination in the 
absence of MDSC between HEU versus HU infants in the first year of life. As shown in Figure 
4.21 (i), there were no significant differences in CD4+ T cell proliferative responses between 




Figure 4.21 (i): CD4+ T cell proliferative responses to TT without MDSC in HEU versus HU infants. (a) 
In the individual time point analysis, CD4+ T cells proliferative responses to TT after MDSC depletion (CD15 
depleted) were measured at 10 and 14 weeks, at 6 and 9 months, and at one year of age, and (b) in the 
grouped analyses, at 10 and 14 weeks (after first and second doses of TT vaccination), at 6 and 9 months and 
one year of age (after last dose of TT vaccination), at 6 and 9 months and one year of age (after last dose of 
TT vaccination) in HEU infants (blue) versus HU infants(black). Each dot on the plot represent an infant. 
Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and statistical 
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Further, Figure 4.21 (ii) shows a combination of CD4+ T cell proliferative responses to TT with 
and without MDSC in HEU vs HU infants. 
 
 
Figure 4.21 (ii): CD4+ T cell proliferative responses to TT with and without MDSC combined in HEU 
versus HU infants. (a) In the individual time point analysis, CD4+ T cells proliferative responses to TT 
before and after MDSC depletion (CD15 depleted) were measured at 10 and 14 weeks, at 6 and 9 months, 
and at one year of age, and (b) in the grouped analyses, at 10 and 14 weeks (after first and second doses of TT 
vaccination), at 6 and 9 months and one year of age (after last dose of TT vaccination), at 6 and 9 months and 
one year of age (after last dose of TT vaccination) in HEU infants (blue/purple) versus HU 
infants(black/brown). Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 





Chapter 4: T-cell proliferation in whole PBMC vs. without MDSC     131 
 
4.3.2.11 TT induced CD4+ T cell proliferation in HIV+ versus HIV- mothers  
We evaluated the frequency of proliferating T cells to TT between HIV+ versus HIV- mothers 
at delivery and at one year postpartum. As shown in Figure 4.22, there were no significant 
differences in CD4+ T cell proliferative responses between groups at all time points. However, 




Figure 4.22: CD4+ T cell proliferative responses to TT in HIV+ versus HIV- mothers in whole PBMC. 
CD4+ T cells proliferative responses to TT were measured at delivery and at one year postpartum in mothers 
in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the plot 
represent a mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
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4.3.2.12 TT induced CD4+ T cell proliferation in HIV+ versus HIV- mothers after MDSC 
depletion  
We also evaluated if depleting MDSC would have different effects in HIV-infected versus 
uninfected mothers on CD4+ T cell proliferation to TT at delivery and at one year postpartum. 
There were no significant differences in CD4+ T cell proliferative responses between groups at 
all-time points. However, responses were very low for both groups and at 1 year postpartum 
the number of HIV+ mothers for which TT proliferative responses were measured was small 
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4.3.2.13 PPD induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in infants 
The CD4+ T cell proliferative responses to Mycobacterium bovis BCG vaccination were 
evaluated in whole PBMC and without MDSC in infants at 6, 10 and 14 weeks, at 6 and 9 
months, and at one year of age, by measuring responses to PPD stimulation.  
 
Figure 4.23 (i): CD4+ T cell proliferative responses to PPD in infants in whole PBMC versus without 
MDSC in the individual time points. In the individual time point analyses, CD4+ T cells proliferative 
responses to PPD were measured in whole PBMC (CD15 non-depleted – green) versus without MDSC 
(CD15 depleted – red) at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants. Matched 
pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 significant level and statistical 
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There were no significant differences either at the individual time points at 6, 10 and 14 weeks 
(p=0.375, p=0.813 and p=0.313 respectively), at 6 and 9 months (p=0.996 and p=0.383 
respectively) and at one year (p=0.779) [(Figure 4.23) (i)]. In the grouped time point analyses 
there was no significant difference with and without MDSC at 6, 10 and 14 weeks (p=0.998) and 
at 6, 9 months and one year (p=0.775) [(Figure 4.23) (ii)]. 
 
 
Figure 4.23 (ii): CD4+ T cell proliferative responses to PPD in infants in whole PBMC versus without 
MDSC in the grouped time point analyses. In the grouped time point analyses, at 6, 10 and 14 weeks (first 
few weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). Matched 
pair of dots on the plot represent an infant. Bars indicate medians; p<0.05 significant level and statistical 
significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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4.3.2.14 PPD induced CD4+ T cell proliferation in total PBMC versus after MDSC 
depletion in mothers 
In mothers, CD4+ T cell proliferative responses to PPD were evaluated in PBMC before and after 
MDSC depletion at delivery and again at one year postpartum. As shown in Figure 4.24, there 
was no significant difference at delivery (p=0.532) and at one year postpartum (p=0.438) (Figure 
4.24). 
 
Figure 4.24: CD4+ T cell proliferative responses to PPD in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to PPD were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted 
– red). Matched pair of dots on the plot represent a mother. Bars indicate medians; p<0.05 significant level 
and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
(b) 
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4.3.2.15 PPD induced CD4+ T cell proliferation in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants  
We compared the frequency of proliferating T cells to PPD stimulation between HEU versus 
HU infants at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in whole PBMC.  
As shown in Figure 4.25, there were no significant differences in CD4+ T cell proliferative 





Figure 4.25: CD4+ T cell proliferative responses to PPD in whole PBMC in HEU versus HU infants. (a) 
In the individual time point analysis, CD4+ T cells proliferative responses to PPD in whole PBMC (CD15 
non-depleted) were measured at 6, 10 and 14 weeks, at 6 and 9 months, and at one year of age, and (b) in the 
grouped analysis, at 6, 10 and 14 weeks (first few weeks after priming), at 6 and 9 months and one year of 
age (the last follow-up time points) in HEU infants (blue) versus HU infants(black). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
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4.3.2.16 PPD induced CD4+ T cell proliferation after MDSC depletion in HEU versus 
HU infants  
To evaluate if HIV-exposure would influence the effect of MDSC on CD4+ T cell proliferation 
to PPD, we compared the frequency of proliferating T cells to PPD stimulation after MDSC 
depletion between HEU versus HU infants at all time points (Figure 4.26). There were no 
significant differences in CD4+ T cell proliferative responses between groups at all time points 
either, at the individual time points (however, at 10 and 14 weeks, the number of HU infants 
for which Hep B proliferative responses were measured was small and statistical analysis 
could not be performed; data not shown), or in the grouped analysis. Further, Figure 4.26 (ii) 
shows a combination of CD4+ T cell proliferative responses to PPD with and without MDSC 
in HEU vs HU infants. 
 
Figure 4.26 (i): CD4+ T cell proliferative responses to PPD without MDSC in HEU versus HU infants. 
CD4+ T cells proliferative responses to PPD without MDSC (CD15 depleted) were measured at 6, 10 and 14 
weeks, at 6 and 9 months and at one year year of age (data not enough for ploting), and in the grouped 
analysis, at 6, 10 and 14 weeks (first few weeks after priming), at 6 and 9 months and one year of age (the last 
follow-up time points) in HEU infants (blue) versus HU infants(black). Each dot on the plot represent an 
infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and statistical 











Figure 4.26 (ii): CD4+ T cell proliferative responses to PPD with and without MDSC in HEU versus HU 
infants. CD4+ T cells proliferative responses to PPD with and without MDSC  were measured at 6, 10 and 14 
weeks, at 6 and 9 months and at one year year of age (data not enough for ploting), and in the grouped 
analysis, at 6, 10 and 14 weeks (first few weeks after priming), at 6 and 9 months and one year of age (the last 
follow-up time points) in HEU infants (blue/purple) versus HU infants(black/brouwn). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
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4.3.2.17 PPD induced CD4+ T cell proliferation in HIV+ versus HIV- mothers  
We looked at the frequency of proliferating T cells to PPD between HIV+ versus HIV- 
mothers at delivery and at one year postpartum. As shown in Figure 4.27, there were no 
significant differences in CD4+ T cell proliferative responses between groups at either time 
point. 
 
Figure 4.27: CD4+ T cell proliferative responses to PPD in HIV+ versus HIV- mothers in whole PBMC. 
CD4+ T cells proliferative responses to PPD were measured at delivery and at one year postpartum in mothers 
in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the plot 
represent a mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using Mann-Whitney U test.   
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4.3.2.18 PPD induced CD4+ T cell proliferation in HIV+ versus HIV- mothers after MDSC 
depletion 
We also evaluated if depleting MDSC would have different effects in HIV infected versus 
uninfected mothers on CD4+ T cell proliferation to PPD at delivery and at one year 
postpartum. As shown in Figure 4.28, there were no significant differences in CD4+ T cell 
proliferative responses between groups observed. 
 
Figure 4.28: CD4+ T cell proliferative responses to PPD in HIV+ versus HIV- mothers without MDSC. 
CD4+ T cells proliferative responses to PPD were measured at delivery and at one year postpartum in mothers 
without MDSC (CD15 depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the plot represent 
a mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and 
statistical significance was tested using Mann-Whitney U test.   
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4.3.2.19 Dynabead induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in infants 
Anti-CD3CD28 (Dynabead) was employed as a positive control in this study, as it has been 
shown to be strong T cell activator acting directly on T cell receptors and does not require feeder 
cells (antigen presenting cells) or antigens(Li et al., 2010)(Oviedo-Orta et al., 2010). To 
investigate the influence of MDSC on T cell proliferation to strong, non-specific stimulation, we 
evaluated CD4+ T cell proliferative responses to α-CD3CD28 (Dynabead) stimulation in whole 
PBMC and without MDSC in infants at birth, at 6, 10 and 14 weeks, at 6 and 9 months, and at 
one year of age [(Figure 4.29 (i)(a-c)]. Proliferation at all time points was robust. There were 
 
Figure 4.29 (i)(a): CD4+ T cell proliferative responses to Dynabead in infants in whole PBMC versus 
without MDSC in the individual time points. CD4+ T cells proliferative responses to Dynabead were 
measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Matched pair of dots on the plot 
represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical significance was 
tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
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some significant differences observed, at birth the frequency of CD4+ T cell proliferative 
responses to Dynabead was significantly lower at birth (median of CD15 Non-depleted=83.600% 
versus CD15 Depleted=68.30% and p=0.012) and at 6 weeks of age (median of CD15 Non-
depleted=62.000% versus CD15 Depleted=54.700% and p=0.049) in infants after MDSC 
depletion but not at 10 and 14 weeks (p=0.548 and p=0.074 respectively); or at 6 and 9 months 
(p=0.425 and p=0.168 respectively) and at one year (p=0.998) [(Figure 4.29 (i)(a-c)]. Also, a 
significantly lower T cell proliferation to Dynabeads was observed in the grouped time point 
analyses at birth and 6 weeks grouped time points after MDSC depletion (median of CD15 Non-
depleted=84.160% versus CD15 Depleted=67.85% and p=0.009) [(Figure 4.29 (ii)]. In general, 
our observation shows that in response to Dynabead stimulation, proliferation decreased post 
MDSC depletion in infants.  
 
Figure 4.29 (i)(b): CD4+ T cell proliferative responses to Dynabead in infants in whole PBMC versus 
without MDSC in the individual time points. CD4+ T cells proliferative responses to Dynabead were 
measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Matched pair of dots on the plot 
represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical significance was 
tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
KIDZERU, 2016 





Figure 4.29 (i)(c): CD4+ T cell proliferative responses to Dynabead in infants in whole PBMC versus 
without MDSC in the individual time points. CD4+ T cells proliferative responses to Dynabead were 
measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Matched pair of dots on the plot 
represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical significance was 
tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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Figure 4.29 (ii): CD4+ T cell proliferative responses to Dynabead in infants in whole PBMC versus 
without MDSC in the grouped time points. In the grouped time point analyses, Dynabead responses were 
measured at birth and 6 weeks, at 10 and 14 weeks, and  at 6 and 9 months and one year of age grouped time 
points. Matched pair of dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 
significant level and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign 
rank test. 
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4.3.2.20 Dynabead induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, the CD4+ T cell proliferative responses to Dynabead were evaluated in whole PBMC 
and without MDSC at delivery and at one year postpartum. As shown in Figure 4.30, there was a 
significantly higher CD4+ T cell proliferation in mothers at one year postpartum after MDSC 
depletion(median of CD15 non-depleted=79.650% versus CD15 depleted=88.060%; p=0.016), 
but not at delivery (median of CD15 non-depleted=72.910% versus CD15 depleted=60.110%; 
p=0.686). 
 
Figure 4.30: CD4+ T cell proliferative responses to Dynabead in mothers in whole PBMC versus 
without MDSC. CD4+ T cells proliferative responses to Dynabead  were measured at delivery and again at 
one year postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 
depleted – red). Matched pair of dots on the plot represent a mother. Bars indicate interquartile range; p<0.05 
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4.3.2.21 Dynabead induced CD4+ T cell proliferation in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants  
To evaluate if HIV-exposure would influence CD4+ T cell proliferation to strong, non-specific 
stimulation, we looked at the frequency of proliferating T cells to Dynabead stimulation in 
whole PBMC between HEU versus HU infants at birth, at 6, 10 and 14 weeks, at 6 and 9 
months and at one year of age. As shown in Figure 4.31, there were no significant differences 
in CD4+ T cell proliferative responses between groups.  
 
Figure 4.31: CD4+ T cell proliferative responses to Dynabead in whole PBMC in HEU versus HU 
infants. CD4+ T cells proliferative responses to Dynabead in whole PBMC (CD15 non-depleted) were 
measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months, and at one year postnatal in HEU infants (blue) 
versus HU infants(black). Each dot on the plot represent an infant. Bars indicate medians and whiskers 
indicate interquartile range; p<0.05 significant level and statistical significance was tested using Mann-
Whitney U test.   
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4.3.2.22 Dynabead induced CD4+ T cell proliferation after MDSC depletion in HEU 
versus HU infants  
We evaluated the frequency of proliferating T cells to Dynabead stimulation in the absence of 
MDSC between HEU versus HU infants at birth; 6, 10 and 14 weeks; at 6 and 9 months and at 
one year of age. As shown in Figure 4.32, there were no significant differences in CD4+ T cell 
proliferative responses. T cell proliferation was robust in both HEU and HU infants after 
Dynabead stimulation. 
 
Figure 4.32: CD4+ T cell proliferative responses to Dynabead without MDSC in HEU versus HU 
infants. CD4+ T cells proliferative responses to Dynabead without MDSC (CD15 depleted) were measured at 
birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in HEU infants (blue) versus HU 
infants(black). Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 
interquartile range; p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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4.3.2.23 Dynabead induced CD4+ T cell proliferation in HIV+ versus HIV- mothers  
We evaluated if HIV infection in mothers would affect CD4+ T cell proliferation to strong, 
non-specific stimulation. We investigated the frequency of proliferative T cells to Dynabead in 
the presence of MDSC (CD15 Non-depleted) between HIV+ versus HIV- mothers at delivery 
and at one year postpartum. As shown in Figure 4.33, there were no significant differences 
observed in CD4+ T cell proliferative responses between groups at all time points.  
 
Figure 4.33: CD4+ T cell proliferative responses to Dynabead in HIV+ versus HIV- mothers in whole 
PBMC. CD4+ T cells proliferative responses to Dynabead were measured at delivery and at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. 
Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile range; 
p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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4.3.2.24 Dynabead induced CD4+ T cell proliferation in HIV+ versus HIV- mothers after 
MDSC depletion 
We evaluated if MDSC depletion would influence CD4+ T cell proliferation to strong, non-
specific stimulation in HIV infection. We looked at the frequency of proliferating T cells to 
Dynabeads in the absence of MDSC (CD15 Depleted) between HIV+ versus HIV- mothers at 
delivery and at one year postpartum. There were no significant differences in CD4+ T cell 
proliferative responses between groups at all time points. However, at 1 year postpartum the 
number of HIV+ mothers for which Dynabead proliferative responses were measured was small 
and statistical analysis could not be performed; data not shown). 
Table 4.6: Summary of the results of all infant and mothers CD4+ T cell proliferation to vaccines and antigens 
in PBMC (presence of MDSC) versus without MDSC (after MDSC depletion) in infants and mothers. P-values 
of infants and mothers CD4+ T cell proliferation in PBMC (presence of MDSC) versus without MDSC (after MDSC 
depletion) after stimulation with the following antigens [Hepatitis B (Hep B), Tetanus toxoid (TT), Purified Protein 
Derivatives of M. bovis (PPD) and anti-CD3CD28 (Dynabead)]. Blue highlights represent the parameters (p-values 
and type of data sets), Red highlights represent the different time points [birth (D0), 6, 10 and 14 weeks (WK6, 
WK10 and WK14), 6 and 9 months (Mth6 and Mth9), and 1 year (YR1)], and Purple highlights represent significant 
differences in CD4+ T cell proliferation in the presence of MDSC versus after MDSC depletion to vaccine antigens. 
GRP=Group, Indv=Individual, TP= Time point, B=Baby, and M=Mother.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B Indv. TP (B)   0.125 0.998 0.094 0.625 0.031 
Hep B GRP TP (B)   0.769 0.209 
Hep B Indv.TP (M) <0.001      0.063 
TT Indv. TP (B)   0.158 0.125 0.750 0.438 0.501 
TT GRP TP (B)   0.078 0.850 
TT Indv.TP (M) 0.012      0.250 
PPD Indv TP (B)  0.375 0.813 0.313 0.998 0.383 0.779 
PPD GRP TP (B)  0.998 0.775 
PPD Indv.TP (M) 0.532      0.438 
Dynabead Indv TP (B) 0.012 0.049 0.548 0.074 0.426 0.168 0.998 
Dynabead GRP TP (B) 0.009 0.252 0.698 
Dynabead Indv.TP (M) 0.686      0.016 
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Table 4.7: Summary of the results of all infant and mothers CD4+ T cell proliferation to vaccines and antigens 
in HEU versus HU infants as well as in HIV+ versus HIV- mothers in PBMC (presence of MDSC) and without 
MDSC (after MDSC depletion). P-values of infants and mothers CD4+ T cell proliferation in PBMC (presence of 
MDSC) and without MDSC (after MDSC depletion) in HEU versus HU infants as well as in HIV+ versus HIV- 
mothers after stimulation with the following antigens [Hepatitis B (Hep B), Tetanus toxoid (TT), Purified Protein 
Derivatives of M. bovis (PPD) and anti-CD3CD28 (Dynabead)]. Blue highlights represent the parameters (p-values 
and type of data sets), Red highlights represent the different time points [birth (D0), 6, 10 and 14 weeks (WK6, 
WK10 and WK14), 6 and 9 months (Mth6 and Mth9), and 1 year (YR1)], and Purple highlights represent significant 
differences in CD4+ T cell proliferation to vaccine antigens in the presence and absence of MDSC in HEU versus HU 
infants. GRP=Group, Indv=Individual, TP= Time point, B=Baby, M=Mother, N=MDSC non-depleted, and 
D=MDSC depleted.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B GRP TP (B) (N)   0.232 0.613 
Hep B GRP TP (B) (D)   0.524 0.739 
Hep B Indv TP (M) (N) 0.626      0.775 
TT Indv TP (B) (N)   0.796 0.723 1.000 0.493 0.672 
TT GRP TP (B) (N)   0.914 0.391 
TT Indv TP (B) (D)   1.000 0.745 1.000 0.466 0.728 
TT GRP TP (B) (D)   0.984 0.449 
TT Indv TP (M) (N) 0.981      0.443 
PPD Indv TP (B) (N)  0.491 0.513 0.556 0.845 0.782 0.576 
PPD GRP TP (B) (N)  0.636 0.905 
PPD GRP TP (B) (D)  0.277 0.517 
PPD Indv TP (M) (N) 0.910      0.117 
PPD Indv TP (M) (D) 0.752      0.237 
Dynabead Indv TP (B) (N) 0.681 0.127 0.687 0.909 0.622 0.734 0.330 
Dynabead Indv TP (B) (D) 0.642 0.880 0.080 0.643 0.315 0.436 0.497 
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4.4 Discussion  
As much as characterising and evaluating the quantity and ontogeny of myeloid derived 
suppressor cells (MDSC) is important, evaluating their effect on vaccine responses is vital. T cell 
proliferation is an essential evaluation of vaccine immunogenicity and T cell function. MDSC 
are known to influence T cell proliferation to non-specific antigens. Rieber et al. showed 
suppression of T cell proliferation to α-CD3 supplemented with IL-2 by cord blood 
MDSC(Rieber et al., 2013). Also, in response to α-CD3CD28 (Dynabead), we have shown that 
in neonates, MDSC dampens T cell responses in cord blood(Gervassi et al., 2014). Little is 
known about the effect of MDSC on T cell proliferative responses to vaccines in infants (Gantt et 
al., 2014)(Gervassi et al., 2014). 
In this chapter, we evaluated CD4+ T cell proliferation in response to Hep B and TT antigens, 
and to Mycobacterium bovis tuberculin PPD and Dynabead antigens. Generally, there was an 
overall good T cell proliferation to Hep B vaccination, but very low T cell proliferation to TT 
in infants post vaccination and in mothers at all time points. T cell proliferation to PPD was 
good post BCG vaccination in infants. As a caveat of the study, understanding that that PPD is 
a cell-free purified protein fraction obtained from a human strain of Mycobacterium 
tuberculosis(Willett, 2014), we cannot completely rule out the impact of environmental 
Mycobacteria tuberculosis exposure when measuring PPD responses. However, the influence 
of environmental M. tb has been shown to be minimal(Mandalakas et al., 2015)(Hesseling et 
al., 2015). Moreover, there were some infants who responded poorly to all the vaccines 
assessed.  
There were little and in most cases no significant differences at most grouped time point 
analyses in MDSC frequency and absolute count between infants whose CD4+ T cell 
responded and those who had poor CD4+ T cell proliferation to most vaccine antigens. Also, 
maternal MDSC frequency was not significantly different in responders versus non-responders 
to all the vaccines stimulation. Moreover, we hypothesized that MDSC frequency will 
influence CD4+ T cell proliferation negatively, but contrary to our hypothesis in infants, there 
was more often a trend towards high MDSC frequency and counts in responders compared to 
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non-responders to most vaccine antigens. This may have been because we compared the in-
vitro response to these antigens to the MDSC count and frequency at the same time point. 
MDSC may influence vaccine responses in-vivo at the time the vaccine is given, rather than 
influence the longevity of the later responses. Furthermore, since MDSC were present at 
higher frequencies at birth, and waned at later time points, their effects in older infants may be 
minimal.  
In chapter 3, we showed that granulocytic MDSC are elevated at birth and rapidly decrease from 
6 weeks onwards, this may account for the lack of effect of MDSC depletion on T cell 
proliferation to vaccines. Also, as one of the limitations of the study, MDSC were depleted by 
CD15 antibody selection for G-MDSC, thus, the suppressive effect of M-MDSC (though less 
than 1% present in healthy infants and adults) cannot be underestimated(Gervassi et al., 
2014).  The study is still accruing data, and with larger numbers, an effect on vaccine T cell 
proliferative responses may become apparent. Alternatively, MDSC may not have an influence 
on proliferative responses to vaccine antigens, or the effect of other suppressor cells elevated 
during gestation may alter the effect of MDSC. Also, MDSC may be vaccine and antigen 
dependent, playing a different role on the immune system yet to be understood.  
Possible other reasons for the lack of MDSC effect on T cell proliferation to vaccine antigens 
could be that the three to four days incubation period employed for cell culture was too long, 
and MDSC are short-lived cells; but cells were assessed for viability and 0.02% of 0.5ug/mL 
recombinant human IL-7 (rhIL-7) was added daily during incubation. In future, as a 
recommendation, studies using the CFSE incorporation assay should perhaps evaluate the 
effect of culturing cells in a fewer number of days (one to two days). Also, we did not evaluate 
CD8+ T cell proliferative responses; we might be ignoring responses of cytotoxic T cell 
proliferation. In the mothers, the effect of MDSC to vaccine antigens was limited.  
Although all mothers will have received BCG and TT vaccination in infancy, only mothers 
younger than 22 years of age will have received Hep B. A large proportion of mothers will have 
been exposed to M. TB and environmental mycobacteria. Also, most of the mothers would 
probably be exposed to Hep B infection and only a proportion of the mothers are likely to have 
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been cleared of the Hep B infection. Hep B may be an innate ligand in the unvaccinated mothers. 
Furthermore, the prevalence of Hepatitis B is approximately 80% in women of childbearing age 
in South Africa(Matthews et al., 2015)(Schweitzer et al., 2015). Therefore, responses in mothers 
may not be measuring vaccine immunogenicity, but rather response to natural infection.   
We found that MDSC may dampen the in-vitro recall response to some antigens, particularly, 
Tetanus and Hepatitis B. In the matched analyses there were significantly higher proliferative 
responses observed to these antigen stimulations after the depletion of CD15+ MDSC. In infants,  
at one year of age (post the last dose of Hep B vaccination and last follow-up time point) after 
Hep B stimulation in the individual time point’s analyses, there was a significantly higher T cell 
proliferation after MDSC were depleted compared to whole PBMC. In the mothers, significant 
differences were evident; we found significantly higher CD4+ T cell proliferative responses to 
both Hep B and TT vaccine stimulation after MDSC depletion compared to whole PBMC 
immediately postpartum. To the best of our knowledge, this study is the first to evaluate the 
effect of MDSC on T cell proliferation to vaccines in infants; and also, the first study to evaluate 
the effect of MDSC on T cell proliferative responses in mothers. The non-responders were both 
HEU as well as HU infants, and HIV+ and HIV- mothers was not mainly HEU infants or HIV+ 
mothers. 
After Dynabead stimulation, there were some significant differences observed. In infants, 
contrary to our hypothesis, at birth and at 6 weeks of age there were significantly lower CD4+ 
T cell proliferative responses after MDSC depletion compared to whole PBMC and a trend at 
14 weeks, and this was evident in the grouped time point analyses at birth and 6 weeks 
grouped time points. This is contrary to our finding in Gervassi et al. where we showed that 
MDSC dampens T cell proliferative responses in infants post Dynabead stimulation(Gervassi 
et al., 2014). The possible reason for this may be due to geographical, genetic, exposure to 
other pathogens and mode of delivery as infants in both studies were residing in different 
countries. Also, at the early time points at birth and 14 weeks since the MDSC frequency is 
expected to be more, the effect of depletion could probably have been felt more than at the 
later time points when MDSC frequency is expected to be low. However, this finding would 
warrant further investigation. 
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Also, at other time points there were trends towards lower T cell proliferation after MDSC 
depletion at 6 weeks and at 9 months of age post Dynabead stimulation. In mothers, in 
conformity with our hypothesis, after Dynabead stimulation at one year postpartum there was a 
significantly higher CD4+ T cell proliferation after MDSC depletion versus in whole PBMC. 
The increase in CD4+ T cell proliferation at one year post MDSC depletion but not at delivery 
could possibly be due to the fact that the frequency of MDSC at a one year postpartum as 
shown in Chapter 3 would be lower compared to immediately after gestation. Even though 
MDSC was depleted at delivery, the effect could still be felt due to the high concentration of 
MDSC at delivery.  
Our results contrast our findings in Gervassi et al. where we showed that MDSC suppressed in-
vitro cord blood T cell responses to Dynabeads(Gervassi et al., 2014). However, there were some 
differences between this study and that of Gervassi et al.  The infants in this study were recruited 
from normal vaginal delivery exposed to maternal vaginal microbiome and some exposed to in-
utero HIV-infection which may play a vital role in the developing infant immunity(Mueller et 
al., 2014)(Valdez et al., 2014), while the infants in the Gervassi et al. study were born from 
caesarean-sections and non-exposed to in-utero HIV-infection(Gervassi et al., 2014). All of 
theirs were American babies in tertiary care settings, ours were all Africans. Exposure to 
helminths prevalent in sub-Saharan Africa, tuberculosis and other infections in-utero have been 
shown to be associated with high MDSC frequencies(Van Ginderachter et al., 2010)(du Plessis 
et al., 2013).  
 In previous studies, we found significantly higher proliferative responses to vaccine antigens 
and non-speicifc stimuli in HEU versus HU (Kidzeru et al., 2014). These differences were not 
seen here. This could be due to differences between the two studies. In the previous study we 
evaluated responses in a larger number of HEU infants (n=46) versus a similar sample size of 
HU infants. Also, we employed the whole blood assay as well as Ki67 proliferation assay while 
in this study the CFSE proliferation assay was used. HIV-exposure did not alter T cell 
proliferation in infants.    
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We hypothesised that HIV-exposure and HIV infection may contribute to the effect of MDSC on 
T cell proliferation to vaccines. However, we found no such influence. This could be secondary 
to small numbers or possibly due to a true lack of difference in MDSC frequency and function in 
HIV-exposed infants. As much as HIV-exposure did not affect T cell proliferation before and 
after MDSC depletion, HIV infection did not in response to all vaccine and antigen stimulation 
in mothers, and this was observed both at delivery and at one year postpartum. However, there 
was a trend towards higher T cell proliferative responses in HIV negative mothers in response to 
Hep B in whole PBMC and after MDSC depletion. We cannot rule out the option that it could be 
as a result of past infection, since Hep B is known to upregulate MDSC(Pallett et al., 
2015)(Weber, 2015).   
Generally, mothers had very low T cell proliferative responses to TT, this shows that, it would be 
advantageous for mothers to be given boosters if cellular immune responses to TT are important. 
It is unlikely that mothers had been vaccinated as in South Africa pregnant women are not 
routinely given Tetanus toxoid vaccine boosters during gestation.  
To the best of our knowledge, this study is the first to evaluate the effect of MDSC on T cell 
proliferation to vaccines in infants; and also, the first study to evaluate the effect of MDSC on T 
cell proliferative responses in mothers. However, earlier studies have assessed the effect of 
MDSC on T cell proliferation in adults. The significant increase in T cell proliferation in mothers 
after MDSC depletion versus in whole PBMC at delivery in line with our hypothesis, could be 
supported as a result of several factors; The immune system of pregnant women is compromised 
and largely suppressed to accommodate for optimum viviparity, with high frequency of Tregs 
and other suppressive mechanisms including MDSC(Burt, 2013)(Gantt et al., 2014)(Bansal, 
2010)(Nair et al., 2015)(Ostrand-rosenberg et al., 2012). The increased frequency of regulatory cells 
may contain a high proportion of MDSC to create a state of equilibrium in the maternal immune 
system. The lack of significant difference at one year postpartum may be due to the fact that the 
quantity of MDSC fades out after gestation to level that would have little effect on T cell 
proliferation as expected. 
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The study as described has a few limitations; retention of participants in the study was 
challenging. Depletion was not always 100% and there was not always enough cells to do the 
assays, due to difficulty in collecting large volumes of blood from infants. The need for 106 cells 
/ well to perform the CFSE proliferation assay which at most times points was a major challenge 
collecting whole blood samples from infants. For the CD15 depletion assay, the lack of 
difference may be due to a function of the assay. After depletion using EasySep® magnetic cell 
separation technique, cells may be less “happy” compared to cells that have not gone through the 
same process. However, experiments where CD15 enriched cells are added back to CD15 
depleted cell are in progress and should may be provide a better comparison between MDSC 
presence and absence, since all cells would have gone through the same process. Furthermore, 
most responses were enhanced after CD15 depletion. 
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5.1 Introduction 
Neonates have limited capacity to produce IFN-γ and therefore, impaired cell-mediated immune 
responses against intracellular pathogens(Siegrist, 2007)(Ota et al., 2012). BCG vaccination at 
birth significantly enhances Th1 responses to mycobacterial antigens(Burl et al., 2012). There is 
evidence that IFN-γ production increases with age in infants(Mazzola, Marcos, & Abramczuk, 
2011).  
Several studies have shown that MDSC can suppress cytokine production, including IL-2 by 
CD4+ T cells and  IL-13, IL-6 and G-MCSF in plasma to SIV vaccination in macaques(Sui et 
al., 2014). Also, reduced TNF-α, IL-10 and IFN- production by CD4+ T cells to anti-
CD3CD28, and G-CSF, G-MCSF and MIP-1β in plasma(du Plessis et al., 2013). The immune 
suppressive effect of MDSC on cytokine responses have been widely described in non-human 
primates(Guo et al., 2012)(Sui et al., 2014) and humans with cancer(Raychaudhuri et al., 
2011). In patients with glioblastoma, accumulation of MDSC in peripheral blood has been 
shown to contribute to suppression of IFN- production by CD4+ T cell after stimulation with 
anti-CD3CD28(Raychaudhuri et al., 2011). However, in mice studies T cells producing IFN- 
have been shown to promote MDSC production in tumour-bearing mice(Guo et al., 2012).  
There is limited data on the effect of MDSC on vaccine cytokine responses. Most of the 
studies have looked at response to non-specific stimulation. Raychaudhuri et al. showed that, 
MDSC suppress IFN-γ production in response to anti-CD3CD28 (Raychaudhuri et al., 2011). 
Also, it has been shown that IFN-γ may contribute to the increase of MDSC in mice exposed to 
cyclophosphamide(Guo et al., 2012). Rieber and colleagues showed that neonatal MDSC 
suppress Th1 (IFN-γ), Th2 (IL-5) and Th17 (IL-17) cytokine production by adult 
PBMC(Rieber et al., 2013).  
As mentioned earlier, we and others have shown that the immune system of HIV infected and 
exposed infants is compromised and makes them susceptible to infections(Epalza et al., 2011), 
and alter their cytokine responses to vaccines(Miles et al., 2010)(Kidzeru et al., 
2014)(Tchakoute et al., 2014). Qin et al. and others have showed that expansion of MDSC in 
HIV infection was associated with decreased IFN-γ production by T cells in HIV-1 positive 
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patients(Qin et al., 2013)(Gama et al., 2012). However, levels of induced MDSC were also 
associated with  reduced protective immune responses to SIV in SIV vaccinated macaques (Sui 
et al., 2014).  
Little is known about the effect of MDSC on cytokine production in infants and in mothers 
postpartum. Hence, we aimed to assess the effect of MDSC on cytokine response to vaccine 
antigens [Bacillus Calmette-Guérin (BCG), Bordetella pertussis (BP) for acellular pertussis (aP) 
vaccine, Tetanus toxoid (TT) and Hepatitis B surface antigen (HepB)]. This was performed by 
enumerating antigen specific IFN- producing cells using the enzyme-linked immunospot 
(ELISpot) assay in whole CBMC and/or PBMC, and MDSC depleted (CD15-) CBMC and/or 
PBMC cultures after stimulating with optimized concentrations of the respective antigens. We 
performed these on samples collected at birth (Day 0), followed-up at 6, 10 and 14 weeks, at 6 
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5.2 Materials and methods 
As described in section 3.2.1, by using the standard ficoll gradients, cord blood mononuclear 
cells (CBMC) and peripheral blood mononuclear cells (PBMC) were isolated, and red blood 
cells (RBC) were depleted using glycophorin A micro beads. Further, as described in section 
4.2.1, after several calculations based on the number of cells required (see Table 4.1), cells were 
allocated for MDSC depletion (CD15-), as well as for the non-depleted experiments. Depletion 
of MDSC was perform by depleting CD15+ cells from whole CBMC and/or PBMC by 
employing the EasySep® magnetic cell separation technique. 
 
 5.2.1 IFN- enzyme-linked immunospot (ELISpot) assay 
After obtaining all the population of cells required for ELISpot i.e. a portion with MDSC that 
have not had CD15+ cells depleted (whole CBMC and/or PBMC), and a portion without MDSC  
with CD15+ cells depleted (CD15-); the IFN- ELISpot assay was performed. The IFN- ELISpot 
assay is incubated for two days in 96 well flat bottom ELISpot polyvinylidene difluoride (PVDF) 
membrane plates (Millipore MultiScreen-IP Filter Plate). 
 5.2.1.1 IFN- enzyme-linked immunospot (ELISpot) assay [Day 1] 
On the first day of the assay (Day 1), pre-labelled 96 well flat bottom ELISpot polyvinylidene 
difluoride (PVDF) membrane plates were coated with 100uL/well of 10ug/mL anti-human IFN- 
monoclonal primary antibody 1-D1K (MABTECH AB), in PBS, containing no protein [i.e. 
serum or bovine serum albumin (BSA)] (Figure 5.1). Any trace of protein may hinder the coating 
process and block the coating solution from penetrating the membrane of the wells(Abcam, 
1983)(ANIARA, 2008)( Brinkmann et al., 1993).  The plates were then covered with aluminium 
foil and incubated at 370C with 5% CO2 in a humidified incubator for ≥4 hours.  
After incubation, the plates were removed from the incubator and excess coating solution washed 
off four times with 250uL/well of sterile PBS using a multichannel pipette. The wash steps were 
performed under aseptic conditions in a biosafety cabinet, and the membranes of the wells were 
prevented from drying out by disallowing the plate sit without liquid at any time. Using a 
multichannel pipette, 200uL of RPMI with 10% FCS was transferred to every washed well on 
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the plates (process known as blocking). The plates covered with aluminium foil were placed 
sterilely at 370C with 5% CO2 in a humidified incubator for ≥2 hours. 
After, the plates were coated and blocked, approximately 2 x 105 cells/well (i.e. 2 x 105 
cells/condition) of the different cell populations i.e. whole CBMC and/or PBMC with MDSC 
and CD15- without 
MDSC, were 
cultured for 18 – 22 




antibiotics and 15% 
Human Serum at 
370C with 5% CO2 
in a humidified 
incubator (Figure 
5.1). For each 
antigen, the cells 
were plated in 
duplicate wells 
(Figure 5.2). The 






(25uL/well) to measure the number of IFN- producing cells in response to various vaccines and 
antigens in infants and their mothers. Specifically, the following antigens were added: 5 x 105 
 
Figure 5.1: Summery of the IFN-γ ELISpot assay from coating to sport 
formation. Plates were coated with the primary IFN- coating antibody, and the 
cells were plated and stimulated with optimized concentrations of the respective 
antigen conditions including controls. Plates were then incubated at 370C with 5% 
CO2 in a humidified incubator for IFN- production. Biotinylated secondary 
antibody was further added for an immunoenzyme reaction to aid the detection of 
IFN- producing cells by employing alkaline phosphatase enzyme and NBT/BCIP 
substrate reactions for a colour change. Areas of the wells where IFN- production 
occurred, appeared as dark-blue circular zones (spots), and could be observed with 
the naked eye. Plates were then analysed using the ELISpot (CTL Immunospot) 
reader.   
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CFU/mL Mycobacterium bovis bacillus Calmette-Guérin (BCG) [Danish strain 1331; SSI], 
5ug/mL Tetanus toxoid (TT) [TETAVAX, Aventis Pharma (Pty) Ltd], 5ug/mL Pertussis 
antigens (BP) [DifcoTM Bordetella Pertussis Antigen, BD] and 5ug/mL Hepatitis B surface 
antigen (Hep B) [Advanced Immunochemical Inc.]. Also, in vitro stimulation with 5ug/mL 
Phytohaemagglutinin (PHA) [PHA-P (Murex), Remel] as positive control, and cells alone with 
medium as negative control (CA), and a test control medium alone (Media) for internal quality 
control to monitor if there was any contamination in the incubation process. In addition to TT 
antigen, 0.5ug/mL BD FastimmuneTM CD28/CD49d co-stimulation was added.  
Plates were placed in the incubator within 30 mins of stimulation. The plates were incubated at 
370C with 5% CO2 in a sterile, humidified incubator for 18-22 hours.  
5.2.1.2 IFN- enzyme-linked immunospot (ELISpot) assay [Day 2] 
On the second day of the assay (Day 2) following 18-22 hours of incubation, plates were 
removed from the incubator and supernatants collected. The plates were washed 4 times with 
250uL/well of PBT/Tween-20 wash buffer. Bound human IFN- secreted by cells were 
demonstrated by means of an immunoenzyme [i.e. alkaline phosphatase-conjugated anti-
biotinylated mouse anti-human IFN- monoclonal antibody (AP-anti-biotin)] procedure in which 
enzyme-substrate reactions were performed. To every well on the plate, the secondary antibody 
(AP-anti-biotin) was added, 100uL of 1ug/mL AP-anti-biotin (i.e. 10uL AP-anti-biotin in 10mL 
0.5% BSA/PBS) was added and the plates incubated at RT for 2 – 4 hours (Figure 5.1).  
Thereafter, the plates were washed 7 times with 250uL/well of PBT/Tween-20 wash buffer. 
Further, 100uL of 1.3ug/mL alkaline phosphatase-conjugated anti-biotin antibody [i.e. AP-anti-
biotin antibody (enzyme)] (13.34uL AP-anti-biotin antibody in 10mL 0.5% BSA/PBS) was 
added to every well and the plate incubated at RT for 2-3 hours (Figure 5.1).  
After incubation, the plates were washed 4 times with 250uL/well of PBT/Tween-20 wash 
buffer. Using a multichannel pipette with sterile pipette tips, 100uL of 1-StepTM nitro-blue 
tetrazolium and 5-bromo-4 chloro-3’-indolyphosphate (NBT/BCIP) for chromogenic blot (i.e. 
the substrates) from the reagent reservoir was transferred to each well of the plates and incubated 
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for 7 minutes at RT, or until distinct dark-blue circular zones (spots) appeared in the positive 
control wells (within manufacturer’s guideline of 5 – 15 minutes). The addition of NBT/BCIP to 
the plates was done in a calculated 
fashion such that each well received 
the required 7 minutes incubation. 
The colour development in wells 
was stopped by rinsing each plate 
three times with 250uL/well of 
distilled water. The plates were kept 
inverted while drying overnight at 
RT.  
The plates were analysed the 
following day (or within the next 
two working days) by using the 
ELISpot (CTL Immunospot) reader, 
allowing accurate estimation of the 
total amount of secreted IFN-/well. 
Figure 5.2 shows a sample ELISpot 
plate generated in our lab. 
Comparisons were made between 
levels of IFN- obtained in the 












Baby-PBMC at birth (Day 0)
      
Baby-PBMC 6-weeks old
 
Figure 5.2: Duplicate experiments showing IFN-γ spot 
forming units recorded in infants PBMC at birth (left) and at 
6 weeks (right) stimulated with antigens. Neonatal and infants 
PBMC IFN-γ production after vaccine antigens i.e. TT, HepB 
and BCG stimulation including PHA as positive control, cells 
alone (CA) as negative control and medium alone (Media) for 
internal quality control of the plate. The experiments performed 
in duplicates and IFN-γ spot forming units analysed using the 
ELISpot (CTL Immunospot) reader. The numbers at the top of 
each column depicts the column number on the plate, and the 
columns represent the sample replecates; and those at the right 
side of each well (i.e. viewers left) represent the total number of 
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5.2.2 Data analysis 
 After ELISpot plates were analyzed using the ELISpot (CTL Immunospot) reader, the data was 
extracted into excel for further analysis. 
5.2.2.1 Standard rules for cut-offs and controls for the ELISpot data 
Following analysis by ELISpot (CTL Immunospot) reader, in order to prevent data bias and to 
perform background subtraction, the following rules were put in place: 
1. Assay validity (before background subtraction): 
The number of IFN-γ Spot Forming Units (SFU)/million cells in response to PHA was 
greater than the median plus 3 times the MAD of the negative control (i.e. Media) IFN-γ 
SFU/million cells, or the sample was excluded.  
i.e. IFN-γ SFU/million cells [PHA] > IFN-γ SFU/million cells (Median + 3MAD)[Media] 
[MAD=Median Absolute Deviation) 
MAD is defined as the median of the absolute values of the deviation  of each sample 
negative control number of spots from the negative control’s median number of 
spots(Rouss et al., 1993). 
 
2. Background subtraction: 
Number of IFN-γ SFU/million cells in response to the test antigens (i.e. BCG, BP, TT, HepB 
and PHA) minus background IFN-γ SFU/million cells in the media control) 
i.e. (BCG, BP, TT, HepB and PHA induced IFN-γ SFU/million cells) – (IFN-γ SFU/million 
cells in the media).  
This study was exploratory and obtaining whole blood samples from infants was challenging.  
From most infants, only a small volume of whole blood could be collected, so we define 
responses as the magnitude of responses measured(Alexander et al., 2013)(Santos et al., 2014). 
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However, in some studies in HIV infected adults and tuberculosis cases, ≥10 SFU/million cells 
after background subtraction have been used in ELISpot assays(Turk et al., 2008)(Lawn et al., 
2007)(Aiken et al., 2006).  
Based on the literature, and on robustness of IFN-γ cytokine responses to the different antigens 
assessed, responses were considered positive (responsive) when IFN-γ cytokine producing cells 
to BCG were greater than or equal 20 SFU/million PBMC (≥20 SFU/106 PBMC), but to Hep B, 
TT and BP when IFN-γ cytokine producing cells were greater than or equal to 10 SFU/million 
PBMC (≥10 SFU/106 PBMC) after background subtraction.  
 
5.2.2.2 Statistical considerations 
Different statistical packages were used to complete the data analysis after the ELISpot plate was 
read, as listed in the table below (Table 5.1). 
Table 5.1: Statistical packages used for data analysis 
No SOFTWARE PROGRAM ANALYSIS TYPE DATA TYPE 
1 Microsoft Excel 2013 To clean and organize data from the ELISpot (CTL Immunospot) reader 
ELISpot data 
analysis 2 Microsoft Excel 2013 To perform background subtraction 
3 
GraphPad Prism v5 (for Windows, GraphPad 
Software, San Diego California USA, 
www.graphpad.com”). 
To analyze differences in IFN-γ 
SFU/million cells between groups 
4 STATA v11 (for windows, StataCorp LP, 
College station, TX77845, USA). 
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5.2.2.3 Statistical data analysis 
Data analysis was performed by applying the following statistical tests; 
 
Table 5.2: Statistical tests used to complete data analysis 
Statistical test Rationale Statistical 
package 
Data type 
Chi-square test Relationship between two 
categorical variables  
STATA v11 Cohort description 
(HEU vs. HU) 
Fisher’s exact test Relationship between two 
categorical variables (one or more of 
the values in the cells has an 
expected frequency ≤5)  
STATA v11 Cohort description 




Relationship between two 
continuous variables 
- GraphPad Prism v5 
- STATA v11 
IFN-γ SFU/million cells 
(CD15+ vs. CD15-) 





Compare continuous data between 
two matched categories that is not 
normally distributed. 
- GraphPad Prism v5 
 
-T cell Proliferation  
 (CD15+ vs. CD15-) 
Spearman 
correlation 
Correlations between two continuous 
non-normally distributed variables 
- GraphPad Prism v5 
 





In this chapter we assessed the effect of MDSC on IFN-γ responses to BCG, B. pertussis (BP), 
TT and Hep B vaccination, with PHA as a positive control mitogen. We compared responses 
between whole CBMC and/or PBMC with versus without MDSC in HEU as well as HIV-
unexposed (HU) infants, and in HIV-infected (HIV+) as well as HIV-uninfected (HIV-) 
mothers postpartum. IFN-γ responses were assessed in infants post vaccination from birth 
through 6, 10 and 14 weeks, 6 and 9 months, to one year of age; and in mothers only at 
delivery after gestation and one year postpartum.   
In this chapter, we hypothesized that in infants and pregnant women, IFN-γ production in 
response to vaccines will be low due to the presence of MDSC, and that, the effect in HEU 
infants as well as HIV+ mothers will be increased compared to the HU infants and HIV- 
mothers respectively. 
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To clearly understand the effect of MDSC on INF-γ production, we employed two analytical 
processes; 
1. We performed binary analyses by comparing MDSC frequency as percentage of 
PBMC as well as MDSC absolute counts per million PBMC of infants in responders 
or non-responders based on the quantity of IFN-γ cytokine producing cells to antigens 
(section 5.2.2.1). The number of IFN-γ cytokine producing cells in response to 
vaccine antigens varied between antigens to be considered as responder or non-
responders. No consensus has been reached as of now on how to determine if an 
immune response has been detected based on the raw data from an ELISpot 
assay(Moodie et al., 2010).  
2. (a) We also compared IFN-γ cytokine producing cells to vaccines and antigens in 
whole PBMC (presence of MDSC) versus without MDSC (after MDSC depletion) 
at all individual time points post vaccination (i.e. at 6, 10 and 14 weeks, at 6 and 9 
months, and at one year of age), and in mothers (i.e. at delivery and one year 
postpartum). 
(b) In infants, we performed grouped analyses, based on the time points the 
different vaccines were administered and followed-up during infancy, to increase 
the sample numbers. BP, TT and HepB vaccinations were evaluated in two groups; 
at 10 and 14 weeks (after the first and second vaccine doses and before the last 
vaccine doses), and at 6 and 9 months and one year (after the last vaccine doses and 
the last follow-up time points where peak responses occur). However, for BCG 
follow-up ages were grouped into two, at 6, 10 and 14 weeks (first few weeks after 
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Generally, after vaccine stimulation at most time points there were very low IFN-γ spot 
forming cells and vaccine responses varied in the different antigens through time. Some 
responses to vaccines were stronger and some low. Appendix 5.2 shows the general ontogeny 
of each vaccine response (median counts of IFN-γ cytokine producing cells) to the different 
antigens in infants and mothers through time.  
Hep B responses were low at 10 and 14 weeks after priming at 6 weeks in infants and 
remained low till 6 months of age. The responses then peaked at 9 months to one year of age 
[Appendix 5.2, Figure U(i)]. In the mothers, Figure U(ii), Hep B responses were higher at one 
year postpartum than at delivery. 
Generally, TT responses were low throughout from after priming at 6 weeks of age to one 
year of age [Appendix 5.2, Figure V(i)]. In the mothers, Figure V(ii), TT responses dropped 
from delivery compared to one year postpartum. 
BP responses were generally low throughout, and varied with age in infants [Appendix 5.2, 
Figure W(i)]. In the mothers, Figure W(ii), BP responses were low at delivery and at one year 
postpartum. 
BCG responses peaked at birth to 6, 10 and 14 weeks after BCG vaccination at birth in infants 
as previously described (Kagina et al., 2009) [Appendix 5.2, Figure X(i)]. The responses then 
dropped to lower levels at 9 months to one year of age comparable to peak responses between 
6 weeks and 6 months of age Figure X(i). In the mothers, Figure X(ii), BCG responses were 
higher at  delivery compared to one year postpartum. 
As expected of a positive control and strong stimulation, PHA responses were strong from 
birth through 6, 10 and 14 weeks in infants till 6 and 9 months of age. [Appendix 5.2, Figure 
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5.3.1 Infant MDSC frequency and absolute counts in IFN-γ producing 
responders versus non-responders to vaccines stimulation 
In section 4.3.1 we looked at the relationship between the frequency and absolute count of 
MDSC and the frequency of CD4+ T cell proliferative responders versus non-responders to 
vaccines and antigens at the time at which responses were measured. Here, we evaluated the 
association between the frequency and absolute count of MDSC and the total spot forming 
IFN-γ cytokine producing cells i.e. net spot forming units per million PBMC (Net SFU/106 
PBMC) in responders compared to non-responders to vaccines and antigens post vaccination to 
one year of age in infants. Further, we evaluated maternal MDSC frequency in IFN-γ cytokine 
producing responders versus non-responders at delivery and one year postpartum to vaccine 
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5.3.1.1 Infant MDSC frequency in IFN-γ responders versus non-responders to Hep B 
stimulation 
At the individual time points post Hep B vaccination, the frequency of MDSC after Hep B 
stimulation in IFN-γ cytokine producing PBMC from infants who responded at 10 weeks of age 
was significantly lower compared to the MDSC frequency in the non-responders (median of 
responders=0.149% versus non-responders=0.770% and p=0.003) Figure 5.3 (a). No significant 
differences were observed at the other time points between responder versus non-responders at 
14 weeks of age (p=0.999), as well as at 6 months and one year of age (p=0.832 and p=0.555 
respectively). However, at 9 months of age, there was a trend towards high MDSC frequency in 
responders compared to the non-responders (p=0.069), but was not significant (Figure 5.3). At 
the grouped time points analyses, the frequency of MDSC after Hep B vaccine stimulation in 
infants who responded versus non-responders of IFN-γ cytokine responses was measured in the 
grouped time point at 10 and 14 weeks grouped time points, and at 6 and 9 months and one year 
of age grouped time points. As shown in Figure 5.3 (b), responders had a significantly lower 
MDSC frequency at 10 and 14 weeks grouped time points compared to non-responders (median 
of responders=0.192% versus non-responders=0.634% and p=0.017), but was not significantly 
different at 6 and 9 months and one year grouped time points (median of responders=0.802% 










Figure 5.3: Infants MDSC frequency in IFN-γ producing responders versus non-responders to Hep B 
stimulation. (a) In the individual time point analysis, the frequency of MDSC as percentage of PBMC was 
measured at 10 and 14 weeks of age, and at 6 and 9 months and one year of age  in infants as well as IFN-γ 
cytokine producing cells to Hep B at the respective time points. (b) Time points were grouped; i.e. 10 and 14 
weeks grouped time points post first dose of Hep B vaccination at 6 weeks and before the second vaccine dose 
at 14 weeks of age, and the last follow-up time points at 6 and 9 months and one year of age grouped time 
points post the last vaccine dose. Each dot on the plot represent an infant. IFN-γ cytokine producing cells to 
Hep B in responders was ≥10 SFU/106 PBMC after Hep B stimulation. Bars indicate medians and whiskers 
indicate interquartile range; p<0.05 significant level and statistical significance was tested using Mann-
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5.3.1.2 Infants MDSC absolute counts in IFN-γ responders versus non-responders to Hep B 
stimulation 
We evaluated the absolute count of MDSC after Hep B vaccine stimulation in infants who 
responded versus non-responders to Hep B induced IFN-γ cytokine producing cells. As shown in 
Figure 5.4 (a) in the individual time points there were no significant differences between the 
absolute count of MDSC in responders at 14 weeks (p=0.875), 6 months (p=0.865), 9 months 
(p=0.362) and 1 year of age (p=0.484) of age. However, at 10 weeks of age post first vaccine 
dose, there was a trend towards high MDSC absolute counts in infants who had poor IFN-γ 
cytokine producing cell to Hep B stimulation compared to responders (median of 
responders=412.5 MDSC counts versus non-responders=1567.0 MDSC counts and p=0.096) 
Figure 5.4 (a). The absolute counts of MDSC after Hep B vaccine stimulation in infants who 
responded compared to infants who responded poorly to Hep B induced IFN-γ cytokine 
producing cells was measured in the grouped time point analysis at 10 and 14 weeks, and at 6 
and 9 months and one year of age. There were no significant differences between responders and 
non-responders MDSC counts at all grouped time points at 10 and 14 weeks (p=0.205), and at 6 













Figure 5.4: Infants MDSC absolute counts in IFN-γ producing responders versus non-responders to 
Hep B stimulation. (a) In the individual time point analysis, the absolute  counts of MDSC per mL of 106 
PBMC was measured at 10 and 14 weeks of age, and at 6 and 9 months and one year of age  in infants as 
well as IFN-γ cytokine producing cells to Hep B at the respective time points. (b) Time points were 
grouped; i.e. 10 and 14 weeks grouped time points post first dose of Hep B vaccination at 6 weeks and 
before the second vaccine dose at 14 weeks of age, and the last follow-up time points at 6 and 9 months and 
one year of age grouped time points post the last vaccine dose. Each dot on the plot represent an infant.. 
IFN-γ cytokine producing cells to Hep B in responders was ≥10 SFU/106 PBMC after Hep B stimulation. 
Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and statistical 
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5.3.1.3 Infant MDSC frequency in IFN-γ responders versus non-responders to TT 
stimulation 
Due to the limited number of samples for which IFN-γ producing cells were to be measured at 
the individual time points, we compared MDSC frequency of infants who were responders 
versus non-responders to TT induced IFN-γ production at grouped time points. The frequency of 
MDSC in infants who responded versus non-responders to TT induced IFN-γ SFU/106 PBMC 
was measured in the grouped time point analysis at 10 and 14 weeks, and at 6 and 9 months and 
one year of age. As shown in Figure 5.5, responders had a significantly higher MDSC frequency 
at 6 and 9 months and one year grouped time points (median of responders=1.250% versus non-
responders=0.359% and p=0.036), but there was a trend towards high MDSC frequency in non-
responders at 10 and 14 weeks grouped time points that was not significant (median of 
responders=0.189% versus non-responders=0.619% and p=0.074) (Figure 5.5). 
 
Figure 5.5: Infants MDSC frequency in IFN-γ producing responders versus non-responders to TT 
stimulation. The frequency of MDSC as percentage of PBMC was measured at 10 and 14 weeks of age, and at 6 
and 9 months and one year of age in infants as well as IFN-γ cytokine producing cells to TT at the respective 
time points. Time points were grouped; i.e. 10 and 14 weeks grouped time points post first dose of TT 
vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last follow-up time points 
at 6 and 9 months and one year of age grouped time points post the last vaccine dose. Each dot on the plot 
represent an infant. IFN-γ cytokine producing cells to TT in responders was ≥10 SFU/106 PBMC after TT 
stimulation. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and 
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5.3.1.4 Infant MDSC absolute counts in IFN-γ producing responders versus non-
responders to TT stimulation 
Due to the limited number of samples for which IFN-γ producing cells were to be measured at 
the individual time points, we compared MDSC absolute counts of infants who were 
responders versus non-responders to TT induced IFN-γ production at grouped time points. The 
absolute counts of MDSC in infants who responded compared to infants produced low or 
undetectable IFN-γ to TT were measured in the grouped time point analysis at 10 and 14 
weeks, and at 6 and 9 months and one year of age. At 10 and 14 weeks grouped time points, 
there was a significantly higher MDSC absolute counts in the non-responders compared to the 
responder of IFN-γ cytokine producing cells to TT (median of responders=128.5 MDSC 
counts versus non-responders=1150.0 MDSC counts and p=0.005), but the difference was not 
significant at 6 and 9 months and one year (p=0.213) (Figure 5.6). 
 
Figure 5.6: Infants MDSC absolute counts in IFN-γ producing responders versus non-responders to 
TT stimulation. The absolute  counts of MDSC per mL of 106 PBMC was measured at 10 and 14 weeks of 
age, and at 6 and 9 months and one year of age  in infants as well as IFN-γ cytokine producing cells to TT at 
the respective time points. Time points were grouped; i.e. 10 and 14 weeks grouped time points post first 
dose of TT vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last 
follow-up time points at 6 and 9 months and one year of age grouped time points post the last vaccine dose. 
Each dot on the plot represent an infant. IFN-γ cytokine producing cells to TT in responders was ≥10 
SFU/106 PBMC after TT stimulation. Bars indicate medians and whiskers indicate interquartile range; 
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5.3.1.5 Infant MDSC frequency in IFN-γ responders versus non-responders to BP 
stimulation 
Due to the limited number of samples for which IFN-γ producing cells were to be measured at 
the individual time points, we compared MDSC frequency of infants who were responders 
versus non-responders to BP induced IFN-γ production at grouped time points. The frequency of 
MDSC in infants who responded (≥10 SFU/106 PBMC) versus non-responders to BP was 
measured in the grouped time point analysis at 10 and 14 weeks grouped time points, and at 6 
and 9 months and one year of age grouped time points. As shown in Figure 5.7, there were no 
significant differences in MDSC frequency between responders and non-responders at 10 and 14 
weeks grouped time points that was not significant (p=0.536), and also at 6 and 9 months and 
one year grouped time points (p=0.801) (Figure 5.7). 
 
Figure 5.7: Infants MDSC frequency in IFN-γ producing responders versus non-responders to BP 
stimulation. The frequency of MDSC as percentage of PBMC was measured at 10 and 14 weeks of age, and at 6 
and 9 months and one year of age in infants as well as IFN-γ cytokine producing cells to BP at the respective 
time points. Time points were grouped; i.e. 10 and 14 weeks grouped time points post first dose of BP 
vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last follow-up time points 
at 6 and 9 months and one year of age grouped time points post the last vaccine dose. Each dot on the plot 
represent an infant. IFN-γ cytokine producing cells to BP in responders was ≥10 SFU/106 PBMC after BP 
stimulation. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level and 
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5.3.1.6 Infants MDSC absolute counts in IFN-γ responders versus non-responders to BP 
stimulation 
Due to the limited number of samples for which IFN-γ producing cells were to be measured at 
the individual time points, we compared MDSC absolute counts of infants who were 
responders versus non-responders to BP induced IFN-γ production at grouped time points. The 
absolute counts of MDSC in infants who responded compared to infants who were poor 
producers of IFN-g to BP was measured in the grouped time point analysis at 10 and 14 weeks 
grouped time points, and at 6 and 9 months and one year of age grouped time points. There 
were no significant differences MDSC absolute counts between responders and non-responders 
at 10 and 14 weeks grouped time points (p=0.701), as well as at 6 and 9 months and one year 
grouped time points (p=0.577) (Figure 5.8). 
 
Figure 5.8: Infants MDSC absolute counts in IFN-γ producing responders versus non-responders to 
BP stimulation. The absolute  counts of MDSC per mL of 106 PBMC was measured at 10 and 14 weeks of 
age, and at 6 and 9 months and one year of age  in infants as well as IFN-γ cytokine producing cells to BP at 
the respective time points. Time points were grouped; i.e. 10 and 14 weeks grouped time points post first 
dose of BP vaccination at 6 weeks and before the second vaccine dose at 14 weeks of age, and the last 
follow-up time points at 6 and 9 months and one year of age grouped time points post the last vaccine dose. 
Each dot on the plot represent an infant. IFN-γ cytokine producing cells to BP in responders was ≥10 
SFU/106 PBMC after BP stimulation. Bars indicate medians and whiskers indicate interquartile range; 
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 5.3.1.7 Infants MDSC frequency in IFN-γ producing responders versus non-responders to 
BCG stimulation 
At the individual time points post BCG vaccination at birth, the frequency of MDSC in PBMC 
from infants who had IFN-γ responses to BCG stimulation at 6 weeks of age was not 
significantly different compared to the MDSC frequency in the non-responders (median of 
responders=0.366% versus non-responders=0.712% and p=0.498) Figure 5.9 (a). Also, no 
significant differences were observed at the other time points between responder versus non-
responders at 10 and 14 weeks of age (p=0.358 and p=0.282 respectively), as well as at 6 and 9 
months of age (p=0.171 and p=0.149 respectively). However, at one year of age, there was a 
trend towards high MDSC frequency in responders compared t non-responders (median of 
responders=0.810% versus non-responders=0.276% and p=0.067), but this was not significant 
Figure 5.9 (a). At the grouped time point analyses, the frequency of MDSC in infants who 
responded versus non-responders of IFN-γ cytokine responses after BCG vaccine stimulation 
was measured in the grouped time points at 6, 10 and 14 weeks, and at 6 and 9 months and one 
year of age grouped together. As shown in Figure 5.9 (b), MDSC frequency in responders did 
not significantly differ to that in the non-responders at 6, 10 and 14 weeks grouped time points 
(median of responders=0.382% versus non-responders=0.648% and p=0.796), as well as at 6 and 
9 months and one year grouped time points (median of responders=0.569% versus non-




















Figure 5.9: Infants MDSC frequency in IFN-γ producing responders versus non-responders to BCG 
stimulation. (a) In the individual time point analysis, the frequency of MDSC as percentage of PBMC was 
measured at 6, 10 and 14 weeks of age, and at 6 and 9 months and one year of age  in infants as well as IFN-γ 
cytokine producing cells to BCG at the respective time points. (b) Time points were grouped; i.e. 6, 10 and 14 
weeks grouped time points post BCG vaccination at birth, and the last follow-up time points at 6 and 9 months 
and one year of age grouped time points. Each dot on the plot represent an infant. IFN-γ cytokine producing 
cells to BCG in responders was ≥20 SFU/106 PBMC after BCG stimulation. Bars indicate medians and 
whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested using 
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5.3.1.8 Infants MDSC absolute counts in IFN-γ producing responders versus non-
responders to BCG stimulation 
We evaluated the absolute count of MDSC in infants whose IFN-γ production was considered 
responsive versus non-responders to BCG. As shown in Figure 5.10 (a) the absolute count of 
MDSC in responders at 10 weeks of age was significantly higher than MDSC absolute counts 
in non-responders (median of responders=1137 MDSC counts versus non-responders=91.000 
MDSC counts and p=0.021), however the number of non-responders was small. On the other 
hand, at 6 months of age the MDSC absolute counts in the non-responders was significantly 
higher than in the responders, however the number of infants that did not respond was small 
(median of responders=487.0 MDSC counts versus non-responders=16807.0 MDSC counts 
and p=0.038). There were no significant differences at other time points at 6 and 14 weeks of 
age (p=0.586 and p=0.956 respectively), and at 9 months (p=0.774) and 1 year of age 
(p=0.485) of age Figure 5.10 (a). The absolute counts of MDSC in infants who responded 
compared to infants who responded poorly to BCG in terms of IFN-γ producing cells was 
measured in the grouped time point analysis at 6, 10 and 14 weeks, and at 6 and 9 months and 
one year of age. The differences were not significant between responders and non-responders 
MDSC counts at all grouped time points at 6, 10 and 14 weeks (p=0.168), and at 6 and 9 
months and one year (p=0.406) Figure 5.10 (b). 
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Figure 5.10: Infants MDSC absolute counts in IFN-γ producing responders versus non-responders to 
BCG stimulation. The absolute  counts of MDSC per mL of 106 PBMC was measured at 6, 10 and 14 
weeks of age, and at 6 and 9 months and one year of age  in infants as well as IFN-γ cytokine producing 
cells to BCG at the respective time points. Time points were grouped; i.e. 6, 10 and 14 weeks grouped time 
points post BCG vaccination at birth, and the last follow-up time points at 6 and 9 months and one year of 
age grouped time points post the last vaccine dose. Each dot on the plot represent an infant. IFN-γ cytokine 
producing cells to BCG in responders was ≥20 SFU/106 PBMC after BCG stimulation. Bars indicate 
medians and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was 
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Generally, MDSC frequency and absolute count between infants who were responders and 
non-responders in terms of vaccine induced IFN-γ cytokine producing cells were significantly 
lower in responders than in non-responders at most time points, particularly to Hep B and TT. 
We hypothesised that MDSC would influence IFN-γ cytokine producing cells to vaccine 
antigens negatively, and in support of our hypothesis in infants, this was evident. These 
experiments evaluated the effect of MDSC count and frequency on vaccine responses in-vivo. 
To further support our findings, we employed a more direct comparisons of IFN-γ cytokine 
producing cells between whole PBMC (the presence of MDSC) and in the absence of MDSC 
(after MDSC depletion), which would give more direct in-vitro evidence for or against our 
hypothesis (section 5.3.2). We also evaluated maternal MDSC frequency with IFN-y 
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5.3.1.9 Maternal MDSC frequency in IFN-γ producing responders versus non-responders 
to Hep B stimulation 
 The frequency of maternal MDSC was not significantly different in mothers with IFN-γ 
cytokine producing cells ≥10 SFU/106 PBMC to Hep B stimulation compared to those who 
responded poorly with IFN-γ cytokine producing cells ≤10 SFU/106 PBMC. As shown in Figure 
5.11, there were no significant differences between maternal responders’ and non-responders’ 
MDSC frequencies at delivery (median of responders=1.003% versus non-responders=1.530% 
and p=0.863), and at one year postpartum (median of responders=1.705% versus non-




Figure 5.11: Maternal MDSC frequency in IFN-γ producing responders versus non-responders to Hep B 
stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as IFN-γ cytokine producing cells to Hep B at the respective time points. IFN-γ 
cytokine producing cells to Hep B in responders was ≥10 SFU/106 PBMC after Hep B stimulation. Bars indicate 
medians and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested 
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5.3.1.10 Maternal MDSC frequency in IFN-γ producing responders versus non-
responders to TT stimulation 
 There was a trend towards a higher maternal MDSC frequency in non-responders compared to 
responders at one year postpartum (median of responders=0.417% versus non-
responders=1.705% and p=0.061), but was not significant and numbers were small. At delivery 
difference in maternal MDSC frequency was not significant between responders and non-
responders to TT stimulation (median of responders=1.645% versus non-responders=0.647% and 
p=0.139) (Figure 5.12). 
 
Figure 5.12: Maternal MDSC frequency in IFN-γ producing responders versus non-responders to TT 
stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as IFN-γ cytokine producing cells to TT at the respective time points. IFN-γ 
cytokine producing cells to TT in responders was ≥10 SFU/106 PBMC after TT stimulation. Bars indicate 
medians and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested 
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5.3.1.11 Maternal MDSC frequency in IFN-γ producing responders versus non-
responders to BP stimulation 
 At delivery, there was no significant difference in maternal MDSC frequency between 
responders and non-responders to BP stimulation (median of responders=0.386% versus non-
responders=0.432% and p=0.489) (Figure 5.13). However, at one year postpartum the number of 
mothers for which responses were to be measured was small and statistical analyses could not be 




Figure 5.13: Maternal MDSC frequency in IFN-γ producing responders versus non-responders to BP 
stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as IFN-γ cytokine producing cells to BP at the respective time points. IFN-γ 
cytokine producing cells to BP in responders was ≥10 SFU/106 PBMC after BP stimulation. Bars indicate 
medians and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested 
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5.3.1.12 Maternal MDSC frequency in IFN-γ producing responders versus non-responders 
to BCG stimulation 
 Maternal MDSC frequency at delivery was not significantly different in mothers who responded 
to BCG stimulation versus those with poor IFN-γ cytokine producing cells to BCG at birth and at 
one year postpartum (Figure 5.14). Maternal MDSC frequencies at delivery were median of 
responders=0.616% versus non-responders=1.143% and p=0.479, and at one year postpartum 
were median of responders=0.996% versus non-responders=7.55% and p=0.100. 
 
 
Figure 5.14: Maternal MDSC frequency in IFN-γ producing responders versus non-responders to BCG 
stimulation. The frequency of MDSC as percentage of PBMC was measured at delivery and at one year 
postpartum in mothers as well as IFN-γ cytokine producing cells to BCG at the respective time points. IFN-γ 
cytokine producing cells to BCG in responders was ≥20 SFU/106 PBMC after BCG stimulation. Bars indicate 
medians and whiskers indicate interquartile range; p<0.05 significant level and statistical significance was tested 
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Table 5.3: Summary of the results of all infant and mothers MDSC frequency and absolute counts measured in 
IFN-γ producing responders versus non-responders to vaccines stimulation.  P-values of infants and mothers 
MDSC frequency (%) and absolute count (#) measured in responders versus non-responders as measured by IFN-γ 
producing cells to the following antigens [Bacillus Calmette-Guérin (BCG), Hepatitis B (Hep B), Tetanus toxoid 
(TT) and Bordetella pertussis (BP)]. Blue highlights represent the parameters (p-values and type of data sets), Red 
highlights represent the different time points [birth (D0), 6, 10 and 14 weeks (WK6, WK10 and WK14), 6 and 9 
months (Mth6 and Mth9), and 1 year (YR1)], and Purple highlights represent significant differences between MDSC 
quantity in responders versus non-responders to vaccine antigens. GRP=Group, Indv=Individual, TP= Time point, 
B=Baby, and M=Mother.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B  Indv. TP (%MDSC) (B)   0.003 0.999 0.832 0.069 0.555 
Hep B  GRP TP (%MDSC) (B)   0.017 0.186 
Hep B  Indv. TP (#MDSC) (B)   0.096 0.875 0.865 0.362 0.484 
Hep B  GRP TP (#MDSC) (B)   0.205 0.842 
TT  GRP TP (%MDSC) (B)   0.074 0.036 
TT GRP TP (#MDSC) (B)   0.005 0.213 
BP GRP TP (%MDSC) (B)   0.536 0.801 
BP GRP TP (#MDSC) (B)   0.701 0.577 
BCG  Indv. TP (%MDSC) (B)  0.498 0.358 0.282 0.171 0.149 0.067 
BCG GRP TP (%MDSC) (B)  0.796 0.243 
BCG Indv. TP (#MDSC) (B)  0.586 0.021 0.956 0.038 0.774 0.485 
BCG GRP TP (#MDSC) (B)  0.168 0.406 
Hep B Indv TP (%MDSC) (M) 0.863      0.100 
TT Indv TP (%MDSC) (M) 0.139      0.061 
BP Indv TP (%MDSC) (M) 0.489       
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5.3.2 Effect of MDSC depletion on IFN-γ production to vaccines and antigens 
in infants and mothers 
The effect of MDSC on IFN-γ production to BCG, TT, BP, and Hep B vaccinations, and to 
PHA, in whole CBMC and/or PBMC were evaluated in infants and mothers in the presence of 
MDSC and after MDSC depletion (Figure 4.1). Since MDSC highly express CD15, as earlier 
described in section 4.2.1 above, CD15+ expressing cells were magnetically depleted from a 
proportion of CBMC and/or PBMC. The effect of MDSC on cells producing IFN-γ to vaccines 
and antigens was then measured by performing the IFN-γ ELISpot assay comparing CD15 
depleted cells (absence of MDSC) and intact CBMC and/or PBMC (presence of MDSC) 
(Figure 4.2). In the MDSC depleted sample group, only samples with depletion purity of 90% 
or more were included in the analysis (Appendix 4.3).  
As described in section 5.3 (2), IFN-γ cytokine producing cells were measured in infants at all 
individual time points post vaccination (i.e. at 6, 10 and 14 weeks, at 6 and 9 months, and at 
one year of age), and in mothers, the cells producing IFN-γ to vaccines and antigens were 
measured at delivery and again at one year postpartum. We also evaluated the ontogeny of the 
effect of MDSC on IFN-γ cytokine producing cells to vaccines and antigens in a grouped time 
points analyses, based on the time points the different vaccines assessed were administered and 
followed-up during infancy as described in section 5.3 (2) (b).   
The data as presented below include matched pair of samples as whole PBMC (presence of 
MDSC) and the absence of MDSC (MDSC depleted).  Also, unmatched comparison between 
HEU versus HU infants as well as HIV+ versus HIV- mothers at the respective time points 
either in whole PBMC (presence of MDSC) and after MDSC depletion when the number of 
participants were enough for statistical analyses to be performed. Table 5.4 and 5.5 below 
shows the summary of the results. 
We prioritised experiments according to blood volume obtained, and often the volume of 
whole blood collected from infants was insufficient for CD15+ depletion. Due to this, there 
were only a limited number of infants and their mothers at most time points for which 
depletion was performed and further permitting MDSC non-depleted versus MDSC depleted 
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match paired analyses to be performed (see Chapter 4, Table 4.1). In Appendix 5.3 is the 
unmatched analyses between MDSC non-depleted versus MDSC depleted samples in all 
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5.3.2.1 BCG induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to BCG vaccination were evaluated in whole PBMC and without 
MDSC in infants at all time points after vaccination. As shown in Figure 5.15 there were no 
significant differences at most time points. However, IFN-γ cytokine producing cells to BCG 
 
Figure 5.15 (i): IFN-γ cytokine producing cells to BCG in infants in whole PBMC versus without 
MDSC in the individual time points. In the individual time point analysis, IFN-γ cytokine producing cells 
to BCG were measured post vaccination at birth in whole PBMC (CD15 non-depleted – green) versus 
without MDSC (CD15 depleted – red) at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in 
infants Matched pair of dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 
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lasted till 9 months. At the individual time points at one year of age, IFN-γ cytokine producing 
cells to BCG were significantly higher in whole PBMC compared to after MDSC depletion in 
infants (median of CD15 non-depleted=26.670 Net SFU/106 PBMC versus CD15 
depleted=6.667 Net SFU/106 PBMC and p=0.016). The differences were not significant at 6, 
10 and 14 weeks (p=0.147, p=0.191 and p=0.203 respectively), and at 6 months of age 
(p=0.109). However, at 9 months of age there was a trend towards higher IFN-γ producing 
cells to BCG in whole PBMC compared to after MDSC depletion in infants (median of CD15 
non-depleted=60.000 Net SFU/106 PBMC versus CD15 depleted=26.670 Net SFU/106 PBMC 
 
Figure 5.15 (ii): IFN-γ cytokine producing cells to BCG in infants in whole PBMC versus without 
MDSC in the grouped time points. IFN-γ cytokine producing cells to BCG were measured in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 6, 10 and 14 weeks, at 6 and 9 
months and at one year of age in infants, and in the grouped analysis at 6, 10 and 14 weeks (first few weeks 
after priming), at 6 and 9 months and one year of age (the last follow-up time points). Matched pair of dots on 
the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical 
significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
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and p=0.061) [Figure 5.15 (i)]. In the grouped time point analyses, IFN-γ cytokine producing 
cells to BCG were significantly higher in intact PBMC compared to after MDSC depletion at 
the earlier grouped time points (median of CD15 non-depleted=80.000 Net SFU/106 PBMC 
versus CD15 depleted=40.000 Net SFU/106 PBMC; p=0.013) and at 6, 9 months and 1 year 
grouped time points (median of CD15 non-depleted=40.000 Net SFU/106 PBMC versus CD15 
depleted=13.330 Net SFU/106 PBMC; p=0.001) [Figure 5.15 (ii)]. 
5.3.2.2 BCG induced IFN-γ production in whole PBMC versus after MDSC depletion in 
mothers 
In mothers, BCG induced IFN-γ producing cells were evaluated in whole PBMC and without 
MDSC at delivery and at one year postpartum. As shown in Figure 5.16, the frequency of cells 
producing IFN-γ to BCG were not significantly different in mothers after gestation at delivery 
(median of CD15 non-depleted=13.330 Net SFU/106 PBMC, IQR=0-33.330 versus CD15 
depleted=13.330 Net SFU/106 PBMC, IQR=0-40.000 and p=0.839), as well as at one year 
 
Figure 5.16: IFN-γ cytokine producing cells to BCG in mothers in whole PBMC versus without 
MDSC. IFN-γ cytokine producing cells to BCG were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 
depleted – red). Matched pair of dots on the plot represent a mother. Bars indicate interquartile range; 
p<0.05 significant level and statistical significance was tested using non-parametric Wilcoxon matched-
pairs* sign rank test.  
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postpartum (median of CD15 non-depleted=16.670 Net SFU/106 PBMC versus CD15 
depleted=0 Net SFU/106 PBMC and p=0.125), but was not significant, and numbers in this 
analysis were small (Figure 5.16). 
5.3.2.3 BCG induced IFN-γ cytokine producing cells in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants 
 Just as we were interested in the effect of HIV-exposure on MDSC with regards to CD4+ T 
cell proliferation in chapter 4, we evaluated if HIV-exposure would alter the effect of MDSC 
on IFN-γ production. First, we evaluated cells producing IFN-γ to BCG in whole PBMC 
between HEU versus HU infants. At most time points there were no significant differences at 
the individual time points in cells producing IFN-γ (however, at one year, there were no 
samples in the HEU infants with sufficient blood for ELISPOT and statistical analysis could 
 
Figure 5.17: IFN-γ cytokine producing cells to BCG in infants with MDSC in HEU versus HU 
infants. IFN-γ cytokine producing cells to BCG in whole PBMC (CD15 non-depleted) were measured at 
6, 10 and 14 weeks, at 6 and 9 months and at one year of age (data not enough for ploting), and in the 
grouped time point analysis at 6, 10 and 14 weeks (first few weeks after priming), at 6 and 9 months and 
one year of age (the last follow-up time points) in HEU infants (blue) versus HU infants(black). Each dot 
on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test. 
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not be performed; data not shown). As shown in Figure 5.17, in the grouped time point 
analysis there were no significant differences at 6, 10 and 14 weeks grouped together in IFN-γ 
producing cells to BCG between HEU compared to HU infants (median of HEU=24.867 Net 
SFU/106 PBMC versus HU=83.670 Net SFU/106 PBMC; p=0.230), or at 6, 9 months and one 
year (median of HEU=29.330 Net SFU/106 PBMC versus HU=33.670 Net SFU/106 PBMC; 
p=0.959) (Figure 5.17). 
5.3.2.4 BCG induced IFN-γ cytokine producing cells after MDSC depletion in HEU 
versus HU infants 
 To further investigate if HIV-exposure could contribute to the effect of MDSC on IFN-γ 
cytokine producing cells, we evaluated IFN-γ production to BCG after MDSC depletion 
between HEU and HU infants at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age. 
At all time points, there were no significant differences at the individual time points in cells 
producing IFN-γ between groups (however, at one year, there were insufficient samples to be 
 
Figure 5.18: IFN-γ cytokine producing cells to BCG in infants without MDSC in HEU versus HU 
infants. IFN-γ cytokine producing cells to BCG without MDSC (CD15 depleted) were measured at 6, 10 and 
14 weeks; at 6 and 9 months and at one year of age (data not enough for ploting), and in the grouped time 
point analysis at 6, 10 and 14 weeks (first few weeks after priming), at 6 and 9 months and one year of age 
(the last follow-up time points) in HEU infants (blue) versus HU infants (black). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using Mann-Whitney U test. 
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measured in the HEU group and statistical analysis could not be performed; data not shown). 
As shown in Figure 5.18, in the grouped time point analysis there were no significant 
differences in IFN-γ producing cells to BCG at 6, 10 and 14 weeks grouped time points in 
HEU compared to HU infants (median of CD15 non-depleted=51.667 Net SFU/106 PBMC 
versus CD15 depleted=40.000 Net SFU/106 PBMC; p=0.958), as well as at 6, 9 months and 
one year grouped time points (median of CD15 non-depleted=36.330 Net SFU/106 PBMC 
versus CD15 depleted=18.000 Net SFU/106 PBMC; p=0.301) (Figure 5.18). 
5.3.2.5 BCG induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers  
We evaluated if HIV infection in mothers would alter the effect of MDSC on IFN-γ cytokine 
producing cells. First, we evaluated cells producing IFN-γ to BCG in whole PBMC (CD15 
non-depleted) between HIV+ versus HIV- mothers at delivery and at one year postpartum, 
since HIV is known to alter T cell responses. As shown in Figure 5.19, there were no 
significant differences in IFN-γ cytokine producing cells between groups at all time points. 
 
Figure 5.19: IFN-γ cytokine producing cells to BCG in HIV+ versus HIV- mothers in whole PBMC. 
IFN-γ cytokine producing cells to BCG were measured at delivery and again at one year postpartum in 
mothers whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the 
plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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5.3.2.6 BCG induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers after 
MDSC depletion 
Also, we evaluated cells producing IFN-γ to BCG in the absence of MDSC (CD15 depleted) 
between HIV+ versus HIV- mothers at delivery and at one year postpartum. There was no 
significant difference observed between groups at delivery (data not shown). However, at one 
year there were no HIV+ mothers for which this assay could be performed. 
5.3.2.7 TT induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to TT were evaluated in whole PBMC and without MDSC in 
infants post TT vaccination at 10 and 14 weeks, at 6 and 9 months, and at one year of age. 
There was no effect of MDSC depletion at any time point. However, IFN-γ producing cells to 
TT lasted till one year of age. There was no significant difference at the individual time points 
(however, at one year, there were not enough infants for which IFN-γ production could be 
measured and statistical analysis could not be performed; data not shown). In the grouped time 
point analysis there were no significant differences at 10 and 14 weeks (median of CD15 non-
depleted=3.330 Net SFU/106 PBMC versus CD15 depleted=0 Net SFU/106 PBMC, p=0.197), 
and at 6, 9 months and one year (median of CD15 non-depleted=0 Net SFU/106 PBMC, 
IQR=0-6.667, versus CD15 depleted=0 Net SFU/106 PBMC, IQR=0-13.330; p=0.185) (Figure 








Figure 5.20: IFN-γ cytokine producing cells to TT in infants in whole PBMC versus without MDSC in 
the grouped time points. IFN-γ cytokine producing cells to TT were measured in whole PBMC (CD15 non-
depleted – green) versus without MDSC (CD15 depleted – red) post TT vaccination at 10 and 14 weeks, at 6 
and 9 months and at one year of age in infants, and in the grouped analysis at 10 and 14 weeks (first few 
weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). Matched pair of 
dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical 
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5.3.2.8 TT induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, TT induced IFN-γ producing cells were evaluated in whole PBMC and without 
MDSC at delivery and again at one year postpartum. As shown in Figure 5.21, cells producing 
IFN-γ to TT were significantly lower before MDSC depletion in mothers at delivery (median 
of CD15 non-depleted=0 Net SFU/106 PBMC versus CD15 depleted=6.667 Net SFU/106 
PBMC and p=0.018), but not at one year postpartum (median of CD15 non-depleted=0 Net 
SFU/106 PBMC, IQR=0-6.667 versus CD15 depleted=0 Net SFU/106 PBMC, IQR=0-5.000 
and p=0.998). 
 
Figure 5.21: IFN-γ cytokine producing cells to TT in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to TT were measured at delivery and again at one year postpartum in mothers 
in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Matched pair of 
dots on the plot represent a mother. Bars indicate interquartile range; p<0.05 significant level and statistical 
significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
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5.3.2.9 TT induced IFN-γ cytokine producing cells in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants 
Next, we evaluated how HIV-exposure would contribute to the effect of MDSC on IFN-γ 
cytokine producing cells to TT. First we assessed whether HIV-exposure itself altered the cells 
producing IFN-γ to TT vaccination at 10 and 14 weeks, at 6 and 9 months and at one year of 
age. As shown in Figure 5.22, HIV-exposure significantly decreased IFN-γ responses at 10 
weeks; cells producing IFN-γ to TT were significantly lower in HEU compared to HU infants 
(median of HEU=0 Net SFU/106 PBMC versus HU=6.667 Net SFU/106 PBMC and p=0.033). 
In the grouped time point analysis cells producing IFN-γ to TT were not significantly different 
between HEU compared to HU infants at at 10 and 14 weeks (p=0.497) as well as at 6, 9 
months and one year (p=0.446). 
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Figure 5.22: IFN-γ cytokine producing cells to TT in whole PBMC in HEU versus HU infants. (a) In the 
individual time point analysis, IFN-γ cytokine producing cells to TT in whole PBMC (CD15 non-depleted) 
were measured in HEU infants (blue) versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at 
one year of age, and (b) in the grouped time point analysis at 10 and 14 weeks (after first and second doses of 
TT vaccination), at 6 and 9 months and one year of age (after last dose of TT vaccination). Each dot on the 
plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant 
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5.3.2.10 TT induced IFN-γ cytokine producing cells after MDSC depletion in HEU 
versus HU infants 
To evaluate if HIV-exposure would alter the effect of MDSC on IFN-γ cytokine producing 
cells, we assessed cells producing IFN-γ to TT vaccination in the absence of MDSC between 
HEU versus HU infants at 10 and 14 weeks, at 6 and 9 months and at one year of age. At the 
individual time points, there were no significant differences in cells producing IFN-γ 
(however, at one year, there were no HEU infants for which IFN-γ cytokine producing cells to 
TT were measured and statistical analysis could not be performed; data not shown). As shown 
in Figure 5.23,  in the grouped time point analysis there were no significant differences in cells 
producing IFN-γ to TT between HEU versus HU infants, at 10 and 14 weeks (median of 
HEU=0 Net SFU/106 PBMC, IQR=0-6.667 versus HU=0 Net SFU/106 PBMC, IQR=0-13.330; 
p=0.894), as well as at 6, 9 months and one year (median of HEU=0 Net SFU/106 PBMC, 
IQR=0-11.670 versus HU=0 Net SFU/106 PBMC, IQR=0-6.667; p=0.779). 
 
 
Figure 5.23: IFN-γ cytokine producing cells to TT in infants without MDSC in HEU versus HU infants. 
IFN-γ cytokine producing cells to TT without MDSC (CD15 depleted) were measured in HEU infants (blue) 
versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at one year of age (data not enough for 
ploting), and in the grouped time point analysis at 10 and 14 weeks (after first and second doses of TT 
vaccination), at 6 and 9 months and one year of age (after last dose of TT vaccination). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using Mann-Whitney U test. 
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5.3.2.11 TT induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers  
We evaluated if HIV infection in mothers would alter IFN-γ cytokine producing cells to 
antigens. We assessed cells producing IFN-γ to TT in undepleted samples between HIV+ 
versus HIV- mothers at delivery and at one year postpartum. As shown in Figure 5.24, there 




Figure 5.24: IFN-γ cytokine producing cells to TT in HIV+ versus HIV- mothers in whole PBMC. IFN-
γ cytokine producing cells to TT were measured at delivery and again at one year postpartum in mothers in 
whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the plot 
represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant 
level and statistical significance was tested using Mann-Whitney U test.   
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5.3.2.12 TT induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers after 
MDSC depletion 
We also evaluated if IFN-γ cytokine production would change after MDSC depletion in 
mothers to assess whether MDSC were functionally different in HIV infection. We assessed 
cells producing IFN-γ to TT in the absence of MDSC (CD15 depleted) between HIV+ versus 
HIV- mothers at delivery and again at one year postpartum. There was no significant 
difference observed between groups at birth. However, at one year, the number of HIV+ 
mothers for which cells producing IFN-γ to TT were to be measured was small and statistical 
analysis could not be performed (data not shown). 
5.3.2.13 BP induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to BP vaccination were evaluated in whole PBMC and without 
MDSC in infants post acellular Pertussis vaccination at 10 and 14 weeks, at 6 and 9 months, 
and at one year of age. There was no significant difference at the individual time points 
(however, at 6 months and one year of age, there were not enough infants for which IFN-γ 
cytokine producing cells to BP were measured and statistical analysis could not be performed; 
data not shown). In the grouped time point analyses, the differences were not significant after 
grouping infants at 10 and 14 weeks (median of CD15 non-depleted=6.667 Net SFU/106 
PBMC, IQR=0-6.677, versus CD15 depleted=6.667 Net SFU/106 PBMC, IQR=0-10.000; 
p=0.779), and at 6, 9 months and one year (median of CD15 non-depleted=0 Net SFU/106 
PBMC, IQR=0-13.330, versus CD15 depleted=0 Net SFU/106 PBMC, IQR=0-10.000; 
p=0.439) (Figure 5.25). Hence, no major differences in cells producing IFN-γ before and after 
MDSC depletion at all time points was observed in infants. 
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Figure 5.25: IFN-γ cytokine producing cells to BP in infants in whole PBMC versus without MDSC in 
the grouped time points. IFN-γ cytokine producing cells to BP were measured in whole PBMC (CD15 non-
depleted – green) versus without MDSC (CD15 depleted – red) post BP vaccination at 10 and 14 weeks, at 6 
and 9 months and at one year of age in infants, and in the grouped analysis at 10 and 14 weeks (first few 
weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). Matched pair of 
dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical 
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5.3.2.14 BP induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
 In mothers, number of BP induced IFN-γ producing cells were evaluated in whole PBMC and 
without MDSC at delivery and again at one year postpartum. As shown in Figure 5.26, MDSC 
depletion did not affect IFN-γ production in mothers at either time point at delivery (median of 
CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-0 versus CD15 depleted=0 Net SFU/106 
PBMC, IQR=0-0 and p=0.484), or at one year postpartum (median of CD15 non-depleted=0 
Net SFU/106 PBMC, IQR=0-0 versus CD15 depleted=0 Net SFU/106 PBMC, IQR=0-13.330 
and p=0.998). It is also important to note that, maternal IFN-γ producing cells to BP 
stimulation were very low, and most mothers did not respond to BP stimulation. 
 
Figure 5.26: IFN-γ cytokine producing cells to BP in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to BP were measured at delivery and again at one year postpartum in mothers 
in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Matched pair of 
dots on the plot represent a mother. Bars indicate interquartile range; p<0.05 significant level and statistical 
significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
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5.3.2.15 BP induced IFN-γ cytokine producing cells in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants 
We evaluated cells producing IFN-γ to BP vaccination between HEU versus HU infants at 10 
and 14 weeks, at 6 and 9 months and at one year of age. At the individual time points, there 
were no significant differences in cells producing IFN-γ (however, at one year, the number of 
HEU infants for which IFN-γ cytokine producing cells to BP was measured was small, and 
statistical analysis could not be performed; data not shown). In the grouped time point analysis 
as shown in Figure 5.27, there were no significant differences in cells producing IFN-γ to BP 
between HEU versus HU infants at all grouped time points.  
 
 
Figure 5.27: IFN-γ cytokine producing cells to BP in whole PBMC in HEU versus HU infants. IFN-γ 
cytokine producing cells to BP with MDSC (CD15 non-depleted) were measured in HEU infants (blue) 
versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at one year of age (data not enough for 
ploting), and in the grouped time point analysis at 10 and 14 weeks (after first and second doses of BP 
vaccination), at 6 and 9 months and one year of age (after last dose of BP vaccination). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using Mann-Whitney U test. 
 
KIDZERU, 2016 
Chapter 5: Cytokine production in whole PBMC vs. without MDSC 215 
 
5.3.2.16 BP induced IFN-γ production after MDSC depletion in HEU versus HU infants 
To assess if HIV-exposure would contribute to the effect of MDSC on IFN-γ cytokine 
producing cells, we evaluated cells producing IFN-γ to BP vaccination in the absence of 
MDSC between HEU versus HU infants at 10 and 14 weeks, at 6 and 9 months and at one year 
of age. There were no significant differences at the individual time points or in grouped time 
points analyses in cells producing IFN-γ (however, at one year, the number of HEU infants for 
which IFN-γ cytokine producing cells to BP was measured was small, and statistical analysis 
could not be performed; data not shown). In the grouped time point analysis as shown in 
Figure 5.28, there were no significant differences in cells producing IFN-γ to BP between HEU 




Figure 5.28: IFN-γ cytokine producing cells to BP in infants without MDSC in HEU versus HU infants. 
IFN-γ cytokine producing cells to BP without MDSC (CD15 depleted) were measured in HEU infants (blue) 
versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at one year of age (data not enough for 
ploting), and in the grouped time point analysis at 10 and 14 weeks (after first and second doses of BP 
vaccination), at 6 and 9 months and one year of age (after last dose of BP vaccination). Each dot on the plot 
represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using Mann-Whitney U test. 
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5.3.2.17 BP induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers  
We assessed if HIV infection in mothers would alter IFN-γ cytokine producing cells. We 
evaluated cells producing IFN-γ to BP in the non-depleted samples between HIV+ versus HIV- 
mothers at delivery and again at one year postpartum. There were no significant differences 
observed in IFN-γ cytokine producing cells between groups at all time points. However, at one 
year, the number of HIV+ mothers for which cells producing IFN-γ to BP were measured was 
small and statistical analysis could not be performed (data not shown). 
5.3.2.18 BP induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers after 
MDSC depletion 
We assessed cell producing IFN-γ to BP in the absence of MDSC (CD15 depleted) between 
HIV+ versus HIV- mothers at delivery and at one year postpartum. There were no significant 
differences observed between groups at delivery. However, at one year, the number of HIV+ 
mothers for which cells producing IFN-γ to BP were measured was small and statistical 
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5.3.2.19 Hep B induced IFN-γ cytokine producing cells in whole PBMC versus after 
MDSC depletion in infants 
The cells producing IFN-γ to Hep B vaccine were evaluated in whole PBMC and without 
MDSC in infants at 10 and 14 weeks, at 6 and 9 months, and at one year of age. There was no 
significant difference at the individual time points (however, at 6 months and one year of age, 
there were not enough infants for which IFN-γ cytokine producing cells to BP were measured 
and statistical analysis could not be performed; data not shown). In the grouped time point 
analysis at 6, 9 months and one year grouped time points cells producing IFN-γ to Hep B 
vaccination stimulation were significantly higher after MDSC depletion than in whole PBMC 
(median of CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-3.330 versus CD15 
depleted=6.667 Net SFU/106 PBMC, IQR=0-13.330; p=0.033), but not at 10 and 14 weeks 
grouped together (median of CD15 non-depleted=6.667 Net SFU/106 PBMC versus CD15 








Figure 5.29: IFN-γ cytokine producing cells to Hep B in infants in whole PBMC versus without MDSC 
in the grouped time points. IFN-γ cytokine producing cells to Hep B were measured in whole PBMC (CD15 
non-depleted – green) versus without MDSC (CD15 depleted – red) post Hep B vaccination at 10 and 14 
weeks, at 6 and 9 months and at one year of age in infants, and in the grouped analysis at 10 and 14 weeks 
(first few weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). 
Matched pair of dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level 
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5.3.2.20 Hep B induced IFN-γ cytokine producing cells in whole PBMC versus after 
MDSC depletion in mothers 
In mothers, Hep B induced IFN-γ producing cells were evaluated with and without MDSC at 
delivery and at one year postpartum. As shown in Figure 5.30, cells producing IFN-γ to Hep B 
were not significantly different with and without MDSC in mothers after gestation at delivery 
(median of CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-13.330 versus CD15 
depleted=0 Net SFU/106 PBMC, IQR=0-3.330; p=0.536), and at one year postpartum (median 
of CD15 non-depleted=6.667 Net SFU/106 PBMC versus CD15 depleted=3.333 Net SFU/106 
PBMC and p=0.696). 
 
Figure 5.30: IFN-γ cytokine producing cells to Hep B in mothers in whole PBMC versus without 
MDSC. IFN-γ cytokine producing cells to Hep B were measured at delivery and again at one year postpartum 
in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). 
Matched pair of dots on the plot represent a mother. Bars indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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5.3.2.21 Hep B induced IFN-γ cytokine producing cells in HIV-exposed uninfected 
(HEU) versus HIV-unexposed (HU) infants 
We evaluated cells producing IFN-γ to Hep B vaccination between HEU versus HU infants at 
10 and 14 weeks, at 6 and 9 months and at one year of age. There were no significant 
differences at the individual time points in cells producing IFN-γ (however, at 9 months, there 
were no HEU infants for which IFN-γ cytokine producing cells to Hep B were measured, and 
statistical analysis could not be performed; data not shown). In the grouped time point analysis 
as shown in Figure 5.31, there were no significant differences in cells producing IFN-γ to Hep 
B between HEU versus HU infants. 
 
 
Figure 5.31: IFN-γ cytokine producing cells to Hep B in whole PBMC in HEU versus HU infants. IFN-γ 
cytokine producing cells to Hep B with MDSC (CD15 non-depleted) were measured in HEU infants (blue) 
versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at one year of age (data not enough for 
ploting), and in the grouped time point analysis at 10 and 14 weeks (after first and second doses of Hep B 
vaccination), at 6 and 9 months and one year of age (after last dose of Hep B vaccination). Each dot on the 
plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant 
level and statistical significance was tested using Mann-Whitney U test. 
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5.3.2.22 Hep B induced IFN-γ cytokine producing cells after MDSC depletion in HEU 
versus HU infants 
We evaluated cells producing IFN-γ to Hep B vaccination in the absence of MDSC between 
HEU versus HU infants at 10 and 14 weeks, at 6 and 9 months and at one year of age. At the 
individual time points, there were no significant differences at most time points in cells 
producing IFN-γ (however, at 6 weeks the number of HEU infants was small, and at 9 months 
and one year of age, there were no HEU infants for which IFN-γ cytokine producing cells to 
Hep B were measured, and statistical analysis could not be performed; data not shown). In the 
grouped time point analysis as shown in Figure 5.32, there were no significant differences in 
cells producing IFN-γ to Hep B between HEU versus HU infants at all grouped time points. 
 
 
Figure 5.32: IFN-γ cytokine producing cells to Hep B in infants without MDSC in HEU versus HU 
infants. IFN-γ cytokine producing cells to Hep B without MDSC (CD15 depleted) were measured in HEU 
infants (blue) versus HU infants(black) at 10 and 14 weeks, at 6 and 9 months, and at one year of age (data 
not enough for ploting), and in the grouped time point analysis at 10 and 14 weeks (after first and second 
doses of Hep B vaccination), at 6 and 9 months and one year of age (after last dose of Hep B vaccination). 
Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; 
p<0.05 significant level and statistical significance was tested using Mann-Whitney U test. 
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5.3.2.23 Hep B induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers 
We assessed cell producing IFN-γ to Hep B in non-depleted samples from HIV+ versus HIV- 
mothers at delivery and at one year postpartum. There were no significant differences in IFN-γ 




Figure 5.33: IFN-γ cytokine producing cells to Hep B in HIV+ versus HIV- mothers in whole PBMC. 
IFN-γ cytokine producing cells to Hep B were measured at delivery and again at one year postpartum in 
mothers in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the 
plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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5.3.2.24 Hep B induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers 
after MDSC depletion 
We evaluated cell producing IFN-γ to Hep B in the absence of MDSC (CD15 depleted) 
between HIV+ versus HIV- mothers at delivery and at one year postpartum. There were no 
significant differences IFN-γ cytokine producing cells between groups at all time points. 
However, at one year, the number of HIV+ mothers for which cells producing IFN-γ to Hep B 
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5.3.2.25 PHA induced IFN-γ cytokine producing cells in the presence of MDSC versus 
after MDSC depletion in infants 
Phytohaemagglutinin (PHA) has been widely described and its use as a mitogen to trigger T 
lymphocyte cell proliferation and IFN-γ production as well as other cytokines(Mire-Sluis et 
al., 1987)(Gondois-Rey et al., 2001).We employed PHA as a positive control and we also 
assessed how MDSC would affect cells producing IFN-γ to PHA. We evaluated IFN-γ 
cytokine producing cells to PHA in whole PBMC and without MDSC in infants at birth, at 6, 
10 and 14 weeks, at 6 and 9 months, and at one year of age (Figure 5.34). IFN-γ cytokine 
 
Figure 5.34 (i): IFN-γ cytokine producing cells to PHA in infants in whole PBMC versus without 
MDSC in the individual time points. In the individual time point analyses, IFN-γ cytokine producing cells 
to PHA were measured in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted 
– red) at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants Matched pair of dots 
on the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical 
significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test.  
 
KIDZERU, 2016 
Chapter 5: Cytokine production in whole PBMC vs. without MDSC 225 
 
producing cells to PHA lasted till one year and responses were robust at all time points. IFN-γ 
cytokine producing cells to PHA were a significantly lower at one year of age in infants after 
MDSC depletion than in whole PBMC (median of CD15 non-depleted=1587.000 Net SFU/106 
PBMC versus CD15 depleted=446.700 Net SFU/106 PBMC and p=0.027) [Figure 5.34 (i) (g)].  
There were no significant differences observed at other time points at birth (p=0.354), at 6, 10 
and 14 weeks (p=0.639, p=0.735 and p=0.383 respectively), and at 6 and 9 months (p=0.375 
and p=0.077 respectively). Also, infants were grouped at birth and 6 weeks, at 10 and 14 
weeks, and at 6 and 9 months and one year of age grouped time points. The difference 
observed at one year of age at the individual time point was evident at the 6 and 9 months and 
one year grouped time point. IFN-γ cytokine producing cells to PHA were a significantly 
lower at 6 and 9 months and one year grouped time points in infants after MDSC depletion 
than in whole PBMC (median of CD15 non-depleted=1620.000 Net SFU/106 PBMC versus 
CD15 depleted=640.000 Net SFU/106 PBMC and p=0.007) [Figure 5.34 (ii)]. There were no 
significant differences at birth and 6 weeks as well as at 10 and 14 weeks grouped time points 









Figure 5.34 (ii): IFN-γ cytokine producing cells to PHA in infants in whole PBMC versus without 
MDSC in the grouped time points. IFN-γ cytokine producing cells to PHA were measured in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at birth, at 6, 10 and 14 weeks, at 
6 and 9 months and at one year of age in infants, and in the grouped analysis at 6, 10 and 14 weeks (first few 
weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). Matched pair of 
dots on the plot represent an infant. Bars indicate interquartile range; p<0.05 significant level and statistical 
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5.3.2.26 PHA induced IFN-γ cytokine producing cells in whole PBMC versus after 
MDSC depletion in mothers 
In mothers, PHA induced IFN-γ producing cells were compared in whole PBMC and without 
MDSC at delivery and at one year postpartum. As shown in Figure 5.35, cells producing IFN-γ 
to PHA were significantly higher in whole PBMC than after MDSC depletion in mothers at 
delivery (median of CD15 non-depleted=3047.000 Net SFU/106 PBMC versus CD15 
depleted=1947.000 Net SFU/106 PBMC and p=0.002), but not at one year postpartum (median 
of CD15 non-depleted=1773.000 Net SFU/106 PBMC versus CD15 depleted=320.000 Net 
SFU/106 PBMC and p=0.067). 
 
Figure 5.35: IFN-γ cytokine producing cells to PHA in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to PHA were measured at delivery and again at one year postpartum in 
mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). 
Matched pair of dots on the plot represent a mother. Bars indicate interquartile range; p<0.05 significant level 
and statistical significance was tested using non-parametric Wilcoxon matched-pairs* sign rank test. 
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5.3.2.27 PHA induced IFN-γ cytokine producing cells in HIV-exposed uninfected (HEU) 
versus HIV-unexposed (HU) infants 
We evaluated cells producing IFN-γ to PHA in the presence of MDSC between HEU versus 
HU infants at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age. As shown 
in Figure 5.36, there were no significant differences at any time point.  
 
Figure 5.36: IFN-γ cytokine producing cells to PHA in whole PBMC in HEU versus HU infants. IFN-γ 
cytokine producing cells to PHA in whole PBMC (CD15 non-depleted) were measured at birth, at 6, 10 and 
14 weeks, at 6 and 9 months and at one year postnatal in HEU infants (blue) versus HU infants(black). Each 
dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.     
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5.3.2.28 PHA induced IFN-γ cytokine producing cells after MDSC depletion in HEU 
versus HU infants 
We assessed cells producing IFN-γ to PHA in the absence of MDSC between HEU versus HU 
infants at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age. At all the time 
points, there were no significant differences in cells producing IFN-γ between groups. 
However, at one year of age there were no HEU infants for which IFN-γ cytokine producing 
cells to PHA were measured (data not shown).  
5.3.2.29 PHA induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers  
We evaluated cell producing IFN-γ to PHA between HIV+ versus HIV- mothers at delivery 
and at one year postpartum. As shown in Figure 5.37, there were no significant differences in 
IFN-γ cytokine producing cells between groups at either time point.  
 
Figure 5.37: IFN-γ cytokine producing cells to PHA in HIV+ versus HIV- mothers in whole PBMC. 
IFN-γ cytokine producing cells to PHA were measured at delivery and again at one year postpartum in 
mothers in whole PBMC (CD15 non-depleted) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the 
plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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5.3.2.30 PHA induced IFN-γ cytokine producing cells in HIV+ versus HIV- mothers 
after MDSC depletion 
We evaluated cell producing IFN-γ to PHA in the absence of MDSC (CD15 depleted) between 
HIV+ versus HIV- mothers at delivery and at one year postpartum. As shown in Figure 5.38, at 
delivery, HIV+ mothers had a significantly higher IFN-γ cytokine producing cells compared to 
their uninfected counterparts (median of CD15 non-depleted=3393.000 Net SFU/106 PBMC 
versus CD15 depleted=930.000 Net SFU/106 PBMC and p=0.007). By one year postpartum, 
this difference was no longer significant between groups (median of CD15 non-
depleted=156.700 Net SFU/106 PBMC versus CD15 depleted=846.700 Net SFU/106 PBMC 
and p=0.582). 
 
Figure 5.38: IFN-γ cytokine producing cells to PHA in HIV+ versus HIV- mothers without MDSC. 
IFN-γ cytokine producing cells to PHA were measured at delivery and again at one year postpartum in 
mothers without MDSC (CD15 depleted ) in HIV+ (blue) versus HIV- (black) mothers. Each dot on the plot 
represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant 
level and statistical significance was tested using Mann-Whitney U test.   
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Table 5.4: Summary results of the quantity of IFN-γ cytokine producing cells in response to vaccines and 
antigens stimulations as measured in PBMC (presence of MDSC) versus without MDSC (after MDSC 
depletion) in infants and mothers. P-values of infants and mothers IFN-γ cytokine producing cells in PBMC 
(presence of MDSC) versus without MDSC (after MDSC depletion) after stimulation with the following antigens 
[Bacillus Calmette-Guérin (BCG), Hepatitis B (Hep B), Tetanus toxoid (TT), Bordetella pertussis (BP) and 
Phytohaemagglutinin (PHA)]. Blue highlights represent the parameters (p-values and type of data sets), Red 
highlights represent the different time points [birth (D0), 6, 10 and 14 weeks (WK6, WK10 and WK14), 6 and 9 
months (Mth6 and Mth9), and 1 year (YR1)], and Purple highlights represent significant differences in IFN-γ 
cytokine producing cells in the presence of MDSC versus after MDSC depletion to vaccine antigens. GRP=Group, 
Indv=Individual, TP= Time point, B=Baby, and M=Mother.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B GRP TP (B)   0.127 0.033 
Hep B Indv.TP (M) 0.516      0.617 
TT GRP TP (B)   0.197 0.185 
TT Indv.TP (M) 0.018      0.998 
BCG Indv TP (B)  0.147 0.191 0.203 0.109 0.061 0.016 
BCG GRP TP (B)  0.013 0.001 
BCG Indv.TP (M) 0.739      0.125 
BP GRP TP (B)   0.779 0.439 
BP Indv.TP (M) 0.484      0.998 
PHA Indv TP (B) 0.354 0.639 0.735 0.383 0.375 0.077 0.027 
PHA GRP TP (B) 0.439 0.406 0.007 
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Table 5.5: Summary results of the quantity of IFN-γ cytokine producing cells in response to vaccines and 
antigens stimulations as measured in HEU versus HU infants as well as in HIV+ versus HIV- mothers in 
PBMC (presence of MDSC) and without MDSC (after MDSC depletion). P-values of infants and mothers IFN-γ 
cytokine producing cells in PBMC (presence of MDSC) and without MDSC (after MDSC depletion) in HEU versus 
HU infants as well as in HIV+ versus HIV- mothers after stimulation with the following antigens [Bacillus Calmette-
Guérin (BCG), Hepatitis B (Hep B), Tetanus toxoid (TT), Bordetella pertussis (BP) and Phytohaemagglutinin 
(PHA)]. Blue highlights represent the parameters (p-values and type of data sets), Red highlights represent the 
different time points [birth (D0), 6, 10 and 14 weeks (WK6, WK10 and WK14), 6 and 9 months (Mth6 and Mth9), 
and 1 year (YR1)], and Purple highlights represent significant differences in IFN-γ cytokine producing cells to 
vaccine antigens in the presence and absence of MDSC in HEU versus HU infants. GRP=Group, Indv=Individual, 
TP= Time point, B=Baby, M=Mother, N=MDSC non-depleted, and D=MDSC depleted.  
Parameters p-values 
Time points D0 WK6 WK10 WK14 Mth6 Mth9 YR1 
Hep B GRP TP (B) (N)   0.563 0.104 
Hep B GRP TP (B) (D)   0.855 0.881 
Hep B Indv TP (M) (N) 0.952      0.261 
TT Indv TP (B) (N)   0.033 0.361 0.129 0.195 0.643 
TT GRP TP (B) (N)   0.497 0.446 
TT GRP TP (B) (D)   0.894 0.779 
TT Indv TP (M) (N) 0.738      0.311 
BCG GRP TP (B) (N)  0.230 0.959 
BCG GRP TP (B) (D)  0.958 0.301 
BCG Indv TP (M) (N) 0.153      0.309 
BP GRP TP (B) (N)   0.528 0.888 
BP GRP TP (B) (D)   0.888 0.114 
PHA Indv TP (B) (N) 0.273 0.608 0.648 0.490 1.000 0.539 0.523 
PHA Indv TP (M) (N) 0.618      0.082 
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5.4 Discussion            
The aims of this chapter were to evaluate the effect of MDSC on IFN-γ cytokine producing cells 
in response to Mycobacterium bovis bacillus Calmette-Guérin (BCG), Tetanus toxoid (TT), 
Bordetella pertussis (BP) and Hepatitis B (Hep B) vaccinations and to Phytohaemagglutinin 
(PHA) in infant-mother pairs. Infants were followed-up from birth, at 6, 10 and 14 weeks, at 6 
and 9 months, and at one year of age. Mothers on their part were followed-up only at delivery 
and again at one year postpartum. 
IFN-γ cytokine producing cells were quantified in whole PBMC and without MDSC after MDSC 
depletion using the EasySep® magnetic cell separation technique described in section 4.2.1. Total 
sport forming IFN-γ cytokine producing cells i.e. net spot forming units per million PBMC (Net 
SFU/106 PBMC) were measured by employing the ELISpot assay described in section 5.2.1. The 
use of the ELISpot assay to measure cytokine producing cells has been well optimised and is a 
powerful tool(Slota et al., 2011)(Maggioli et al., 2015)(Janetzki, 2015). However, we used 
whole cord blood and peripheral blood mononuclear cells from infants and mothers, which 
rendered the ELISpot to lack the ability to measure cytokine production at the cellular level. The 
responses measured are reported as total cytokine responses; we do not know specifically the 
source of IFN-γ. 
The effect of myeloid derived suppressor cells (MDSC) on immune responses can be 
investigated by evaluating several immune parameters. In chapter 4, we evaluated the effect of 
MDSC on CD4+ T cell proliferation. In this chapter, the effect of MDSC on IFN production was 
investigated. Cytokines are the molecules that mediate communication between immune cells 
and vital for evaluating immune function and vaccine immunogenicity(Gasparoni et al., 
2003)(Peoples et al., 2009). There is limited understanding of the effect of MDSC on cytokine 
production in the very first few weeks of life in infants, and in mothers postpartum(Gervassi et 
al., 2014).  
Generally, in infants MDSC frequency and absolute count between infants who were 
responders and non-responders to vaccine induced IFN-γ cytokine producing cells were 
significantly lower in responders than in non-responders at most time points. However, MDSC 
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frequency and count varied between responders and non-responders to different vaccine 
antigens and at different grouped time points.  
We hypothesis that MDSC frequency will influence IFN-γ cytokine producing cells to vaccine 
antigens negatively, in conformity with our hypothesis in infants, this was evident, as MDSC 
frequency and counts in responders was significantly lower and there were trends towards low 
quantities of MDSC at most time points in the different vaccine antigen stimulation. A 
significantly lower MDSC frequency was observed in infants who responded to Hep B induced 
IFN-γ cytokine producing cells at 10 weeks of age, also evident at 10 and 14 weeks grouped 
time points, and trends towards low MDSC frequency at 9 months of age in Hep B vaccinated 
infants and at 10 and 14 weeks grouped time points in TT vaccinated infants. Also, we 
observed that the MDSC frequency and count in responders to TT increased with age but 
remained the same in the non-responders. Further, Significantly lower MDSC counts was 
observed at 6 months post BCG vaccination in infants who responded to BCG stimulation 
(however the number of non-responders was small), and at 10 and 14 weeks grouped time 
points in infants who responded to TT stimulation. There was also a trend towards low MDSC 
counts in infants who responded to Hep B stimulation at 10 weeks of age.  
 However, there were a few differences between responders and non-responders contrary to 
our hypothesis as also observed in Chapter 4, section 4.3.1 on CD4+ T cell proliferation. In the 
grouped time point analysis, at 6 and 9 months and one year grouped time points, MDSC 
frequency was significantly higher in infants who responded to TT stimulation versus the non-
responders, and a trend towards high MDSC frequency at one year of age in infants who 
responded to BCG vaccine stimulation. Also, at 10 weeks of age post BCG vaccination MDSC 
absolute count was significantly higher in responder than non-responders, but there were few 
non-responders.  
The effect of MDSC on cytokine production to non-specific antigens has been studied previously 
but there is limited information to vaccines. Rieber et al. showed suppression of infant and adult 
T helper type 1 (Th1), Th2 and Th17 cytokine secretion by cord blood MDSC(Rieber et al., 
2013). After stimulations with anti-CD3CD28 (Dynabeads), we have also shown that MDSC 
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decrease the frequency of IFN-γ producing cells in cord blood of caesarean section delivered 
neonates(Gervassi et al., 2014). In infants, detectable IFN-γ cytokine producing cells to BCG 
lasted to approximately 9 months. Cells producing IFN-γ were significantly lower after depleting 
MDSC at one year of age and a trend towards lower IFN-γ cytokine producing cells to BCG at 6 
months of age. The decrease in IFN-γ cytokine producing cells to BCG after MDSC depletion 
was also evident in the grouped time point analyses at 6, 10 and 14 weeks grouped time points 
post BCG vaccination in infants as well as at 6 and 9 months and one year, the last follow-up 
grouped time points. This finding supported our observation of a trend towards high MDSC 
frequency at one year of age in infants who responded to BCG vaccine stimulation. We think 
that the difference in the responses observed could be due to the function of the assay. It has 
been shown that MDSC themselves can make IFN-γ(Matsumura et al., 2012)(Guo et al., 
2012)(Cripps et al., 2010) and may depend on the type of antigen stimulation, and may be the 
reason for the lower IFN-γ producing cells post BCG stimulation.  
Detectable IFN-γ cytokine producing cells to TT were observed to approximately one year of age 
in infants, but there seems to be little effect of MDSC on these responses. IFN-γ cytokine 
responses to TT were really small and have been fairly undescribed. IFN-γ cytokine may not be 
an important component for TT vaccination which may be the reason why MDSC had little 
effect on cells producing IFN-γ. In Italian infants Graziani et al. showed that cell-mediated 
immune responses to TT may be important for long-term immunity after a required vaccine 
recall(Graziani et al., 2013). Humoral immunity to tetanus vaccination have extensively been 
described(Siegrist, 2008)(Abramczuk et al., 2011).  
Detectable IFN-γ cytokine producing cells to BP vaccination were observed to about 9 months of 
age, but were not significantly different in whole PBMC and after MDSC depletion in infants. It 
must be noted that IFN-γ cytokine producing cells to BP in most infants was poorly induced at 
most time points and most infants did not respond to BP stimulation. In infants, there is evidence 
of good antibody induction by BP vaccination, and cellular immune responses to BP increased 
over the course of the vaccination schedule and after booster vaccination(Fadugba et al., 
2014)(Zepp et al., 1996)(Edwards et al., 2014).   
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IFN-γ cytokine producing cells to Hepatitis B vaccination did not significantly differ in whole 
PBMC and without MDSC in infants in the individual time point analyses. However, in line with 
our hypothesis after grouping infants at 6 and 9 months and one year grouped time points, IFN-γ 
cytokine producing cells were significantly higher after MDSC depletion. This observation is in 
support of our finding of significantly lower MDSC frequency in infants who responded to Hep 
B induced IFN-γ cytokine producing cells at 10 weeks of age, also evident at 10 and 14 weeks 
grouped time points, and trends towards low MDSC frequency at 9 months of age in Hep B 
vaccinated infants who responded post Hep B stimulation. In Chapter 3 we showed that MDSC 
is significantly present at birth but decreases over time. The quantity of MDSC at 9 months of 
age may be enough for immune suppression, and after depletion the effect on IFN-γ cytokine 
producing cells to Hep B was evident. Hep B vaccination have been shown to induce antibody 
responses(Siegrist, 2008)(Spradling et al., 2013) and there is evidence that Hep B induced 
immunologic T cell in infants are able to trigger specific antibody responses to Hep B later 
during the vaccination schedule(Bauer et al., 2006).  
IFN-γ cytokine producing cells to PHA lasted till one year and the magnitude of responses was 
high in whole PBMC and after MDSC depletion in infants as expected of a mitogen(Mire-Sluis 
et al., 1987)(Barcellini et al., 1994)(Lawn et al., 2007). Contrary to our hypothesis, the effect of 
MDSC was evident post PHA stimulation, at one year of age IFN-γ cytokine producing cells 
were significantly lower after MDSC depletion, and this was also observed at 6 and 9 months 
and one year grouped time points.  
In mothers, it is important to note that, it is unlikely that they had been vaccinated against all the 
vaccines we assessed including BCG, TT, BP and Hep B, as in South Africa pregnant women are 
not routinely given these vaccines boosters during gestation. The magnitudes of the responses in 
mothers were often small making it challenging to detect the role of MDSC. After BCG 
stimulation, there was a trend towards higher IFN-γ cytokine producing cells in the presence of 
MDSC at one year postpartum, but not after gestation at delivery. We think that with a higher 
sample size, when the study is completed a significant difference would be evident. Also, we 
think that the maternal immune system may be in a state of dis-equilibrium between the 
frequency of Tregs and other regulatory cells including MDSC during gestation, and by one year 
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postpartum the MDSC level normalised and could be the source of IFN-γ as there is evidence 
that MDSC can make IFN-γ(Matsumura et al., 2012)(Cripps et al., 2010). Also, the increased 
IFN-γ production at one year postpartum could be either non-specific or due to TB infection as 
most of the mothers have not been administered BCG vaccination for about 20 years or more.  
Furthermore, in mothers, after gestation at delivery IFN-γ cytokine producing cells to TT 
stimulation were significantly higher after depleting MDSC. This is in support of our hypothesis, 
but contrary to our findings in response to BCG where at one year postpartum we observed a 
trend towards lower IFN-γ cytokine producing cells to BCG stimulation in mothers after 
removing MDSC. For the first time, we show that after gestation at delivery IFN-γ cytokine 
producing cells were significantly higher after depleting MDSC in response to TT at delivery. 
This also shows that maternal MDSC levels during gestation may be influenced by other 
regulatory cells. MDSC could be suppressed by Tregs during gestation eliminating its effect on 
IFN-γ cytokine producing cells to BCG after gestation at delivery in mothers. This further, shows 
that the effect of MDSC on IFN-γ cytokine producing cells may be antigen dependent. Besides 
the articles by Fujimura et al., there is no direct evidence yet on how Tregs shape the functional 
phenotype of MDSC to the best of our knowledge. Fujimura et al. recently reported that Tregs 
are maintained by B7-H1 signalling and intern B7-H1 is immunosuppressive on MDSC. This 
functional crosstalk between Treg and MDSC may play an important role in the induction of 
immunosuppression by MDSC(Fujimura et al., 2012).   
On the contrary, MDSC had little effect on IFN-γ cytokine producing cells to BP and Hep B 
stimulations in mothers. In South Africa Hepatitis B vaccination was only started 15 years ago, 
so none of the mothers should have been immunized, due to that any significant differences in 
Hep B responses would be either non-specific or due to infection. Recently, Pallett et al. showed 
that Hepatitis B virus (HBV) immunopathology was metabolically regulated by MDSC(Pallett et 
al., 2015)(Weber, 2015). Higher IFN-γ cytokine producing T cells have been shown after 
depleting MDSC in hepatitis B patients(Pallett et al., 2015)(Weber, 2015). Also, in Hepatitis C 
virus (HCV) infection, MDSC have been shown to suppress IFN-γ production by CD4+ and 
CD8+ T cells(Tacke et al., 2013). The prevalence of Hep B infection in South Africa is highly 
variable, a study carried out on South African and Botswanan women by Matthews et al. and a 
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systematic review estimating worldwide prevalence of chronic Hep B virus infection in South 
African women found that about 7% of women had detectable HBsAg(Matthews et al., 
2015)(Schweitzer et al., 2015). However, mothers in this study were not tested for Hep B 
infection.  
In mothers, IFN-γ cytokine producing cells to PHA were significantly lower after removing 
MDSC at delivery, but not at one year postpartum. This is contrary to our hypothesis, but in 
support of the observation that the source of IFN-γ may be from MDSC, as MDSC have been 
shown to produce IFN-γ themselves(Matsumura et al., 2012)(Cripps et al., 2010).  
As part of our objectives, we evaluated the impact of MDSC in HIV-exposure in infants and HIV 
infection in mothers on cytokine producing cells. There is no literature to date assessing the 
suppressive function of MDSC on cytokine production in HIV-exposed uninfected (HEU) 
infants in their very first few weeks of life to one year of age. We do not know what effect 
MDSC would have on cytokine responses to vaccine stimulations in HIV+ mothers after 
gestation at delivery and sometime postpartum.  
We have shown that HEU infants have an altered cytokine production profile in response to 
vaccine and nonspecific antigens(Kidzeru et al., 2014). We showed that in utero HIV-exposure, 
significantly dampens measurable cytokine polyfunctional responses(Kidzeru et al., 2014). The 
effect of MDSC has also been studied in some clinical conditions in infants. In Chinese children, 
Pan et al. showed that high MDSC frequency in children that presented with recurrent wheezing 
contributed to high IL-17 cytokine producing cells(Pan et al., 2015). In this study, IFN-γ 
cytokine producing cells to BCG were generally lower in HEU infants. In support of our 
hypothesis, others have shown that HIV-exposure contributed to decreased IFN-γ cytokine 
production, as we show here that IFN-γ cytokine producing cells to BCG were lower in HEU, 
but was not significant(Hesseling et al., 2015)(van Rie et al., 2006)(Jones et al., 2015).   
IFN-γ cytokine producing cells to TT in HEU infants were significantly lower at 10 weeks after 
the first vaccine dose. However, the number of HEU infants was small. This is in support of our 
hypothesis that MDSC may be a player in the altered immune system of HEU infants, reducing 
IFN-γ cytokine producing cells to BCG and TT vaccination(Kidzeru et al., 2014).  
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Generally, HIV infection had little effect on IFN-γ cytokine producing cells in response to most 
vaccines stimulations assessed and to PHA. However, after depleting MDSC IFN-γ cytokine 
producing cells to PHA were significantly higher in HIV+ mothers at delivery. This could be as a 
result of hyper-activation or reactivation due to HIV infection. In contrast, HIV infection should 
be immunosuppressive(Hammond et al., 2008). Hammond et al. have shown that IFN-γ cytokine 
producing cells to PPD are suppressed in HIV infected patients(Hammond et al., 2008). Also, 
contrary to our findings in HIV infection in mothers, Garg et al. showed that HIV gp120-
expanded MDSC inhibited IFN-γ responses from autologous T cells in HIV+ participants(Garg 
et al., 2013). 
HIV has been well documented for its incredible immune activation much more than other 
disease states(Paiardini et al., 2013)(Chang et al., 2010)(Catalfamo et al., 2011)(d’Ettorre et al., 
2011). The main source of IFN-γ secretion have been shown to be CD4+ T cells that are 
decreased in chronic HIV infected patients due to immune activation(Hammond et al., 2008). 
Interestingly, we found that the frequency of MDSC at delivery was not significantly different 
between HIV+ and HIV- mothers but not at one year postpartum (section 3.3.1.2 b). HIV 
infection may create a hyper-reactive immune environment leading to increased IFN-γ 
production to non-HIV antigens as observed in HIV infection in the mothers in this study after 
PHA stimulation. We recommend that further investigations would be warranted. 
This study is not without limitations. One limitation is that the number of infants and mothers 
was small and often volume of blood insufficient for the IFN-γ ELISPOT assay at certain time 
points. The study is still accruing data and some participants were yet to reach the later follow-up 
time points. The source of IFN-γ could not be determined as whole PBMC was used. However, 
this is as a function of the assay, and in future studies Flow cytometry could be used to measure 
cytokine production at the cellular level using ICS. Also, after depletion using EasySep® 
magnetic cell separation technique, cells seem to be less “happy” compared to cells that have not 
gone through the same process. This could be one of the reasons why responses decreased after 
depletion, although the beads are nanoparticles that are not supposed to alter cells functionally in 
any way(Tomlinson et al., 2013). However, experiments where CD15 enriched cells are added 
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back to CD15 depleted cells are in progress and should provide a clearer understanding of the 
effect of the depletion process on IFN-γ cytokine production. 
In summary, the findings presented in this chapter suggest that the magnitude of IFN-γ cytokine 
producing cells to vaccines were generally present in infants to approximately 9 months of age, 
and the effect of MDSC on IFN-γ cytokine producing cells may be antigen dependent. This 
antigen dependency may be associated with responses after HIV-exposure in infants. Also, in 
HIV infection in mothers, IFN-γ cytokine producing cells may be antigen dependent and may be 
associated with different maternal immune states both at delivery and one year postpartum. 
Future immune functional studies would be warranted; we think that MDSC may be playing a 
different role to vaccines and antigens yet to be understood. Also, we think that, the complex 
immune environment during gestation rich in different immune regulatory cells in the mothers 
may suppress MDSC’s effect. 
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  241 
 
5.5 References 
• Z. M., Britten, L. P. • C. G. • A. M. • S. J. • M. L. ¨. • M. J. P. W. • C. O. • S. H. van der B. • C. 
M., & Received: (2010). Response definition criteria for ELISPOT assays revisited, 1489–
1501. doi:10.1007/s00262-010-0875-4 
A. C. Hesseling*, H. B. Jaspan†,‡, G. F. Black§, N. Nene§,  and G. W. (2015). Immunogenicity 
of BCG in HIV-exposed and non-exposed infants following routine birth or delayed 
vaccination. Int J Tuberc Lung Dis, 73(4), 389–400. doi:10.1530/ERC-14-0411.Persistent 
abcam. (1983). ELISPOT. Culture, 5–7. 
Abramczuk, B. M., Mazzola, T. N., Moreno, M. F., Zorzeto, T. Q., Wolf, P. S., Blotta, M. H., … 
Quintilio, W. (2011). Impaired Humoral Response to Vaccines among HIV-Exposed 
Uninfected Infants Impaired Humoral Response to Vaccines among HIV-Exposed 
Uninfected Infants . doi:10.1128/CVI.05065-11 
Aiken, A. M., Hill, P. C., Fox, A., Mcadam, K. P. W. J., Jackson-sillah, D., Lugos, M. D., … 
Brookes, R. H. (2006). Reversion of the ELISPOT test after treatment in Gambian 
tuberculosis cases, 6, 1–6. doi:10.1186/1471-2334-6-66 
Alexander, N., Fox, A., Lien, V. T. K., Dong, T., Lee, L. Y. H., Le Khanh Hang, N., … Horby, 
P. (2013). Defining ELISpot cut-offs from unreplicated test and control wells. Journal of 
Immunological Methods, 392(1-2), 57–62. 
ANIARA. (2008). Guidelines and troubleshooting for ELISPOT analyses, 5–8. 
Barcellini, W., Rizzardi, G. P., Borghi, M. O., Fain, C., Lazzarin, A., & Meroni, P. L. (1994). 
Th1 and Th2 Cytokine Production by Peripheral-Blood Mononuclear-Cells from Hiv-
Infected Patients. Aids, 8(6), 757–762. Retrieved from WOS:A1994NP43600006 
Bauer, T., & Jilg, W. (2006). Hepatitis B surface antigen-specific T and B cell memory in 
individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine, 24(5), 
572–577. 
Burl, S., Adetifa, U. J., Cox, M., Touray, E., Ota, M. O., Marchant, A., … Mcshane, H. (2012). 
Delaying Bacillus Calmette-Gue ´rin Vaccination from Birth to 4 1/2 Months of Age 
Reduces Postvaccination Th1 and IL-17 Responses but Leads to Comparable Mycobacterial 
Responses at 9 Months of Age. doi:10.4049/jimmunol.1000552 
Catalfamo, M., Wilhelm, C., Tcheung, L., Proschan, M., Friesen, T., Park, J.-H., … Lane, C. 
(2011). CD4 and CD8 T cell immune activation during chronic HIV infection: roles of 
homeostasis, HIV, type I IFN, and IL-7. Journal of Immunology (Baltimore, Md. : 1950), 
186, 2106–2116. doi:10.4049/jimmunol.1002000 
Chang, J. J., & Altfeld, M. (2010). Innate immune activation in primary HIV-1 infection. The 
Journal of Infectious Diseases, 202 Suppl (Suppl 2), S297–301. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2945608&tool=pmcentrez&ren
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  242 
 
dertype=abstract 
Cripps, J. G., Wang, J., Maria, A., Blumenthal, I., & Gorham, J. D. (2010). Type 1 T helper cells 
induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 
knockout mouse liver. Hepatology (Baltimore, Md.), 52(4), 1350–1359. 
Cripps, J., Wang, J., Maria, A., & Blumenthal, I. (2010). Liver Th1 cells drive the accumulation 
of Myeloid Derived Suppressor Cells during acute hepatitis in an IFN- -dependent manner ., 
2. 
d’Ettorre, G., Paiardini, M., Ceccarelli, G., Silvestri, G., & Vullo, V. (2011). HIV-associated 
immune activation: from bench to bedside. AIDS Research and Human Retroviruses, 27(4), 
355–364. 
du Plessis, N., Loebenberg, L., Kriel, M., von Groote-Bidlingmaier, F., Ribechini, E., Loxton, A. 
G., … Walzl, G. (2013). Increased frequency of myeloid-derived suppressor cells during 
active tuberculosis and after recent mycobacterium tuberculosis infection suppresses T-cell 
function. American Journal of Respiratory and Critical Care Medicine, 188(6), 724–32. 
doi:10.1164/rccm.201302-0249OC 
Edwards, K. M., & Berbers, G. a M. (2014). Immune responses to pertussis vaccines and disease. 
The Journal of Infectious Diseases, 209 Suppl (Suppl 1), S10–5. doi:10.1093/infdis/jit560 
Epalza, C., Goetghebuer, T., Hainaut, M., Prayez, F., Barlow, P., Dediste, A., … Epalza, A. C. 
(2011). High Incidence of Invasive Group B Streptococcal Infections in HIV-Exposed 
Uninfected Infants. Pediatrics. doi:10.1542/peds.2010-0183 
Fadugba, O. O., Wang, L., Chen, Q., & Halasa, N. B. (2014). Immune responses to pertussis 
antigens in infants and toddlers after immunization with multicomponent acellular pertussis 
vaccine. Clinical and Vaccine Immunology, 21(12), 1613–1619. doi:10.1128/CVI.00438-14 
Fujimura, T., Kambayashi, Y., & Aiba, S. (2012). Crosstalk between regulatory T cells (Tregs) 
and myeloid derived suppressor cells (MDSCs) during melanoma growth. 
Oncoimmunology, 1(8), 1433–1434. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3518528&tool=pmcentrez&ren
dertype=abstract 
Gama, L., Shirk, E. N., Russell, J. N., Carvalho, K. I., Li, M., Queen, S. E., … Kallas, E. G. 
(2012). Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally 
similar to myeloid-derived suppressor cells during SIV and HIV infection. Journal of 
Leukocyte Biology, 91(5), 803–16. doi:10.1189/jlb.1111579 
Garg, A., & Spector, S. a. (2013). HIV type 1 gp120-induced expansion of myeloid derived 
suppressor cells is dependent on interleukin 6 and suppresses immunity. The Journal of 
Infectious Diseases, 209(3), 441–51. doi:10.1093/infdis/jit469 
Gasparoni, A., Ciardelli, L., Avanzini, A., Castellazzi, A. M., Carini, R., Rondini, G., & Chirico, 
G. (2003). Age-Related Changes in Intracellular Th1/Th2 Cytokine Production, 
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  243 
 
Immunoproliferative T Lymphocyte Response and Natural Killer Cell Activity in 
Newborns, Children and Adults. Biology of the Neonate, 84(4), 297–303. 
doi:10.1159/000073638 
Gervassi, A., Lejarcegui, N., Dross, S., Jacobson, A., Itaya, G., Kidzeru, E., … Horton, H. 
(2014). Myeloid derived suppressor cells are present at high frequency in neonates and 
suppress in vitro T cell responses. PloS One, 9(9), e107816. 
doi:10.1371/journal.pone.0107816 
Gondois-Rey, F., Biancotto,  a, Pion, M., Chenine,  a L., Gluschankof, P., Horejsi, V., … Hirsch, 
I. (2001). Production of HIV-1 by resting memory T lymphocytes. AIDS (London, 
England), 15(15), 1931–1940. doi:10.1097/00002030-200110190-00004 
Graziani, S., Romiti, M. L., Capponi, C., Di Cesare, S., Corrente, S., Monteferrario, E., … 
Moschese, V. (2013). Immune responses to tetanus vaccination in Italian healthy subjects 
and children with recurrent infections. Journal of Biological Regulators and Homeostatic 
Agents, 27(1), 95–103. Retrieved from 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=2
3489690 
Guo, Q., Lv, Z., Fu, Q., Jiang, C., Liu, Y., Lai, L., … Wang, Q. (2012). IFN-γ producing T cells 
contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after 
cyclophosphamide treatment. International Immunopharmacology, 12(2), 425–32. 
doi:10.1016/j.intimp.2011.12.016 
Hammond, A. S., McConkey, S. J., Hill, P. C., Crozier, S., Klein, M. R., Adegbola, R. a, … 
Jaye, A. (2008). Mycobacterial T cell responses in HIV-infected patients with advanced 
immunosuppression. The Journal of Infectious Diseases, 197(2), 295–299. 
doi:10.1086/524685 
Janetzki, S. (2015). Immune monitoring technology primer: the enzyme-linked immunospot 
(Elispot) and Fluorospot assay. Journal for Immunotherapy of Cancer, 3(1), 30. 
doi:10.1186/s40425-015-0074-0 
Jones, C. E., Hesseling, A. C., Tena-Coki, N. G., Scriba, T. J., Chegou, N. N., Kidd, M., … 
Kampmann, B. (2015). The impact of HIV exposure and maternal Mycobacterium 
tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. 
AIDS (London, England), 29(2), 155–65. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4284011&tool=pmcentrez&ren
dertype=abstract 
Kagina, B. M. N., Abel, B., Bowmaker, M., Scriba, T. J., Gelderbloem, S., Smit, E., … 
Hanekom, W. A. (2009). Delaying BCG vaccination from birth to 10 weeks of age may 
result in an enhanced memory CD4 T cell response, 27, 5488–5495. 
doi:10.1016/j.vaccine.2009.06.103 
Kidzeru, E. B., Hesseling, A. C., Passmore, J. S., Myer, L., Gamieldien, H., Toukam, C., … 
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  244 
 
Town, C. (2014). In-utero exposure to maternal HIV infection alters T-cell immune 
responses to vaccination in HIV-uninfected infants. AIDS, (January). 
doi:10.1097/QAD.0000000000000292 
Lawn, S. D., Bangani, N., Vogt, M., Bekker, L.-G., Badri, M., Ntobongwana, M., … Wood, R. 
(2007). Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-
exposed patients with advanced HIV infection in South Africa. BMC Infectious Diseases, 7, 
99. 
Maggioli, M. F., Palmer, M. V., Vordermeier, H. M., Whelan, A. O., Fosse, J. M., Nonnecke, B. 
J., & Waters, W. R. (2015). Application of Long-term cultured Interferon-&amp;#947; 
Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in 
Cattle. Journal of Visualized Experiments, (101), 1–8. doi:10.3791/52833 
Matsumura, T., Ato, M., Ikebe, T., Ohnishi, M., Watanabe, H., & Kobayashi, K. (2012). 
Interferon-γ-producing immature myeloid cells confer protection against severe invasive 
group A Streptococcus infections. Nature Communications, 3, 678. 
doi:10.1038/ncomms1677 
Matthews, P. C., Beloukas, A., Malik, A., Carlson, J. M., Jooste, P., Ogwu, A., … Klenerman, P. 
(2015). Prevalence and characteristics of hepatitis B virus (HBV) coinfection among HIV-
Positive women in South Africa and Botswana. PLoS ONE, 10(7). 
Mazzola, N., Marcos, T. N., & Abramczuk, B. M. (2011). Impaired Bacillus Calmette – Gue 
response in HIV-exposed , uninfected infants. AIDS, 25(July), 2079–2087. 
doi:10.1097/QAD.0b013e32834bba0a 
Miles, D. J. C., Gadama, L., Gumbi, A., Nyalo, F., Makanani, B., & Heyderman, R. S. (2010). 
Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T-cell 
differentiation and modulates responses to Bacille Calmette-Guérin (BCG) vaccine in HIV-
uninfected infants. Immunology, 129(3), 446–54. doi:10.1111/j.1365-2567.2009.03186.x 
Mire-Sluis,  a R., Wickremasinghe, R. G., Hoffbrand,  a V, Timms,  a M., & Francis, G. E. 
(1987). Human T lymphocytes stimulated by phytohaemagglutinin undergo a single round 
of cell division without a requirement for interleukin-2 or accessory cells. Immunology, 
60(1), 7–12. 
Ota, M. O. C., Vekemans, J., Susanna, E., Fielding, K., Sanneh, M., Kidd, M., … Marchant, A. 
(2012). Influence of Mycobacterium bovis Bacillus Calmette-Guerin on Antibody and 
Cytokine Responses to Human Neonatal Vaccination. 
Paiardini, M., & Müller-Trutwin, M. (2013). HIV-associated chronic immune activation. 
Immunological Reviews, 254(1), 78–101. 
Pallett, L. J., Gill, U. S., Quaglia, A., Sinclair, L. V, Jover-Cobos, M., Schurich, A., … Maini, M. 
K. (2015). Metabolic regulation of hepatitis B immunopathology by myeloid-derived 
suppressor cells. Nature Medicine, 21(6). doi:10.1038/nm.3856 
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  245 
 
Peoples, J. D., Cheung, S., Nesin, M., Lin, H., Ph, D., Tatad, A. M. F., … Cunningham-rundles, 
S. (2009). Neonatal Cord Blood Subsets and Cytokine Response to Bacterial Antigens, 
1(212), 647–657. doi:10.1055/s-0029-1220788. 
Qin, A., Cai, W., Pan, T., Wu, K., Yang, Q., Wang, N., … Zhou, J. (2013). Expansion of 
monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive 
individuals. Journal of Virology, 87(3), 1477–90. doi:10.1128/JVI.01759-12 
Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., … Finke, J. (2011). 
Myeloid-derived suppressor cell accumulation and function in patients with newly 
diagnosed glioblastoma, 13(6), 591–599. 
Rie, A. Van, Madhi, S. A., Heera, J. R., Meddows-taylor, S., Wendelboe, A. M., Anthony, F., … 
Tiemessen, C. T. (2006). Gamma Interferon Production in Response to Mycobacterium 
bovis BCG and Mycobacterium tuberculosis Antigens in Infants Born to Human 
Immunodeficiency Virus-Infected Mothers, 13(2), 246–252. doi:10.1128/CVI.13.2.246 
Rieber, N., Gille, C., & Köstlin, N. (2013). Neutrophilic myeloid-derived suppressor cells in cord 
blood modulate innate and adaptive immune responses, 45–52. doi:10.1111/cei.12143 
Rieber, N., Gille, C., Köstlin, N., Schäfer, I., Spring, B., Ost, M., … Hartl, D. (2013). 
Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive 
immune responses. Clinical and Experimental Immunology, 174(1), 45–52. 
doi:10.1111/cei.12143 
Rouss, P. J., & Christophe, C. (1993). Alternatives to the Median Absolute Deviation, 88(424). 
Santos, R., Buying, A., Sabri, N., Yu, J., Gringeri, A., Bender, J., … Judkowski, V. a. (2014). 
Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen 
PBMC Samples Confirmed Through Rigorous Statistical Analysis. Cells, 4(1), 1–18. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25546016 
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015). Estimations of 
worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data 
published between 1965 and 2013. Lancet (London, England), 6736(15), 1–10. 
doi:10.1016/S0140-6736(15)61412-X 
Siegrist, C. (2007). The Challenges of Vaccine Responses in Early Life : Selected Examples, 
137, 4–9. doi:10.1016/j.jcpa.2007.04.004 
Siegrist, C. (2008). Vaccine immunology 2. 
Slota, M., Lim, J., Dang, Y., & Disis, M. (2011). ELISpot for measuring human immune 
response to vaccines. Expert Review of Vaccines, 10(3), 299–306. 
doi:10.1586/erv.10.169.ELISpot 
Spradling, P. R., Xing, J., Williams, R., Masunu-Faleafaga, Y., Dulski, T., Mahamud, A., … 
Teshale, E. H. (2013). Immunity to hepatitis B virus (HBV) infection two decades after 
KIDZERU, 2016 
Chapter 5: References (Style: American Psychological Association 6th Edition)  246 
 
implementation of universal infant HBV vaccination: Association of detectable residual 
antibodies and response to a single HBV challenge dose. Clinical and Vaccine Immunology, 
20(4), 559–561. doi:10.1128/CVI.00694-12 
Sui, Y., Hogg, A., Wang, Y., Frey, B., Yu, H., Xia, Z., … Berzofsky, J. A. (2014). Vaccine-
induced myeloid cell population dampens protective immunity to SIV. The Journal of 
Clinical Investigation, 124(124(6)). doi:10.1172/JCI73518 
Tacke, R. S. ., Lee, H.-C., Goh, C., Courtney, J., Polyak, S. J. ., Rosen, H. R. ., & Hahn, Y. S. 
(2013). Myeloid Suppressor Cells Induced by Hepatitis C virus Suppress T-cell Repsonses 
Through the prduction of Raective Oxygen Species, 55(2), 343–353. 
doi:10.1002/hep.24700.Myeloid 
Tchakoute, C. T., Hesseling, A. C., Kidzeru, E. B., Gamieldien, H., Passmore, J.-A. S., Jones, C. 
E., … Jaspan, H. B. (2014). Delaying BCG Vaccination Until 8 Weeks of Age Results in 
Robust BCG-Specific T-Cell Responses in HIV-Exposed Infants. The Journal of Infectious 
Diseases, 1–9. doi:10.1093/infdis/jiu434 
Tomlinson, M. J., Tomlinson, S., Yang, X. B., & Kirkham, J. (2013). Cell separation: 
Terminology and practical considerations. Journal of Tissue Engineering, 4, 
2041731412472690. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3578272&tool=pmcentrez&ren
dertype=abstract 
Turk, G., Gherardi, M. M., Laufer, N., Saracco, M., Luzzi, R., Cox, J. H., … Salomon, H. 
(2008). Magnitude, breadth, and functional profile of T-cell responses during human 
immunodeficiency virus primary infection with B and BF viral variants. J Virol, 82(6), 
2853–2866. doi:JVI.02260-07 [pii] 10.1128/JVI.02260-07 
Volker Brinkmann, Thomas Geiger, Sefik Alkan,  and C. H. H. (1993). Interferon α Increases the 
Frequency of interferon γ-producing human CD4+ T cells, 178(November). 
WANG Pan, LV Jian-Ping, L. J.-Q. (2015). Measurement of myeloid-derived suppressor cells 
and T-helper 17 cells in peripheral blood of young children with recurrent wheezing, 17(4), 
312–316. doi:10.7499/j.issn.1008-8830.2015.04.004 
Weber, C. (2015). Metabolic regulation of hepatitis B immunopathology by myeloid-derived 
suppressor cells. Nature Reviews, Gastroenterology and Hepatology Gastroenterology and 
Hepatology, 12(May), 3856. doi:10.1038/nm.3856 
Zepp, F., Knuf, M., Habermehl, P., Schmitt, H. J., Rebsch, C., Schmidtke, P., … Slaoui, M. 
(1996). Pertussis-specific cell-mediated immunity in infants after vaccination with a 
tricomponent acellular pertussis vaccine. Infection and Immunity, 64(10), 4078–4084. 
KIDZERU, 2016 






In this thesis, our objectives were to evaluate the quantity and ontogeny of MDSC in Chapter 3, 
the effect of MDSC on T cell proliferation in Chapter 4, and in Chapter 5 MDSC’s effect on 
cytokine production in infants and mothers from birth to one year postpartum.  
In Chapter 3, we found a significant positive correlation between infants and maternal MDSC 
frequencies and absolute counts both at delivery and one year postpartum. This illustrates that 
the quantity of infants’ MDSC is directly associated to maternal MDSC immediately after 
gestation at delivery and through time postpartum as seen at one year. This implies that factors 
responsible for MDSC induction in infants and mothers is similar, and suggests that this may be 
an in utero event, such as the degree of materno-fetal mismatch. This is supported by evidnce in 
mice, whereby MDSC are crucial for maintaining fetomaternal tolerance(Pan et al., 2016).  
As expected, we found that the quantity of MDSC in cord and peripheral blood was not 
significantly different in infants at birth, even though the cord blood samples show a definite 
trend for reduced MDSC frequency. This finding demonstrates that the immune composition of 
cord and peripheral blood in infants at birth is similar. However, since to the best of our 
knowledge this is the first study to perform such analysis, we recommend further experiments 
and with a higher sample size to confirm the finding. In line with our hypothesis, MDSC 
frequency and counts were highest at birth, and declined over time.  From birth through 6, 10 and 
14 weeks, and to 6 and 9 months, there was a significant decrease in MDSC frequency in infants. 
We think that, the tolerance and anti-inflammatory environment during gestation necessary to 
provide for full-term viviparity, may persist postnatally and wane rapidly postpartum(Nair et al., 
2015)(Makrigiannakis et al., 2008)(Makrigiannakis et al., 2011)(Bansal, 2010).  
We also found that in mothers, MDSC frequency was significantly higher at delivery compared 
to one year postpartum. In line with our expectation, this finding further reiterates that these cells 
are present in both maternal and fetal circulation to maintain tolerance. Our findings illustrate 
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that pregnancy as a condition favours the accumulation of MDSC in mothers, and further persist 
in infants after birth, and may be immunosuppressive. In support of our finding, we have 
previously shown that granulocytic MDSC in infants were similar to those reported in peripheral 
blood of cancer patients and are immunosuppressive(Gervassi et al., 2014). These cells have 
been well described in other conditions including in cancer patients and very few can be detected 
in healthy adults but the frequency increase with ageing(Gabrilovich et al., 2012)(Gantt et al., 
2014)(Verschoor et al., 2013)(Brandau et al., 2011)(Khaled et al., 2014)(Gabitass et al., 2011).  
HIV-exposure had little effect on MDSC frequency, and as discussed in Chapter 3, this may be 
because HEU infants though are exposed to HIV infection in-utero but are not infected with or 
directly exposed to viral antigens such as gp120. There is substantial evidence that HIV infection 
is associated with high MDSC levels in infected individuals(Vollbrecht et al., 2012)(Garg et al., 
2013). Although studies have evaluated the effect of HIV infection on MDSC in 
adults(Vollbrecht et al., 2012)(Garg et al., 2013), to the best of our knowledge they have not 
investigated the effect in mothers postpartum. We found no significant difference in MDSC 
frequency between HIV+ versus HIV- mothers at delivery. However, in accordance with our 
hypothesis, at one year postpartum, HIV+ mothers presented with a significantly higher MDSC 
frequency compared to their uninfected counterparts. This is not surprising since high levels of 
MDSC are described in disease states(Tacke et al., 2013)(Qin et al., 2013)(Gama et al., 
2012)(Vollbrecht et al., 2012)(Garg et al., 2013)(du Plessis et al., 2013). 
This is to our knowledge, the first time that the effect of MDSC on antigen-specific responses 
has been evaluated. In Chapter 4, there were no significant differences in MDSC frequency and 
absolute count between infants whose CD4+ T cells responded and those who had poor CD4+ T 
cell proliferation to antigens. However, there was a trend towards high MDSC counts in 
responders compared to the non-responders to Hep B vaccine stimulation.   
Likewise, MDSC had little effect on T cell proliferation in response to vaccine antigens 
including Hep B, TT and PPD at most time points in whole PBMC versus after MDSC depletion 
in infants. However, in response to non-specific stimulation with anti-CD3CD28 (Dynabead) in 
infants CD4+ T cell proliferation in whole PBMC was significantly higher compared to after 
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MDSC depletion at birth and at 14 weeks of age. In contrast to this finding, our group and others 
have previously observed high MDSC frequency in cord blood that suppressed T cell responses 
to non-specific antigens(Rieber et al., 2013)(Gervassi et al., 2014). In mothers, though they had 
not been vaccinated with the vaccine antigens assessed for a long time, we found significantly 
higher CD4+ T cell proliferative responses to Hep B and TT vaccine stimulation after MDSC 
depletion compared to whole PBMC at delivery but not at one year postpartum. At one year 
postpartum, maternal Dynabead-induced CD4+ T cell proliferation was significantly higher after 
MDSC depletion versus in whole PBMC. This is opposite to the effects we saw in infants on 
Dynabead-induced T cell proliferation, and suggest that MDSC may be functionally distinct in 
neonates versus in mothers. As discussed in Chapter 4, several factors could be responsible for 
the lack of significant differences in CD4+ T cell proliferation to vaccines in whole PBMC and 
after MDSC depletion including the fact that MDSC depletion was not always 100% and there 
were not always enough cells to do the assays. In Chapter 3, we found that MDSC are elevated at 
birth and rapidly decrease from 6 weeks onwards, this may account for the lack of effect of 
MDSC on T cell proliferation to specific antigens in infants. Since we could not test responses to 
antigens other than Dynabeads in infants at birth (when they are antigen-naive), the effect of 
MDSC could not be assessed. On the other hand, in mothers, who are antigen experienced, we 
could assess responses at delivery when MDSC frequency was highest and the effects were 
likely more apparent.  
HIV-exposure in infants and maternal HIV infection had little effect on T cell proliferation to 
vaccine antigens at most time points neither in whole PBMC in the presence of MDSC nor after 
MDSC removal. The lack of significant differences was also observed after stimulation with 
Dynabead in both infants and mothers. The findings are not surprising in the HIV-exposed 
infants, since we saw no differences in MDSC number and frequency in these infants. In mothers 
with HIV-infection, the lack of effect of MDSC may be because MDSC are not functionally 
affected by HIV infection, but rather instead just increased in frequency. Another possible reason 
may be due to the limited number of samples for which responses were measured. However, 
there is evidence that MDSC suppress T cell proliferation in HIV-infected individuals(Qin et al., 
2013)(Gama et al., 2012)(Nagaraj et al., 2013)(Vollbrecht et al., 2012). 
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In Chapter 5, we evaluated the effect of MDSC on IFN-γ cytokine producing cells to vaccines. 
Generally, in infants MDSC frequency and absolute count between infants who were 
responders and non-responders to vaccine induced IFN-γ cytokine producing cells were 
significantly lower in responders than in non-responders at most time points, as hypothesized, 
implying that MDSC do indeed have suppressive effects on Th1 cytokine production at least to 
protein antigens. This finding was confirmed by our experiments evaluating the impact of 
MDSC on IFN-γ cytokine producing cells by MDSC depletion to most vaccine antigens. IFN-γ 
cytokine producing cells to Hepatitis B at the later grouped time points (6, 9 and 12 months) 
were significantly higher after MDSC depletion. This observation is in support of our finding 
of significantly lower MDSC frequency in infants who responded to Hep B in IFN-γ cytokine 
production. Hep B vaccination have been shown to induce antibody responses(Siegrist, 
2008)(Spradling et al., 2013) and there is evidence that Hep B induced immunologic T cell in 
infants are able to trigger specific antibody responses to Hep B later during the vaccination 
schedule(Bauer et al., 2006). Although frequency of MDSC was lower in non-responders to 
TT at later time points, absolute counts of MDSC in infants who responded to TT a similar 
antigen to Hep B in that it is a protein, albeit with a different adjuvant was significantly higher 
in non-responders. 
On the other hand, detectable IFN-γ production to BCG was significantly lower after depleting 
MDSC at one year of age, also evident in the grouped time point analyses and a trend towards 
lower IFN-γ cytokine producing cells to BCG at 9 months of age. Detectable IFN-γ cytokine 
producing cells to BCG lasted until approximately 9 months and were more robust than those 
to Hep B, TT and BP. It is possible that the difference in the responses observed could be due 
to the function of the assay. It has been shown that MDSC themselves can make IFN-
γ(Matsumura et al., 2012)(Guo et al., 2012)(Cripps et al., 2010) and this may depend on the 
type of antigen stimulation present, and may be the reason for the lower IFN-γ producing cells 
post BCG stimulation. On the other hand, the effect of MDSC on BCG may indeed be different 
to that of Hep B and TT, as BCG is a live-attenuated vaccine that is known to be particularly 
successfully immunogenic in infants(Ota et al., 2002).  
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Similarly, at one year of age IFN-γ cytokine producing cells were significantly lower after 
MDSC depletion after PHA stimulation, also evident in the grouped time point’s analyses. The 
possible reason for this is that MDSC could have a different function in pregnancy than post 
pregnancy where the maternal immune state may be normalized post gestation at a later time 
point at one year. This effect may be highly felt in non-specific and stronger stimulation. Most 
studies have investigated the impact of MDSC on non-specific antigens on Dynabead. 
Contrary to this finding, our group and others have previously observed suppressed IFN-γ 
responses to Dynabead by MDSC(Rieber et al., 2013)(Gervassi et al., 2014). The possible 
reason for this may be that, the mechanism by which PHA and Dynabead stimulate IFN-γ 
responses may be different, and warrant further investigation. 
IFN-γ cytokine producing cells to TT in whole PBMC were significantly lower in HEU infants at 
10 weeks after vaccination in whole PBMC. This is in conformity with our finding in a previous 
study and that of others that HIV-exposure may have a negative effect on cytokine 
responses(Kidzeru et al., 2014)(Hesseling et al., 2015)(van Rie et al., 2006)(Jones et al., 2015). 
However, no significant differences were observed between HEU and HU infants in other 
antigen stimulations. Our data illustrates that in whole PBMC in the presence of MDSC in 
infants, IFN-γ cytokine production varies between vaccine antigens and is also dependent on the 
infant age. Also, there was limited number of HEU infants for which IFN-γ cytokine producing 
cells could be measured. HIV infection also had little effect on IFN-γ cytokine producing cells in 
whole PBMC in the presence of MDSC in response to all the vaccines assessed. After depleting 
MDSC IFN-γ cytokine producing cells to PHA were significantly higher in HIV+ mothers at 
delivery, but not at one year postpartum. These findings suggest that MDSC may be functionally 
different during HIV infection in terms of their effects on IFN-γ.   
In this study, we evaluated the effects of MDSC on IFN-γ responses. It would be important to 
measure other cytokines. The effect of MDSC has also been studied in some clinical conditions 
in infants evaluating other cytokines. In Chinese children, Pan et al. showed that high MDSC 
frequency that presented with recurrent wheezing contributed to high IL-17 cytokine producing 
cells(Pan et al., 2015). We have stored collected plasmas and supernatants from which other 
cytokines would be measured by ELISA and Luminex analysis in future. Also, other suspected 
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immunosuppressive mechanisms other than Arginase-1 (ARG) production could be explored in 
future including the evaluation of the quantity of reactive oxygen species (ROS) as well as nitric 
oxide synthase (NOS). The quantity of ROS and NOS could be evaluated with their respective 
antibodies for ELISA in plasmas from the infants(Wu et al., 2011)(Held, 2012)(Sun et al., 2003). 
We would also recommend future studies to consider measuring the expression of these factors 
in the cells using flow cytometry(Jia et al., 2010) (Jayaraman et al., 2012).     
In summary, the results from this dissertation show that MDSC may have an influence on early 
childhood vaccines, and that may be vaccine and antigen dependent. These cells may therefore 
play a partial role in the increased immune vulnerability in infants in early life. Consideration of 
these effects of these and other immunoregulatory cells should be taken into consideration when 
designing vaccines for neonates.  
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APPENDICES 
Appendix 3.1: Correlation between the frequencies and counts of 
MDSC versus neutrophil, maternal MDSC, infant weight and 
gestation age  
We obtained full blood counts (FBC) from infants at birth and at 6 months of age. The 
maternal MDSC at birth and one year postnatal was obtained during follow-up, and the 
infant’s weights and gestational ages were obtained as part of the cohort characteristics. 
Spearman correlations were performed between MDSC versus neutrophil frequencies and 
counts at birth and later at 6 months of life [Figures A1(i-ii)] and [Figure B1(i-ii)].  
Spearman correlations were performed between infants MDSC and infant’s weights at the 
follow-up time points i.e. at birth, 6, 10 and 14 weeks, at 6 and 9 months and one year of 
age[Figures A2(i-vii)] and [Figure B2(i-vii)]. 
Furthermore, we performed Spearman correlations between infants MDSC at all time points 
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(i) Correlation between the frequencies of MDSC versus the frequencies of 
neutrophils in infants 
At birth, there was a significant positive correlation between the frequencies of MDSC versus 
neutrophils at birth [Figure A1(i)]. While at 6 months of age, there was a negative correlation 
but was not significant [Figure A1(ii)]. 
 
 
Figure A1: Correlation between the frequencies of MDSC versus the frequencies of neutrophils in 
infants. (i) MDSC and neutrophil frequencies correlated at birth, and (ii) MDSC and neutrophil frequencies 
correlated at 6 months of age in infants. The line indicate the correlation curve and r indicate the correlation 
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(ii) Correlation between the counts of MDSC versus the counts of 
neutrophils in infants 
At birth, there was a positive correlation between the counts of MDSC versus neutrophils at 
birth [Figure B1(i)], while at 6 months of age, there was a negative correlation [Figure B1(ii)]. 




Figure B1: Correlation between the counts of MDSC versus the counts of neutrophils in infants. (i) 
MDSC and neutrophil counts correlated at birth, and (ii) MDSC and neutrophil counts correlated at 6 months 
of age in infants The line indicate the correlation curve and r indicate the correlation coefficient, p<0.05 
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(v) Correlation between the infants MDSC frequencies versus infants 
weights 
At birth, there was no significant correlation between the infants MDSC frequencies versus 
birth weights [Figure A2(i)]. This lack of significant correlation between MDSC frequency 
and infants weights was also observed at other time points [Figure A2(ii-vii)]. 
       
 
Figure A2: Correlation between infants MDSC frequency versus infants weights. (i) Infants MDSC 
frequencies and weights correlated at birth, (ii-iv) at 6, 10 and 14 weeks, (v-vi) at 6 and 9 months, and (vii) at 
one year of age. The line indicate the correlation curve and r indicate the correlation coefficient, p<0.05 




(iii) (iv) (v) 
(vi) (vii) 
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(vi) Correlation between the infants MDSC counts versus infants weights 
At birth, there was no significant correlation between the infants MDSC counts versus birth 
weights [Figure B2(i)]. This lack of significant correlation between MDSC counts and infants 
weights was also observed at other time points [Figure B2(ii-vii)]. 
            
   
  
Figure B2: Correlation between infants MDSC counts versus infants weights. (i) Infants MDSC counts and 
weights correlated at birth, (ii-iv) at 6, 10 and 14 weeks, (v-vi) at 6 and 9 months, and (vii) at one year of age. 
The line indicate the correlation curve and r indicate the correlation coefficient, p<0.05 significant level and 
statistical significance was tested using the spearman correlation test.   
 
(i) (ii) 
(iii) (iv) (v) 
(vi) (vii) 
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(vii) Correlation between the infants MDSC frequencies versus gestational 
age 
At birth, there was no significant correlation between the infants MDSC frequencies versus 
gestational ages [Figure A3(i)]. This lack of significant correlation between MDSC frequency 
and infants gestational ages was also observed at other time points [Figure A3(ii-vii)]. 
        
 
 
Figure A3: Correlation between infants MDSC frequency versus infants gestational ages. (i) Infants 
MDSC frequencies and gestational ages correlated at birth, (ii-iv) at 6, 10 and 14 weeks, (v-vi) at 6 and 9 
months, and (vii) at one year of age. The line indicate the correlation curve and r indicate the correlation 
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(viii) Correlation between the infants MDSC counts versus gestational ages 
At birth, there was no significant correlation between the infants MDSC counts versus 
gestational ages [Figure B3(i)]. This lack of significant correlation between MDSC counts and 
infants gestational age was also observed at other time points [Figure B3(ii-vii)]. 
                     
 
 
Figure B3: Correlation between infants MDSC counts versus gestational ages. (i) Infants MDSC counts 
and gestational age correlated at birth, (ii-iv) at 6, 10 and 14 weeks, (v-vi) at 6 and 9 months, and (vii) at one 
year of age. The line indicate the correlation curve and r indicate the correlation coefficient, p<0.05 significant 
level and statistical significance was tested using the spearman correlation test.   
 
(i) (ii) 
(iii) (iv) (v) 
(vi) (vii) 
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Appendix 4.1: CFSE proliferation assay validity 
(i) Dynabead (Dyna) (anti-CD3CD28) causes CD4 T-cell proliferation in 




































































Figure C: CD4+ T cell proliferative responses to Dynabead vs. Cell alone in infants with MDSC. CD4+ T 
cells proliferative responses to Dynabead versus CA were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 
months and at one year postnatal in infants with MDSC (CD15 Non-depleted). All p-values were <0.05, 
p<0.05 significant level and statistical significance was obtained using Mann-Whitney U test.   
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(ii) Dynabead (Dyna) (anti-CD3CD28) causes CD4 T-cell proliferation in 


























































Figure D: CD4+ T cell proliferative responses to Dynabead vs. Cell alone in infants without MDSC. 
CD4+ T cells proliferative responses to Dynabead versus CA were measured at birth, at 6, 10 and 14 weeks, 
at 6 and 9 months and at one year postnatal in infants without MDSC (CD15 depleted). All p-values were 
<0.05, p<0.05 significant level and statistical significance was obtained using Mann-Whitney U test.   
KIDZERU, 2016 
Appendices     266 
 
(iii) Dynabead (Dyna) (anti-CD3CD28) causes CD4 T-cell proliferation in 
mothers vs. Cells alone (CA) with MDSC 
 
 





































Figure E: CD4+ T cell proliferative responses to Dynabead vs. Cell alone in mothers with MDSC. CD4+ 
T cells proliferative responses to Dynabead versus CA were measured at delivery and at one year postnatal in 
mothers with MDSC (CD15 Non-depleted). All p-values were <0.001, p<0.05 significant level and statistical 
significance was obtained using Mann-Whitney U test.   
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(iv) Dynabead (Dyna) (anti-CD3CD28) causes CD4 T-cell proliferation in 
mothers vs. Cells alone (CA) without MDSC 
 
 



































Figure F: CD4+ T cell proliferative responses to Dynabead vs. Cell alone in mothers without MDSC. 
CD4+ T cells proliferative responses to Dynabead versus CA were measured at delivery and at one year 
postnatal in mothers with MDSC (CD15 depleted). All p-values were <0.001, p<0.05 significant level and 
statistical significance was obtained using Mann-Whitney U test.   
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Appendix 4.2: T cell proliferative responses to vaccines in infants 
and mothers through time 
Generally, vaccine responses varied in the different antigens through time. Some responses to 
vaccines were stronger and some low. Also, responses varied between infants and their 
mothers. Below is the general dynamic in vaccine responses (median frequency of 
proliferating cells) to the different antigens in infants and mothers through time regardless of 
MDSC. 
(i) T cell proliferative responses to vaccines in infants and mothers through 
time after Hep B stimulation 
Generally, Hep B responses peaked at 10 weeks after priming at 6 weeks in infants and then 
dropped at 14 weeks post second vaccine dose. The responses then further rose after the last 
and third vaccine dose at 14 weeks then varied till one year of age [Figure G(i)]. While in the 


















Figure G: CD4+ T cell proliferative responses to Hep B in infants and mothers. (i) CD4+ T cells 
proliferative responses to Hep B were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one 
year of age in infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile 
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(ii) T cell proliferative responses to vaccines in infants and mothers through 
time after TT stimulation 
Generally, TT responses were low throughout, from priming at 6 weeks of age, through 10 
weeks in infants and also, at 14 weeks post second vaccine dose. The responses then further 
remained low at 9 months and one year of age [Figure H(i)]. Likewise in the mothers, Figure 
H(ii), TT responses were low from delivery to one year postpartum. 
 
 
Figure H: CD4+ T cell proliferative responses to TT in infants and mothers. (i) CD4+ T cells proliferative 
responses to TT were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in 
infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 
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(iii) T cell proliferative responses to vaccines in infants and mothers 
through time after PPD stimulation 
Generally, PPD responses peaked between 6, 10 and 14 weeks after BCG vaccination at birth 
in infants and then dropped by 6 months of age. The responses then rose again at 6 months 
through 9 months to one year of age [Figure I(i)]. While in the mothers, Figure I(ii), PPD 
responses increased from delivery to one year postpartum. 
 
 
Figure I: CD4+ T cell proliferative responses to PPD in infants and mothers. (i) CD4+ T cells 
proliferative responses to PPD were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one 
year of age in infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile 
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(iv) T cell proliferative responses to Dynabead (α-CD3CD28) in infants and 
mothers through time 
Generally, Dynabead responses as expected were strong from birth through 6, 10 and 14 
weeks in infants till 6 and 9 months of age. The responses increased with age and were 
significantly higher by one year of age [Figure J(i)]. While in the mothers, Figure J(ii), 
Dynabead responses increased from delivery to one year postpartum. 
 
 
Figure J: CD4+ T cell proliferative responses to Dynabead in infants and mothers. (i) CD4+ T cells 
proliferative responses to Dynabead were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at 
one year of age in infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate 
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Appendix 4.3: CD15-depletion purity 
Since, MDSC highly express CD15, selectively depletion of MDSC was done using EasySep® 
magnetic cell separation technique (Section 4.2.1) and the cells were stained for flow cytometry in 
a 96 well round bottom plate. After sample acquisition by flow cytometry, the flow files were 
analyzed using FlowJo v9.4.7 (Tree Star). Comparison of CD4+ T cell proliferation and IFN-γ 
cytokine producing cells to vaccines and antigens in whole PBMC and after MDSC depletion was 
only done when the CD15-depletion purity was 90% and above for samples to be included in the 
data for further analysis.  
(i) Validation of MDSC depletion in infants 
 
 
Figure K: MDSC stain infant CBMC/PBMC before and after CD15 depletion from birth to one year of 
age. Frequency of MDSC measured at birth in cord blood (CB) and peripheral blood (PB) combined, and at 
weeks 6, 10 and 14, and at months 6 and 9, and at one year determined by flow cytometry. MDSC was 
measured as frequency of CD11b+CD15+ expressing cells. CD15 Non-depleted (oval) paired with CD15 
Depleted (triangles),   all p-values were <0.05, p<0.05 significant level and statistical significance was 
obtained using Mann-Whitney U test.   
   
 
KIDZERU, 2016 
Appendices     274 
 





Figure L: MDSC stain matenal PBMC before and after CD15 depletion at delivery and one year of age. 
Frequency of MDSC measured at delivery in peripheral blood (PB) and at one year determined by flow 
cytometry. MDSC was measured as frequency of CD11b+CD15+ expressing cells. CD15 Non-depleted (oval) 
paired with CD15 Depleted (triangles),   all p-values were <0.001, p<0.05 significant level and statistical 
significance was obtained using Mann-Whitney U test.   
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Appendix 4.4: CD4+ T cell proliferation to vaccines and antigens in 
unmatched whole PBMC (presence of MDSC) versus without 
MDSC (after MDSC depletion) in all infants and mothers enrolled 
from who whole blood samples were collected 
The T cell proliferative responses to HepB and TT vaccinations and to PPD and Dynabead 
antigens in CBMC and/or PBMC were evaluated in infants and mothers in the presence and 
absence of MDSC, to evaluate the effects of MDSC more directly (Figure 4.1). Since MDSC 
highly express CD15, as described in section 4.2.1, the EasySep® magnetic cell separation 
technique was performed to deplete CD15+ expressing cells from a portion of the CBMC 
and/or PBMC. The effect of MDSC on T cell proliferative responses to vaccines and antigens 
was then measured by performing the CFSE incorporation technique on cells depleted of 
CD15+ cells (absence of MDSC) and in whole PBMC (presence of MDSC) (Figure 4.2). 
Among the MDSC depleted sample group, only samples with depletion purity of 90% or more 
were included in the analysis (Appendix 4.3).  
As described in section 4.3 (2), T cell proliferative responses were measured in infants at all 
individual time points post vaccination  (i.e. at 6, 10 and 14 weeks, at 6 and 9 months, and at 
one year of age), and in mothers, the T cell proliferation was performed at delivery and again 
at one year postpartum. We also evaluated the ontogeny of the effect of MDSC on CD4+ T cell 
proliferation to vaccines and antigens in a grouped analyses, based on the time points the 
different vaccines assessed were administered and followed-up for sample collection during 
infancy as described in section 4.3 (2) (b).   
One of the limitations of the study was the challenge of whole blood collection from infants, 
and at most time points the quantity of whole blood collected from most infants was not 
always enough for CD15+ depletion. MDSC depletion was only performed when there was 
enough PBMC to perform the assays (section 4.3.2). Due to this, there were only a limited 
number of infants and their mothers at most time points for which depletion was performed 
and further permitting MDSC non-depleted versus MDSC depleted match paired analyses to 
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be performed(section 4.3.2). In this Appendix, unmatched analyses between MDSC non-
depleted versus MDSC depleted samples in all participants enrolled and from who whole 
blood samples were collected are presented. 
(i) Hep B induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion 
in infants 
As shown in Figure M1(i), there were no significant differences in either, (a) at the individual 
time points between groups in whole PBMC and without MDSC in infants at 10 and 14 weeks 
(p=0.9789 and p=0.7255 respectively); at 6 and 9 months (p=0.066 and p=0.279 respectively) 
and at 1 year of age (p=0.512), or (b) in the grouped analysis in whole PBMC and without 
MDSC at 10 and 14 weeks (median of CD15 non-depleted=0.330% versus CD15 
depleted=0.180%; p=0.718) and at 6, 9 months and 1 year (median of CD15 non-
depleted=0.170% versus CD15 depleted=0.587%; p=0.481). 
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Figure M1 (i): CD4+ T cell proliferative responses to Hep B in infants in whole PBMC versus without 
MDSC. (a) In the individual time point analysis, CD4+ T cells proliferative responses to Hep B were 
measured in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 10 
and 14 weeks, at 6 and 9 months and at one year of age in infants, and (b) in the grouped analysis, at 10 and 
14 weeks (after first and second doses of Hep B vaccination), at 6 and 9 months and one year of age (after 
last dose of Hep B vaccination). Each dot on the plot represent an infant. Bars indicate medians and whiskers 
indicate interquartile range; p<0.05 significant level and statistical significance was tested using Mann-
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(ii) Hep B induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion 
in mothers 
In mothers, the CD4+ T cell proliferative responses to Hep B were evaluated in whole PBMC 
and without MDSC at delivery and again at one year postpartum. As shown in Figure M1(ii), 
there was no significant difference at delivery (median of CD15 non-depleted=0.160% versus 
CD15 depleted=0.340%, p=0.643) and at one year postpartum (median of CD15 non-
depleted=0.410% versus CD15 depleted=0.051%; p=0.652). 
 
 
Figure M1(ii): CD4+ T cell proliferative responses to Hep B in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to Hep B were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 Non-depleted – green) versus without MDSC (CD15 Depleted 
– red). Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
range; p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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(iii) TT induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion 
in infants 
The CD4+ T cell proliferative responses to TT vaccination were evaluated in whole PBMC and 
without MDSC in infants at all time points post TT vaccination (Figure M1(iii). We compared 
(a) the individual time points between groups in whole PBMC and without MDSC in infants. 
There was no significant difference at 10 and 14 weeks (p=0.265 and p=0.199 respectively), at 
6 and 9 months (p=0.584 and p=0.198 respectively) and at one year (p=0.295); or (b) in the 
grouped analysis in T cell proliferation in whole PBMC and without MDSC there was no 
significant difference at 10 and 14 weeks (p=0.109) and at 6, 9 months and one year (p=0.973). 
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Figure M1(iii): CD4+ T cell proliferative responses to TT in infants in whole PBMC versus without 
MDSC. (a) In the individual time point analysis, CD4+ T cells proliferative responses to TT were measured in 
whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 10 and 14 weeks, 
at 6 and 9 months and at one year of age in infants, and (b) in the grouped analysis, at 10 and 14 weeks (after 
first and second doses of TT vaccination), at 6 and 9 months and one year of age (after last dose of TT 
vaccination). Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 
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(iv) TT induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion in 
mothers 
In mothers, the CD4+ T cell proliferative responses to TT were evaluated in whole PBMC and 
without MDSC at delivery and again at one year postpartum. As shown in Figure M1(iv), there 
was no significant difference at delivery (median of CD15 non-depleted=0%, IQR=0-0 versus 
CD15 depleted=0%, IQR=0-0.670 and p=0.167) and at one year postpartum (median of CD15 
non-depleted=0%, IQR=0-0 versus CD15 depleted=0%, IQR=0-0.626 and p=0.112). 
 
Figure M1(iv): CD4+ T cell proliferative responses to TT in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to TT  were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted 
– red). Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
range; p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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(v) PPD induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion 
in infants 
The CD4+ T cell proliferative responses to Mycobacterium bovis BCG vaccination were 
evaluated in whole PBMC and without MDSC in infants at birth, at 6, 10 and 14 weeks, at 6 
and 9 months, and at one year of age, by measuring responses to PPD.  
 
 
Figure N(i): CD4+ T cell proliferative responses to PPD in infants in whole PBMC versus without 
MDSC. (a) In the individual time point analysis, CD4+ T cells proliferative responses to PPD were measured 
in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red)  at 6, 10 and 14 
weeks, at 6 and 9 months and at one year of age in infants, and (b) in the grouped analysis, at 6, 10 and 14 
weeks (first few weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). 
Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; 
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There were no significant differences in either, (a) at the individual time points at 6, 10 and 14 
weeks (p=0.1247, p=0.2513 and p=0.5916 respectively), at 6 and 9 months (p=0.935 and 
p=0.455 respectively) and at one year  (p=0.704), or (b) in the grouped analysis with and without 
MDSC at 6, 10 and 14 weeks (median of CD15 non-depleted=0.684% versus CD15 
depleted=0.15%; p=0.188) and at 6, 9 months and one year (median of CD15 non-
depleted=0.830% versus CD15 depleted=0.480%; p=0.531) (Figure N(i)). 
(vi) PPD induced CD4+ T cell proliferation in whole PBMC versus after MDSC depletion in 
mothers 
In mothers, CD4+ T cell proliferative responses to PPD were evaluated in whole PBMC and 
without MDSC at delivery and again at one year postpartum. As shown in Figure N(ii), there was 
no significant difference at delivery (median of CD15 non-depleted=0.100% versus CD15 
depleted=0.00% and p=0.241) and at one year postpartum (median of CD15 non-
depleted=0.370% versus CD15 depleted=0.200% and p=0.877). 
 
Figure N(ii): CD4+ T cell proliferative responses to PPD in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to PPD  were measured at delivery and again at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted 
– red). Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
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(vii) Dynabead induced CD4+ T cell proliferation in in whole PBMC versus after MDSC 
depletion in infants 
Anti-CD3CD28 (Dynabead) was employed as a positive control in this study, as it has been 
shown to be strong T cell activator acting directly on T cell receptors and does not require 
feeder cells (antigen presenting cells) or antigens(Li et al., 2010)(Oviedo-Orta et al., 2010). To 
investigate the influence of MDSC on T cell proliferation to strong, non-specific stimulation, 
we evaluated CD4+ T cell proliferative responses to α-CD3CD28 (Dynabead) stimulation in 
whole PBMC and without MDSC in infants at birth, at 6, 10 and 14 weeks, at 6 and 9 months, 
and at one year of age (Figure O). Proliferation at all time points was robust. There was no 
significant difference at birth (median of CD15 Non-depleted=80.73% versus CD15 
Depleted=67.40% and p=0.073); at 6, 10 and 14 weeks (p=0.177, p=0.299 and p=0.111 
respectively); at 6 and 9 months (p=0.738 and p=0.159 respectively) and at one year 
(p=0.763). In general, proliferation decreased post depletion.  
 
Figure O: CD4+ T cell proliferative responses to Dynabead in infants in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to Dynabead were measured at birth, at 6, 10 and 14 weeks, at 6 
and 9 months and at one year of age in infants in whole PBMC (CD15 non-depleted – green) versus without 
MDSC (CD15 depleted – red). Each dot on the plot represent an infant. Bars indicate medians and whiskers 
indicate interquartile range; p<0.05 significant level and statistical significance was tested using Mann-
Whitney U test.   
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4.3.2.20 Dynabead induced CD4+ T cell proliferation in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, the CD4+ T cell proliferative responses to Dynabead were evaluated in whole PBMC 
and without MDSC at delivery and at one year postpartum. As shown in Figure P, there was no 
significant difference at delivery (median of CD15 non-depleted=72.91% versus CD15 
depleted=58.88%; p=0.224) and at one year postpartum (median of CD15 non-depleted=83.45% 
versus CD15 depleted=77.23%; p=0.838). 
 
 
Figure P: CD4+ T cell proliferative responses to Dynabead in mothers in whole PBMC versus without 
MDSC. CD4+ T cells proliferative responses to Dynabead  were measured at delivery and at one year 
postpartum in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted 
– red). Each dot on the plot represent a mother. Bars indicate medians and whiskers indicate interquartile 
range; p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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Appendix 5.1: IFN-γ ELISpot assay validity 
(i) Phytohaemagglutinin (PHA) causes IFN-γ production in infants vs. Cells 

















































































































Figure Q: IFN-γ cytokine producing cells to PHA vs. Cell alone in infants with MDSC. IFN-γ 
cytokine producing cells to PHA versus CA were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months 
and at one year postnatal in infants with MDSC (CD15 Non-depleted). All p-values were <0.05, p<0.05 
significant level and statistical significance was obtained using Mann-Whitney U test.   
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Figure R: IFN-γ cytokine producing cells to PHA vs. Cell alone in infants without MDSC. IFN-γ 
cytokine producing cells to PHA versus CA were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months 
and at one year postnatal in infants without MDSC (CD15 depleted). All p-values were <0.05, p<0.05 
significant level and statistical significance was obtained using Mann-Whitney U test.   
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Figure S: IFN-γ cytokine producing cells to PHA vs. Cell alone in mothers with MDSC. IFN-γ 
cytokine producing cells to PHA versus CA were measured at delivery and at one year postnatal in mothers 
with MDSC (CD15 Non-depleted). All p-values were <0.001, p<0.05 significant level and statistical 
significance was obtained using Mann-Whitney U test.   
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Figure T: IFN-γ cytokine producing cells to PHA vs. Cell alone in mothers without MDSC. IFN-γ 
cytokine producing cells to PHA versus CA were measured at delivery and at one year postnatal in mothers 
with MDSC (CD15 depleted). All p-values were <0.001, p<0.05 significant level and statistical significance 
was obtained using Mann-Whitney U test.   
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Appendix 5.2: IFN-γ cytokine producing cells to vaccines in 
infants and mothers through time 
Generally, vaccine responses varied in the different antigens through time. Some responses to 
vaccines were stronger and some low. Also, responses varied between infants and their 
mothers. Below is the general dynamic in vaccine responses (median counts of IFN-γ cytokine 
producing cells) to the different antigens in infants and mothers through time regardless of 
MDSC. 
The number of infants excluded due to invalid ELISpot assay (IFN-γ 
SFU/million cells [PHA] > IFN-γ SFU/million cells (Median + 
3MAD)[Media]) 
In total 70 mother-infant pairs were recruited at delivery, 39 followed up at 6 weeks, 32 at 10 
weeks, 30 at 14 weeks, 20 at 6 months, 15 at 9 months and lastly 14 infant-mother pairs 
completed the study at one year postpartum (section 2.2). Experiments were valid when the 
number of IFN-γ Spot Forming Units (SFU)/million cells in response to PHA was greater than 
the median plus 3 times the MAD of the negative control (i.e. Media) IFN-γ SFU/million cells, 
or the sample was excluded; i.e. IFN-γ SFU/million cells [PHA] > IFN-γ SFU/million cells 
(Median + 3MAD)[Media] where MAD is the Median Absolute Deviation Section 5.2.2. Table A 
shows the proportion of samples excluded from the analyses.   
Table A: The number of infants excluded from ELISpot analyses. Time point include the different time points 
post vaccination i.e. WK6 post Mycobacterium bovis bacillus Calmette-Guérin (BCG), WK10 post Bordetella 
pertussis (BP) and tetanus toxoid (TT) and the further respective time points WK14, Mth6, Mth9 and one year.   














 6 6 6 1 7 1 6 6 8 4 1 1 
13 7 7 6 8 8 7 7 10 9 12 12 
26 8 8 7 18 18 8 8  10   
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 13 19 9 22  11 18     
 20 20 12 27  14 20     
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(i) IFN-γ cytokine producing cells to vaccines in infants and mothers 
through time after Hep B stimulation 
Generally, Hep B responses were low at 10 and 14 weeks after priming at 6 weeks in infants 
and remained low till 6 months of age. The responses then peaked at 9 months to one year of 
age [Figure U(i)]. While in the mothers, Figure U(ii), Hep B responses increased from 
delivery to one year postpartum. 
 
 26 23 18   18 22     
 29  19   22      
 35  20         
   22         
   23         
Total # 
Excluded 
4 9 7 11 6 4 8 7 2 4 2 2 
Total # 
recruited 
39 39 32 32 30 30 20 20 15 15 14 14 
Proportion 
excluded (%) 
10.3 23.1 21.9 34.4 20.0 13.3 40.0 35.0 13.3 26.7 14.3 14.3 
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Figure U: IFN-γ cytokine producing cells to Hep B in infants and mothers. (i) IFN-γ cytokine producing 
cells to Hep B were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in 
infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 






Appendices     293 
 
(ii) IFN-γ cytokine producing cells to vaccines in infants and mothers 
through time after TT stimulation 
Generally, TT responses were low at birth before priming at 6 weeks of age, then peaked at 10 
weeks before the second vaccine dose in infants and dropped at 14 weeks before the third 
vaccine dose. The responses then further remained low post the third vaccine dose at 14 
weeks of age till 6, 9 months and one year of age [Figure V(i)]. In the mothers, Figure V(ii), 
TT responses dropped from delivery to one year postpartum. 
 
 
Figure V: IFN-γ cytokine producing cells to TT in infants and mothers. (i) IFN-γ cytokine producing 
cells to TT were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants, 
and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 
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(iii) IFN-γ cytokine producing cells to vaccines in infants and mothers 
through time after BP stimulation 
Generally, BP responses were low before priming at 6 weeks of age, remained low till 10 
weeks of age before the second vaccine dose. BP responses then peaked at 14 weeks and 
varied till one year of age [Figure W(i)]. In the mothers, Figure W(ii), BP responses remained 
low from delivery to one year postpartum. 
 
 
Figure W: IFN-γ cytokine producing cells to BP in infants and mothers. (i) IFN-γ cytokine producing 
cells to BP were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in infants, 
and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 
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(iv) IFN-γ cytokine producing cells to vaccines in infants and mothers 
through time after BCG stimulation 
Generally, BCG responses peaked from birth to 6, 10 and 14 weeks after BCG vaccination at 
birth in infants and then dropped at 6 months of age. The responses then remained low from 6 
months through 9 months to one year of age [Figure X(i)]. While in the mothers, Figure X(ii), 
BCG responses dropped from delivery to one year postpartum. 
 
 
Figure X: IFN-γ cytokine producing cells to BCG in infants and mothers. (i) IFN-γ cytokine producing 
cells to BCG were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in 
infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 
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(v) IFN-γ cytokine producing cells to Phytohaemagglutinin (PHA) in infants 
and mothers through time 
Generally, PHA responses as expected were strong from birth through 6, 10 and 14 weeks in 
infants till 6 and 9 months of age. The responses increased with age. [Figure Y(i)]. While in 




Figure Y: IFN-γ cytokine producing cells to PHA in infants and mothers. (i) IFN-γ cytokine producing 
cells to PHA were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and at one year of age in 
infants, and (ii) at delivery and one year postpartum in mothers. Whiskers indicate interquartile range; p<0.05 
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Appendix 5.3: Effect of MDSC depletion on IFN-γ production to 
vaccines and antigens in all infants and mothers enrolled from who 
whole blood samples were collected 
The effect of MDSC on IFN-γ cytokine producing cells to BCG, TT, BP, and Hep B 
vaccinations, and to PHA, in whole CBMC and/or PBMC were evaluated in infants and 
mothers in the presence of MDSC and after MDSC depletion (Figure 4.1). Since MDSC highly 
express CD15, as earlier described in section 4.2.1, CD15+ expressing cells were magnetically 
depleted from a proportion of whole CBMC and/or PBMC. The effect of MDSC on cells 
producing IFN-γ to vaccines and antigens was then measured by performing the IFN-γ 
ELISpot assay on CD15 depleted cells (absence of MDSC) and whole CBMC and/or PBMC 
(presence of MDSC) (Figure 4.2). In the MDSC depleted sample group, only samples with 
depletion purity of 90% or more were included in the analyses (Appendix 4.3).  
As described in section 5.3 (2), IFN-γ cytokine producing cells were measured in infants at all 
individual time points post vaccination (i.e. at 6, 10 and 14 weeks, at 6 and 9 months, and at 
one year of age), and in mothers, the cells producing IFN-γ to vaccines and antigens were 
measured at delivery and again at one year postpartum. We also evaluated the ontogeny of the 
effect of MDSC on IFN-γ cytokine producing cells to vaccines and antigens in a grouped time 
points analyses, based on the time points the different vaccines assessed were administered and 
followed-up for sample collection during infancy as described in section 5.3 (2) (b).   
Generally, vaccine responses to the different antigens varied through time. Also, responses 
varied between infants and their mothers. Regardless of MDSC, in Appendix 5.2, is the general 
dynamic in vaccine responses (median counts of IFN-γ cytokine producing cells) to the 
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(i) BCG induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to BCG vaccination were evaluated in whole PBMC and without 
MDSC in infants at 6, 10 and 14 weeks, at 6 and 9 months, and at one year of age. As shown in 
Figure Z there were no significant differences at most time points. However, IFN-γ cytokine 
producing cells to BCG lasted till 9 months. (a) At the individual time points there were no 
 
 
Figure Z: IFN-γ cytokine producing cells to BCG in infants in whole PBMC versus without MDSC. (a) 
In the individual time point analysis,  IFN-γ cytokine producing cells to BCG were measured in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 6, 10 and 14 weeks, at 6 and 9 
months and at one year of age in infants, and (b) in the grouped analysis at 6, 10 and 14 weeks (first few 
weeks after priming), at 6 and 9 months and one year of age (the last follow-up time points). Each dot on the 
plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; p<0.05 significant 
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significant differences at 6, 10 and 14 weeks (p=0.063, p=0.081 and p=0.858 respectively), at 
6 and 9 months (p=0.589 and p=0.127 respectively) and at one year (p=0.083). However, (b) in 
the grouped analysis IFN-γ cytokine producing cells to BCG were significantly higher in 
whole PBMC compared to after MDSC depletion at 6, 10 and 14 weeks (median of CD15 non-
depleted=103.330 Net SFU/106 PBMC versus CD15 depleted=39.670 Net SFU/106 PBMC; 
p=0.016) and at 6, 9 months and 1 year (median of CD15 non-depleted=43.670 Net SFU/106 
PBMC versus CD15 depleted=15.330 Net SFU/106 PBMC; p=0.019) (Figure Z). 
(ii) BCG induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, BCG induced IFN-γ producing cells were evaluated in whole PBMC and without 
MDSC at delivery and at one year postpartum. As shown in Figure AA, the frequency of cells 
producing IFN-γ to BCG were not significantly different in mothers after gestation at delivery 
(median of CD15 non-depleted=20.000 Net SFU/106 PBMC versus CD15 depleted=13.330 
Net SFU/106 PBMC and p=0.125), but were significantly higher before MDSC depletion at 
one year postpartum (median of CD15 non-depleted=20.000 Net SFU/106 PBMC versus CD15 
depleted=0.000 Net SFU/106 PBMC and p=0.037). 
 
Figure AA: IFN-γ cytokine producing cells to BCG in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to BCG were measured at delivery and again at one year postpartum in 
mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Each 
dot on the plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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(iii) TT induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to TT were evaluated in whole PBMC and without MDSC in 
infants at 10 and 14 weeks, at 6 and 9 months, and at one year of age. There was no effect of 
MDSC depletion at any time point as shown in Figure AB. However, IFN-γ cytokine 
producing cells to TT lasted till one year of age. There was no significant difference (a) at the 
individual time points between groups  at 10 and 14 weeks (p=0.681 and p=0.172 
respectively), at 6 and 9 months (p=0.212 and p=0.526 respectively) and at one year of age 
(p=0.753); or (b) in the grouped time point analysis at 10 and 14 weeks (median of CD15 non-
depleted=0 Net SFU/106 PBMC, IQR=0-12.413 versus CD15 depleted=0 Net SFU/106 PBMC, 
IQR=0-11.330; p=0.578), and at 6, 9 months and one year (median of CD15 non-depleted=0 
Net SFU/106 PBMC, IQR=0-11.213, versus CD15 depleted=0 Net SFU/106 PBMC, IQR=0-
6.141; p=0.393). Hence, no major difference in cells producing IFN-γ in whole PBMC and 
after MDSC depletion at all time points was observed in infants. 
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Figure AB: IFN-γ cytokine producing cells to TT in infants in whole PBMC versus without MDSC. (a) 
In the individual time point analysis, IFN-γ cytokine producing cells to TT were measured whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 10 and 14 weeks, at 6 and 9 
months and at one year of age, and (b) in the grouped time point analysis at 10 and 14 weeks (after first and 
second doses of TT vaccination), at 6 and 9 months and one year of age (after last dose of TT vaccination). 
Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; 




Appendices     302 
 
(iv) TT induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, TT induced IFN-γ producing cells were evaluated in whole PBMC and without 
MDSC at delivery and again at one year postpartum. As shown in Figure AC, cells producing 
IFN-γ to TT were significantly lower before MDSC depletion in mothers after gestation at 
delivery (median of CD15 non-depleted=0 Net SFU/106 PBMC versus CD15 depleted=6.667 
Net SFU/106 PBMC and p=0.048), but not at one year postpartum (median of CD15 non-
depleted=0 Net SFU/106 PBMC, IQR=0-33.330 versus CD15 depleted=0 Net SFU/106 PBMC, 




Figure AC: IFN-γ cytokine producing cells to TT in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to TT were measured at delivery and again at one year postpartum in mothers 
in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Each dot on the 
plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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(v) BP induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to BP vaccination were evaluated in whole PBMC and without 
MDSC in infants at 10 and 14 weeks, at 6 and 9 months, and at one year of age (Figure AD). 
There was no significant difference (a) at the individual time points between groups at 10 and 
14 weeks (p=0.663 and p=0.684 respectively), at 6 and 9 months (p=0.533 and p=1.000 
respectively) and at one year of age (p=0.359); or (b) in the grouped time point analysis after 
grouping infants at 10 and 14 weeks (median of CD15 non-depleted=3.333 Net SFU/106 
PBMC versus CD15 depleted=6.667 Net SFU/106 PBMC; p=0.549), and at 6, 9 months and 
one year (median of CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-13.330, versus CD15 
depleted=0 Net SFU/106 PBMC, IQR=0-6.677; p=0.907). Hence, no major difference in cells 
producing IFN-γ before and after MDSC depletion at all time points was observed in infants. 
KIDZERU, 2016 





Figure AD: IFN-γ cytokine producing cells to BP in infants in whole PBMC versus without MDSC. (a) 
In the individual time point analysis, IFN-γ cytokine producing cells to BP were measured in whole PBMC 
(CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 10 and 14 weeks, at 6 and 9 
months and at one year of age, and (b) in the grouped time point analysis at 10 and 14 weeks (after first and 
second doses of BP vaccination), at 6 and 9 months and one year of age (after last dose of BP vaccination). 
Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate interquartile range; 
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(vi) BP induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, quantities of BP induced IFN-γ producing cells were evaluated in whole PBMC 
and without MDSC at delivery and again at one year postpartum. As shown in Figure AE, 
MDSC depletion did not affect IFN-γ production in mothers at either time point (median of 
CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-66.670 versus CD15 depleted=0 Net 
SFU/106 PBMC, IQR=0-53.330 and p=0.143), and at one year postpartum (median of CD15 
non-depleted=0 Net SFU/106 PBMC, IQR=0-13.330 versus CD15 depleted=0 Net SFU/106 




Figure AE: IFN-γ cytokine producing cells to BP in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to BP were measured at delivery and again at one year postpartum in mothers 
in whole PBMC (CD15 Non-depleted – green) versus without MDSC (CD15 Depleted – red). Each dot on 
the plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; p<0.05 
significant level and statistical significance was tested using Mann-Whitney U test.   
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(vii) Hep B induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in infants 
The cells producing IFN-γ to Hep B vaccination were evaluated in whole PBMC and without 
MDSC in infants at 10 and 14 weeks, at 6 and 9 months, and at one year of age. There was no 
significant difference (a) at the individual time points at 10 and 14 weeks (p=0.463 and 
p=0.252 respectively), at 6 and 9 months (p=0.826 and p=0.861 respectively) and at one year 
of age (p=0.361); or (b) in the grouped time point analysis at 10 and 14 weeks (median of 
CD15 non-depleted=0 Net SFU/106 PBMC, IQR=0-13.333 versus CD15 depleted=0 Net 
SFU/106 PBMC, IQR=0-3.330; p=0.175), and at 6, 9 months and one year (median of CD15 
non-depleted=0 Net SFU/106 PBMC, IQR=0-6.333 versus CD15 depleted=0 Net SFU/106 
PBMC, IQR=0-13.330; p=0.421) (Figure AF). Hence, no major difference in cells producing 










Figure AF: IFN-γ cytokine producing cells to Hep B in infants in whole PBMC versus without MDSC. 
(a) In the individual time point analysis, IFN-γ cytokine producing cells to Hep B were measured in whole 
PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red) at 10 and 14 weeks, at 6 
and 9 months and at one year of age, and (b) in the grouped time point analysis at 10 and 14 weeks (after first 
and second doses of Hep B vaccination), at 6 and 9 months and one year of age (after last dose of Hep B 
vaccination). Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 
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(viii) Hep B induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, Hep B induced IFN-γ producing cells were evaluated with and without MDSC at 
delivery and at one year postpartum. As shown in Figure AG, cells producing IFN-γ to Hep B 
were not significantly different with and without MDSC in mothers after gestation at delivery 
(median of CD15 non-depleted=6.667 Net SFU/106 PBMC versus CD15 depleted=0 Net 
SFU/106 PBMC and p=0.303), and at one year postpartum (median of CD15 non-





Figure AG: IFN-γ cytokine producing cells to Hep B in mothers in whole PBMC versus without 
MDSC. IFN-γ cytokine producing cells to Hep B were measured at delivery and again at one year postpartum 
in mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Each 
dot on the plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; 
p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
KIDZERU, 2016 
Appendices     309 
 
(ix) PHA induced IFN-γ cytokine producing cells in the presence of MDSC versus after 
MDSC depletion in infants 
Phytohaemagglutinin (PHA) has been widely described and its use as a mitogen to trigger T 
lymphocyte cell division and to activate latent HIV-1 from human peripheral lymphocytes has 
been well documented(Mire-Sluis et al., 1987)(Gondois-Rey et al., 2001). We employed PHA 
as a positive control and we also assessed how MDSC would affect cells producing IFN-γ to 
PHA. We evaluated IFN-γ cytokine producing cells to PHA with and without MDSC in infants 
at birth, at 6, 10 and 14 weeks, at 6 and 9 months, and at one year of age (Figure AH). IFN-γ 
cytokine producing cells to PHA lasted till one year and were very strong at all time points. 
There was no significant difference at birth (median of CD15 non-depleted=353.300 Net 
SFU/106 PBMC versus CD15 depleted=390.000 Net SFU/106 PBMC and p=0.908), at 6, 10 
and 14 weeks (p=0.180, p=0.561 and p=0.333 respectively), at 6 and 9 months (p=0.124 and 
p=0.309 respectively) and at one year of age (p=0.178). Hence, no big difference in cells 
producing IFN-γ before and after MDSC depletion was observed in infants. 
 
Figure AH: IFN-γ cytokine producing cells to PHA in infants in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to PHA were measured at birth, at 6, 10 and 14 weeks, at 6 and 9 months and 
at one year postnatal in infants in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 
depleted – red). Each dot on the plot represent an infant. Bars indicate medians and whiskers indicate 
interquartile range; p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
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(x) PHA induced IFN-γ cytokine producing cells in whole PBMC versus after MDSC 
depletion in mothers 
In mothers, PHA induced IFN-γ producing cells were compared in whole PBMC and without 
MDSC at delivery and at one year postpartum. As shown in Figure AI, cells producing IFN-γ 
to PHA were significantly higher in whole PBMC than after MDSC depletion in mothers at 
delivery (median of CD15 non-depleted=2927.000 Net SFU/106 PBMC versus CD15 
depleted=1947.000 Net SFU/106 PBMC and p=0.047), but not at one year postpartum (median 
of CD15 non-depleted=1440.000 Net SFU/106 PBMC versus CD15 depleted=320.000 Net 
SFU/106 PBMC and p=0.061). 
 
Figure AI: IFN-γ cytokine producing cells to PHA in mothers in whole PBMC versus without MDSC. 
IFN-γ cytokine producing cells to PHA were measured at delivery and again at one year postpartum in 
mothers in whole PBMC (CD15 non-depleted – green) versus without MDSC (CD15 depleted – red). Each 
dot on the plot represent each mother. Bars indicate medians and whiskers indicate interquartile range; 
p<0.05 significant level and statistical significance was tested using Mann-Whitney U test.   
